var title_f34_4_34880="Fluorouracil: Pediatric drug information";
var content_f34_4_34880=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fluorouracil: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12624501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12644965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/10/1190?source=see_link\">",
"       Fluorouracil (systemic): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/52/29508?source=see_link\">",
"       Fluorouracil (topical): Pediatric drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13314 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-91.202.164.29-FFA7B79098-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_4_34880=[""].join("\n");
var outline_f34_4_34880=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/10/1190?source=related_link\">",
"      Fluorouracil (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/52/29508?source=related_link\">",
"      Fluorouracil (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_4_34881="Patient information: Nursemaid’s elbow (The Basics)";
var content_f34_4_34881=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/86742\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/0/44047\">",
"         Elbow joint",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/12/39108\">",
"          Nursemaid���������s elbow",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/5/28767\">",
"           Arm position for Nursemaid's elbow",
"          </a>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?19/35/20018\">",
"         Patient information: Elbow fracture in children (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Nursemaid&rsquo;s elbow (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H93611708\">",
"      <span class=\"h1\">",
"       What is nursemaid&rsquo;s elbow?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Nursemaid&rsquo;s elbow is an injury that causes elbow pain. It is a common injury that happens most often in children ages 1 to 4 years.",
"     </p>",
"     <p>",
"      This injury involves the elbow joint (",
"      <a class=\"graphic graphic_figure graphicRef58954 \" href=\"mobipreview.htm?43/0/44047\">",
"       figure 1",
"      </a>",
"      ). It usually happens when someone pulls hard on a child&rsquo;s arm by the hand, wrist, or forearm when the child is not expecting it. The injury can also happen when someone grabs a child&rsquo;s arm suddenly, for instance, when the child is about to fall. These types of movements cause tissue to move between 2 of the bones in the elbow joint, called the radius and the humerus (",
"      <a class=\"graphic graphic_figure graphicRef86688 \" href=\"mobipreview.htm?38/12/39108\">",
"       figure 2",
"      </a>",
"      ). This causes symptoms.",
"     </p>",
"     <p>",
"      Nursemaid&rsquo;s elbow is common in young children because the tissues holding the elbow joint together are loose in young children. After age 5, nursemaid&rsquo;s elbow doesn&rsquo;t happen. That&rsquo;s because the tissues around the elbow joint are tighter. They don&rsquo;t let the bones move out of place.",
"     </p>",
"     <p>",
"      The medical term for nursemaid&rsquo;s elbow is &ldquo;radial head subluxation.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H93611757\">",
"      <span class=\"h1\">",
"       What are the symptoms of nursemaid&rsquo;s elbow?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Nursemaid&rsquo;s elbow is very painful. When the injury happens, children usually cry and are upset. They usually hold their injured arm straight or slightly bent and close to their body (",
"      <a class=\"graphic graphic_figure graphicRef86687 \" href=\"mobipreview.htm?28/5/28767\">",
"       figure 3",
"      </a>",
"      ). They will avoid using the injured arm.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H93611789\">",
"      <span class=\"h1\">",
"       Should I try to move or straighten my child&rsquo;s arm on my own?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. Do not try to move your child&rsquo;s arm. You should bring your child to the doctor or nurse right away.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H93611804\">",
"      <span class=\"h1\">",
"       Will my child need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Probably not. The doctor or nurse should be able to tell if your child has nursemaid&rsquo;s elbow by asking about the injury and doing an exam.",
"     </p>",
"     <p>",
"      Some children need X-rays. Your doctor or nurse will order an X-ray if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        He or she thinks the injury caused a broken bone.",
"       </li>",
"       <li>",
"        The procedure to fix the injury (described below) does not work.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H93611819\">",
"      <span class=\"h1\">",
"       How is nursemaid&rsquo;s elbow treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Nursemaid&rsquo;s elbow is treated with a procedure to move the tissue and bones back into place. This procedure is very quick. The doctor or nurse usually does this in the office or emergency department.",
"     </p>",
"     <p>",
"      Children do not usually need pain medicine for the procedure. Although the procedure can hurt, your child will feel much better 5 to 10 minutes after it is done.",
"     </p>",
"     <p>",
"      After the procedure, your child will probably not need any further treatment.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H93611834\">",
"      <span class=\"h1\">",
"       Can nursemaid&rsquo;s elbow be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To prevent nursemaid&rsquo;s elbow, do not pull hard on your child&rsquo;s arm or lift him or her up by the hand, wrist, or forearm. Instead, to lift your child up, hold him or her by the upper arms or under the arms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H93611849\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/35/20018?source=see_link\">",
"       Patient information: Elbow fracture in children (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?34/4/34881?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86742 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-A6501CF067-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_4_34881=[""].join("\n");
var outline_f34_4_34881=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93611708\">",
"      What is nursemaid&rsquo;s elbow?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93611757\">",
"      What are the symptoms of nursemaid&rsquo;s elbow?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93611789\">",
"      Should I try to move or straighten my child&rsquo;s arm on my own?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93611804\">",
"      Will my child need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93611819\">",
"      How is nursemaid&rsquo;s elbow treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93611834\">",
"      Can nursemaid&rsquo;s elbow be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93611849\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/86742\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/0/44047\">",
"      Elbow joint",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/12/39108\">",
"       Nursemaid���������s elbow",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/5/28767\">",
"        Arm position for Nursemaid's elbow",
"       </a>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/35/20018?source=related_link\">",
"      Patient information: Elbow fracture in children (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_4_34882="Alcohol induced fatty liver - high power";
var content_f34_4_34882=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F57614&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F57614&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Alcohol induced fatty liver (high power, Masson trichrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 281px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Large fatty droplets fill hepatocytes. Nuclei are at the periphery of these cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_4_34882=[""].join("\n");
var outline_f34_4_34882=null;
var title_f34_4_34883="Ovulation induction with clomiphene";
var content_f34_4_34883=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Ovulation induction with clomiphene (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?34/4/34883/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/4/34883/contributors\" id=\"au5916\">",
"       Mark D Hornstein, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/4/34883/contributors\" id=\"au1939\">",
"       William E Gibbons, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?34/4/34883/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/4/34883/contributors\" id=\"se4464\">",
"       Robert L Barbieri, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?34/4/34883/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/4/34883/contributors\" id=\"de5123\">",
"       Kathryn A Martin, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?34/4/34883?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INFERTILITY TREATMENT OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Infertility is defined as a couple's inability to become pregnant after one year of unprotected intercourse. In any given year, about 15 percent of couples in North America and Europe who are trying to conceive are infertile.",
"    </p>",
"    <p>",
"     The fertility of a couple depends upon several factors in both the male and female partner. Among all cases of infertility in developed countries, about 8 percent can be traced to male factors, 37 percent can be traced to female factors, 35 percent can be traced to factors in both the male and female partners, and 5 percent cannot be traced to obvious factors in either partner.",
"    </p>",
"    <p>",
"     When infertility occurs, the male and female partners are evaluated to determine the cause and best treatment options. If the woman is not ovulating regularly, one treatment option involves taking an oral medication, clomiphene citrate (Clomid&reg; or Serophene&reg;).",
"    </p>",
"    <p>",
"     This topic will review the use of clomiphene in the treatment of female infertility. The evaluation of the infertile couple, as well as the causes and treatment of male infertility, are discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/42/22180?source=see_link\">",
"      \"Patient information: Evaluation of the infertile couple (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/5/32851?source=see_link\">",
"      \"Patient information: Treatment of male infertility (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Other articles about infertility treatment are also available. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/14/10468?source=see_link\">",
"      \"Patient information: Infertility treatment with gonadotropins (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/62/40932?source=see_link\">",
"      \"Patient information: In vitro fertilization (IVF) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      OVULATION",
"     </span>",
"    </p>",
"    <p>",
"     To understand why and how clomiphene is used, it is important to have a basic understanding of normal ovulation. Normally, a woman's ovaries produce one egg every 24 to 35 days. Ovulation usually occurs about 12 to 14 days before the next menstrual period (",
"     <a class=\"graphic graphic_figure graphicRef79496 \" href=\"mobipreview.htm?13/13/13530\">",
"      figure 1",
"     </a>",
"     ). A woman's best chance for becoming pregnant occurs around the day of ovulation and one to two days before ovulation. This would be approximately 12 to 14 days after the first day of a 28 day menstrual cycle (day 1 of the menstrual cycle is the first day of bleeding).",
"    </p>",
"    <p>",
"     Women who are most likely to respond to clomiphene include those who do not have an excessively elevated level of FSH and who have uterine bleeding when treated with a progestin (WHO class 2). This includes women with polycystic ovary syndrome (PCOS).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      WHAT IS CLOMIPHENE?",
"     </span>",
"    </p>",
"    <p>",
"     Clomiphene is an estrogen-like hormone that acts on the hypothalamus, pituitary gland, and ovary to increase levels of FSH and luteinizing hormone (LH, which is also important in the process of ovulation).",
"    </p>",
"    <p>",
"     An increased level of these hormones improves the chances of growing an ovarian follicle that can then trigger ovulation. In women who ovulate irregularly, approximately 80 percent who take clomiphene will ovulate, and 30 to 40 percent of all women who take clomiphene become pregnant. These numbers apply to women who have taken up to three cycles of clomiphene.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Pretreatment evaluation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Before any infertility treatment begins, a woman and her partner should undergo an infertility evaluation to be sure that clomiphene is the best treatment. This evaluation may include a complete history and physical examination, a semen analysis (for men), blood testing, and other tests depending upon the individual situation. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/42/22180?source=see_link\">",
"      \"Patient information: Evaluation of the infertile couple (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Dosing",
"     </span>",
"     &nbsp;&mdash;&nbsp;Clomiphene is usually started on day three, four, or five of the menstrual cycle at a dose of 50 mg (one pill) once daily for five days. The first day of bleeding is called cycle day one. If the woman does not have regular menstrual cycles (which is usually the situation), she may be given a course of progestin medication (eg, Provera&reg;, medroxyprogesterone acetate) to induce a period. Although, a recent study suggests that this may not always be necessary.",
"    </p>",
"    <p>",
"     Ovulation usually occurs between cycle day 14 and 19. Most fertility specialists recommend the use of an ovulation predictor kit to plan intercourse. The kit uses a urine sample to predict when ovulation is about to occur by measuring the LH level; these are available without a prescription in most pharmacies. If an ovulation predictor kit is not used, the couple is advised to have intercourse every other day for one week, beginning around day 10 (10 days after the menstrual period starts).",
"    </p>",
"    <p>",
"     Some healthcare providers recommend ultrasound monitoring for women undergoing clomiphene treatment. This involves inserting a thin probe into the vagina and using sound waves to view the size and number of developing follicles (which contain an egg).",
"    </p>",
"    <p>",
"     Use of an ovulation predictor kit, blood testing,",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     ultrasound are not required for women using clomiphene, and testing does not improve pregnancy rates significantly. However, almost all fertility specialists recommend use of an ovulation predictor kit",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     blood testing to confirm ovulation. Some recommend ultrasound, although this requires more office visits and increases the cost of treatment.",
"    </p>",
"    <p>",
"     If ovulation does not occur during the first month, the clomiphene dose may be increased. There is no benefit of increasing the clomiphene dose if ovulation occurs, even if pregnancy does not occur. Nearly all pregnancies occur within the first six cycles while using clomiphene, and there is little benefit of continuing clomiphene treatment after six unsuccessful ovulatory cycles. If this occurs it would suggest the need to evaluate other causes of infertility [",
"     <a class=\"abstract\" href=\"mobipreview.htm?34/4/34883/abstract/1\">",
"      1",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Benefits",
"     </span>",
"     &nbsp;&mdash;&nbsp;The benefit of clomiphene is that it is relatively inexpensive and can be used before other, more expensive testing (such as hysterosalpingogram or laparoscopy) or infertility treatments (eg, gonadotropin therapy, in vitro fertilization). It does not require monitoring with ultrasound or blood hormone levels, although monitoring may be recommended in some cases. Clomiphene improves the chances of becoming pregnant for most women who ovulate irregularly, and it carries a low risk of dangerous side effects.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Risks",
"     </span>",
"     &nbsp;&mdash;&nbsp;Risks of clomiphene therapy include a slightly increased rate of multiple pregnancies; approximately 6 percent of women who use clomiphene have twins, while less than 0.5 percent have triplets or greater. There is a small risk of the ovaries becoming enlarged, although severe enlargement (known as ovarian hyperstimulation syndrome) is rare.",
"    </p>",
"    <p>",
"     Common side effects of clomiphene include hot flashes, headaches, abdominal bloating and pain, nausea and vomiting, mood changes, and breast tenderness. Visual symptoms such as blurring, double vision, or seeing spots occur in 1 to 2 percent of women, and usually resolve when treatment stops.",
"    </p>",
"    <p>",
"     Most studies do not show an increased risk of birth defects, miscarriage, or learning disability in children of women who took clomiphene. There is no increased risk of breast cancer or uterine cancer. There may be a slightly increased risk of ovarian cancer if more than 12 cycles of clomiphene are used.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      IMPROVING CLOMIPHENE SUCCESS",
"     </span>",
"    </p>",
"    <p>",
"     Women who do not become pregnant after three cycles of clomiphene are usually encouraged to have further testing before continuing with infertility treatment. This may include a hysterosalpingogram (an X-ray test showing the uterus and fallopian tubes), blood testing, and if not previously done, a semen analysis of the male partner. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/42/22180?source=see_link\">",
"      \"Patient information: Evaluation of the infertile couple (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     If these tests are normal and the couple would like to continue with clomiphene treatment, other interventions, such as weight loss or gain, might be suggested.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Weight loss",
"     </span>",
"     &nbsp;&mdash;&nbsp;Women who are overweight or obese and who ovulate infrequently often benefit from weight loss as a treatment for their infertility. Overweight is defined as having a body mass index (BMI) greater than 25",
"     <span class=\"nowrap\">",
"      kg/m2.",
"     </span>",
"     A BMI calculator is available here (",
"     <a class=\"calc calc_patient\" href=\"mobipreview.htm?41/23/42366?source=see_link\">",
"      calculator 1",
"     </a>",
"     and",
"     <a class=\"calc calc_patient\" href=\"mobipreview.htm?36/47/37630?source=see_link\">",
"      calculator 2",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Weight loss is an inexpensive and low-risk treatment with no side effects that has been proven to improve the chances of ovulation and pregnancy in women who are overweight. In addition, having a normal or near-normal weight can reduce the risk of complications during pregnancy. Furthermore, achieving and maintaining a weight in the normal range has lifelong health benefits.",
"    </p>",
"    <p>",
"     A combination of decreased calorie intake and exercise are recommended to achieve a 5 to 10 percent weight loss. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/62/28642?source=see_link\">",
"      \"Patient information: Diet and health (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Weight gain",
"     </span>",
"     &nbsp;&mdash;&nbsp;Women who are underweight (defined as a BMI less than 17",
"     <span class=\"nowrap\">",
"      kg/m2),",
"     </span>",
"     have eating disorders (eg, bulimia or anorexia), or who participate in strenuous exercise regimens may ovulate irregularly or not at all. These women may be advised to gain weight to a goal BMI of at least 19",
"     <span class=\"nowrap\">",
"      kg/m2",
"     </span>",
"     (",
"     <a class=\"calc calc_patient\" href=\"mobipreview.htm?41/23/42366?source=see_link\">",
"      calculator 1",
"     </a>",
"     and",
"     <a class=\"calc calc_patient\" href=\"mobipreview.htm?36/47/37630?source=see_link\">",
"      calculator 2",
"     </a>",
"     ), increase calorie intake, and modify exercise habits to include less strenuous activities.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Treatment with human chorionic gonadotropin",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some women do not have an increase in their LH level midcycle and do not ovulate (",
"     <a class=\"graphic graphic_figure graphicRef79496 \" href=\"mobipreview.htm?13/13/13530\">",
"      figure 1",
"     </a>",
"     ), despite having a normally developed follicle (which contains an egg). These women often benefit from using an injection of human chorionic gonadotropin (hCG), which triggers ovulation.",
"    </p>",
"    <p>",
"     Transvaginal ultrasound is used to determine when the follicle is ready, and the woman or her partner can be taught to give the injection at home. Ovulation occurs 36 to 44 hours after the injection, and intercourse can be timed accordingly. hCG may also be recommended for women who will have a procedure, such as intrauterine insemination. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/14/10468?source=see_link&amp;anchor=H8#H8\">",
"      \"Patient information: Infertility treatment with gonadotropins (Beyond the Basics)\", section on 'Intrauterine insemination'",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Metformin",
"     </span>",
"     &nbsp;&mdash;&nbsp;Metformin (Glucophage&reg;, Gumetza&reg;, Riomet&reg;, Fortamet&reg;) is a medication that is used in the treatment of type 2 diabetes mellitus. It has also been used in women with polycystic ovary syndrome (PCOS) and infertility if clomiphene treatment and weight loss are not successful.",
"    </p>",
"    <p>",
"     Although metformin increases the chance of ovulating, it may not improve pregnancy rates when compared with clomiphene-only treatment. Therefore, adding metformin to clomiphene is not recommended for women with PCOS unless they have \"pre-diabetes\" or type 2 diabetes [",
"     <a class=\"abstract\" href=\"mobipreview.htm?34/4/34883/abstract/2\">",
"      2",
"     </a>",
"     ]. Women should be attentive to the association of polycystic ovary disease and insulin resistance, particularly when the response to clomiphene citrate is unsuccessful.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      CLOMIPHENE FAILURE",
"     </span>",
"    </p>",
"    <p>",
"     If a woman with anovulation does not become pregnant despite ovulating during three cycles of clomiphene, there may be other causes of infertility (eg, endometriosis, adhesions, male factors). If a complete infertility evaluation has not been done, it should be done at this point. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/42/22180?source=see_link\">",
"      \"Patient information: Evaluation of the infertile couple (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Other infertility treatments may be recommended if clomiphene treatment is not successful; these include surgical treatment (to eliminate scar tissue or fibroids), ovulation induction with injectable gonadotropins,",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     in vitro fertilization. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/14/10468?source=see_link\">",
"      \"Patient information: Infertility treatment with gonadotropins (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      COSTS OF INFERTILITY TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The costs of infertility treatments can be high, depending upon what tests are required, the type and dose of medication(s) used, and the number of months that it takes to become pregnant. Insurance policies cover the costs of infertility treatment in some states, although this varies by location and individual insurance policy. Less than half of the states within the US have laws requiring insurers to cover infertility treatment.",
"    </p>",
"    <p>",
"     More information about a state's laws can be obtained by calling the state Insurance Commissioner's office. More information can also be found by visiting the website for the American Society of Reproductive Medicine (",
"     <a class=\"external\" href=\"file://www.asrm.org/detail.aspx?id=2850\">",
"      www.asrm.org/detail.aspx?id=2850",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1784896313\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10151310\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/16/11523?source=see_link\">",
"      Patient information: Infertility in women (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/42/40610?source=see_link\">",
"      Patient information: Infertility in men (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/25/6547?source=see_link\">",
"      Patient information: Infertility in couples (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/8/5251?source=see_link\">",
"      Patient information: Endometriosis (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10151288\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/42/22180?source=see_link\">",
"      Patient information: Evaluation of the infertile couple (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/5/32851?source=see_link\">",
"      Patient information: Treatment of male infertility (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/14/10468?source=see_link\">",
"      Patient information: Infertility treatment with gonadotropins (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/62/40932?source=see_link\">",
"      Patient information: In vitro fertilization (IVF) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/62/28642?source=see_link\">",
"      Patient information: Diet and health (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/36/39495?source=see_link\">",
"      Diagnosis of polycystic ovary syndrome in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/0/24583?source=see_link\">",
"      Laparoscopic surgery for ovulation induction in polycystic ovary syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/5/37976?source=see_link\">",
"      Management of couples with recurrent pregnancy loss",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/27/16826?source=see_link\">",
"      Metformin for treatment of the polycystic ovary syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/10/13482?source=see_link\">",
"      Overview of ovulation induction",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/5/14425?source=see_link\">",
"      Overview of treatment of female infertility",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/25/9626?source=see_link\">",
"      Ovulation induction with clomiphene citrate",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/15/38136?source=see_link\">",
"      Pathogenesis and treatment of infertility in women with endometriosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/6/16487?source=see_link\">",
"      Strategies for improving the efficacy of clomiphene induction of ovulation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/57/25496?source=see_link\">",
"      Unexplained infertility",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Society for Reproductive Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.asrm.org/\">",
"      www.asrm.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Resolve: The National Infertility Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.resolve.org/\">",
"      www.resolve.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The International Council on Infertility Information Dissemination",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.inciid.com/\">",
"      www.inciid.com",
"     </a>",
"     )",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Patient support",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are a number of online forums where patients can find information and support from other people with similar conditions.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://about.com/\">",
"        About.com",
"       </a>",
"       Infertility Conditions Forum",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://infertility.about.com/forum\">",
"      file://infertility.about.com/forum",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?34/4/34883/abstract/3-5\">",
"      3-5",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 3, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?34/4/34883?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34883/abstract/1\">",
"      Gysler M, March CM, Mishell DR Jr, Bailey EJ. A decade's experience with an individualized clomiphene treatment regimen including its effect on the postcoital test. Fertil Steril 1982; 37:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34883/abstract/2\">",
"      Legro RS, Barnhart HX, Schlaff WD, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 2007; 356:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34883/abstract/3\">",
"      Practice Committee of the American Society for Reproductive Medicine. Use of clomiphene citrate in women. Fertil Steril 2003; 80:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34883/abstract/4\">",
"      Smith YR, Randolph JF Jr, Christman GM, et al. Comparison of low-technology and high-technology monitoring of clomiphene citrate ovulation induction. Fertil Steril 1998; 70:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34883/abstract/5\">",
"      Barbieri RL. Induction of ovulation in infertile women with hyperandrogenism and insulin resistance. Am J Obstet Gynecol 2000; 183:1412.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f34_4_34883=[""].join("\n");
var outline_f34_4_34883=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INFERTILITY TREATMENT OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           OVULATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           WHAT IS CLOMIPHENE?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           IMPROVING CLOMIPHENE SUCCESS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           CLOMIPHENE FAILURE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           COSTS OF INFERTILITY TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/13/13530\" title=\"figure 1\">",
"           Menstrual cycle PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        CALCULATORS",
"       </h1>",
"       <div id=\"relatedCalculators\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a class=\"calc calc_patient\" href=\"mobipreview.htm?41/23/42366?source=related_link\" title=\"calculator 1\">",
"           Calculator: Body mass index for adults (Patient information)",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a class=\"calc calc_patient\" href=\"mobipreview.htm?36/47/37630?source=related_link\" title=\"calculator 2\">",
"           Calculator: Body mass index for adults (Metric, Patient information)",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f34_4_34884="Atheroma v cardiac allograft vasculopathy";
var content_f34_4_34884=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F82741&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F82741&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Atherosclerosis versus cardiac allograft vasculopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 420px; height: 315px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the anatomic differences between coronary nontransplant atherosclerosis and cardiac allograft vasculopathy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Arbustini E, Roberts WC. Am J Cardiol 1996; 78:814.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_4_34884=[""].join("\n");
var outline_f34_4_34884=null;
var title_f34_4_34885="Salmeterol: Pediatric drug information";
var content_f34_4_34885=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Salmeterol: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?33/63/34806?source=see_link\">",
"    see \"Salmeterol: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/25/40341?source=see_link\">",
"    see \"Salmeterol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F219869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Serevent&reg; Diskus&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F219870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Serevent&reg; Diskhaler&reg; Disk;",
"     </li>",
"     <li>",
"      Serevent&reg; Diskus&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1061999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Adrenergic Agonist Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiasthmatic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Beta",
"       <sub>",
"        2",
"       </sub>",
"       -Adrenergic Agonist",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Bronchodilator",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1061992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?33/63/34806?source=see_link\">",
"      see \"Salmeterol: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &ge;4 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Asthma, maintenance treatment; prevention:",
"     </b>",
"     Inhalation, oral: 50 mcg (1 actuation/puff) twice daily, 12 hours apart;",
"     <b>",
"      Note:",
"     </b>",
"     For long-term asthma control, long-acting beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists should be used in combination with inhaled corticosteroids and",
"     <b>",
"      not",
"     </b>",
"     as monotherapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Exercise-induced bronchospasm, prevention:",
"     </b>",
"     Inhalation: 50 mcg (1 inhalation/puff) 30 minutes prior to exercise; additional doses should not be used for 12 hours; patients who are using salmeterol twice daily should",
"     <b>",
"      not",
"     </b>",
"     use an additional salmeterol dose prior to exercise; if twice daily use is not effective during exercise, consider other appropriate therapy;",
"     <b>",
"      Note:",
"     </b>",
"     Because long-acting beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists (LABAs) may disguise poorly-controlled persistent asthma, frequent or chronic use of LABAs for exercise-induced bronchospasm is discouraged by the NAEPP Asthma Guidelines (NAEPP, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      COPD, maintenance treatment:",
"     </b>",
"     Adults: 50 mcg (1 inhalation/puff) twice daily (~12 hours apart); maximum: 1 inhalation twice daily",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F219849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, for oral inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Serevent&reg; Diskus&reg;: 50 mcg (28s, 60s) [contains lactose]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F219834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089125.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089125.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1062003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhalation: Not for use with a spacer",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1061995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at controlled room temperature 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F) in a dry place away from direct heat or sunlight; stable for 6 weeks after removal from protective foil pouch.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1062002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Concomitant therapy with inhaled corticosteroids for maintenance treatment of asthma and prevention of bronchospasm in patients with reversible obstructive airway disease, including patients with nocturnal symptoms (FDA approved in ages &ge;4 years and adults); prevention of exercise-induced bronchospasm as concomitant therapy in patients with persistent asthma and as monotherapy in those without persistent asthma (FDA approved in ages &ge;4 years and adults); maintenance treatment of bronchospasm associated with COPD (FDA approved in adults);",
"     <b>",
"      NOT",
"     </b>",
"     indicated for the relief of acute bronchospasm",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F219922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Salmeterol may be confused with Salbutamol, Solu-Medrol&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Serevent&reg; may be confused with Atrovent&reg;, Combivent&reg;, sertraline, Sinemet&reg;, Spiriva&reg;, Zoloft&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F219920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema, hypertension, pallor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, dizziness, fever, headache, migraine, sleep disturbance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Contact dermatitis, eczema, photodermatitis, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Dental pain, dyspepsia, gastrointestinal infection, nausea, oropharyngeal candidiasis, throat irritation, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Liver enzymes increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, articular rheumatism, joint pain, muscular cramps/spasm/stiffness, pain, paresthesia, rigidity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Keratitis/conjunctivitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Asthma, cough, influenza, nasal congestion, pharyngitis, rhinitis, sinusitis, tracheitis/bronchitis, viral respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abdominal pain, agitation, aggression, anaphylactic reaction (some in patients with severe milk allergy [Diskus&reg;]), angioedema, aphonia, arrhythmia, atrial fibrillation, cataracts, chest congestion, chest tightness, choking, contusions, Cushing syndrome, Cushingoid features, depression, dysmenorrhea, dyspnea, earache, ecchymoses, edema (facial, oropharyngeal), eosinophilic conditions, glaucoma, growth velocity reduction in children/adolescents, hypercorticism, hypersensitivity reaction (immediate and delayed), hypokalemia, hypothyroidism, intraocular pressure increased, laryngeal spasm/irritation, irregular menstruation, myositis, oropharyngeal irritation, osteoporosis, pallor, paradoxical bronchospasm, paradoxical tracheitis, paranasal sinus pain, PID, QTc prolongation, restlessness, stridor, supraventricular tachycardia, syncope, tremor, vaginal candidiasis, vaginitis, vulvovaginitis, rare cases of vasculitis (Churg-Strauss syndrome), ventricular tachycardia, weight gain",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1062007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to salmeterol, adrenergic amines, or any component; severe hypersensitivity to milk proteins; monotherapy in the treatment of asthma (ie, use without a concomitant long-term asthma control medication, such as an inhaled corticosteroid); treatment of status asthmaticus or other acute episodes of asthma or COPD",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1061991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with cardiovascular disorders (especially coronary insufficiency, arrhythmias, hypertension, heart failure), although uncommon at recommended doses, beta-agonists may cause elevation in BP and HR and result in CNS stimulation and excitation. Caution should also be used in patients with thyrotoxicosis, seizure disorders, or conditions that are unusually sensitive to sympathomimetic amines. Transient hypokalemia from intracellular shunting may occur and produce adverse cardiovascular effects. Use with caution in patients with diabetes mellitus (DM); beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists can increase serum glucose aggravating pre-existing DM and ketoacidosis. Use caution in patients with hepatic impairment. Immediate hypersensitivity reactions (urticaria, angioedema, rash, bronchospasm) have been reported. Powder for oral inhalation contains lactose; very rare anaphylactic reactions have been reported in patients with severe milk protein allergy.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1061990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Long-acting beta",
"     <sub>",
"      2",
"     </sub>",
"     -adrenergic agents (LABAs), including salmeterol, increase the risk of asthma-related deaths",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Salmeterol should only be prescribed in patients not adequately controlled on  long-term asthma-controller medications (ie, inhaled corticosteroid) or  whose disease severity requires initiation of two maintenance therapies. Monotherapy with a LABA is contraindicated in the treatment of asthma. In a large clinical trial, LABA (salmeterol) use was associated with an increase in asthma-related deaths compared to placebo (when added to usual asthma therapy); risk is considered a class effect among all LABAs. Data are not available to determine if the addition of an inhaled corticosteroid lessens this increased risk of death associated with LABA use or if LABA use also increases the risk of death in patients with COPD. Assess patients at regular intervals once asthma control is maintained on combination therapy to determine if step-down therapy is appropriate (without loss of asthma control), and the patient can be maintained on an inhaled corticosteroid only. LABAs are not appropriate in patients whose asthma is adequately controlled on low- or medium-dose inhaled corticosteroids. LABAs may increase the risk of asthma-related hospitalization in pediatric and adolescent patients",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; when addition of a LABA is clinically indicated in patients &lt;18 years of age, a combination product containing a LABA and an inhaled corticosteroid is preferred to ensure compliance.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Salmeterol should not be used to relieve acute asthmatic or COPD symptoms, rapidly deteriorating, or potentially life-threatening episodes of asthma or COPD; acute episodes should be treated with short-acting beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonist. Routine use of inhaled, short-acting beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists should be discontinued prior to initiation of salmeterol. Corticosteroids should not be stopped or reduced when salmeterol is initiated. Salmeterol should not be used more frequently than recommended (twice daily), at higher doses or with any additional long-acting beta",
"     <sub>",
"      2",
"     </sub>",
"     -adrenergic agonist; adverse cardiovascular effects (possibly fatal) have been reported with excessive beta",
"     <sub>",
"      2",
"     </sub>",
"     -adrenergic overstimulation. Not recommended for use with strong CYP3A4 inhibitors (eg, ketoconazole, ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) due to potential for an increased risk of cardiovascular events. Paroxysmal bronchospasm (which can be fatal) has been reported with salmeterol and other beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonist inhaled agents; if this occurs, discontinue treatment; most commonly occurs with first use of a new canister or vial. Symptoms of laryngeal spasm, irritation, or swelling, such as stridor and choking, have been reported; if  occurs, discontinue treatment. Because LABAs may disguise poorly-controlled persistent asthma, frequent or chronic use of LABAs for exercise-induced bronchospasm is discouraged by the NAEPP Asthma Guidelines (NAEPP, 2007).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F219909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F219843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Blockers: May diminish the therapeutic effect of Beta2-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the tachycardic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atosiban: Beta2-Agonists may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers (Beta1 Selective): May diminish the bronchodilatory effect of Beta2-Agonists. Of particular concern with nonselective beta-blockers or higher doses of the beta1 selective beta-blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers (Nonselective): May diminish the bronchodilatory effect of Beta2-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: May diminish the therapeutic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F219845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2869570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have demonstrated (dose-dependent) teratogenicity. There are no adequate and well-controlled studies in pregnant women. Beta-agonists may interfere with uterine contractility if administered during labor. Use only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1061998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pulmonary function tests, vital signs, CNS stimulation, serum glucose, serum potassium",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1061989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relaxes bronchial smooth muscle by selective action on beta",
"     <sub>",
"      2",
"     </sub>",
"     -receptors with little effect on heart rate; acts locally in the lung",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1062005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Asthma: 30-48 minutes; COPD: 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peak effect: Asthma: 3 hours; COPD: 2-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Up to 12 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1062006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 96%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive hydroxylation via CYP3A4",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 5.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 60% in feces and 25% in urine over a 7-day period",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1061997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/25/40341?source=see_link\">",
"      see \"Salmeterol: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not use to treat acute symptoms; do not exceed the prescribed dose of salmeterol; do not stop using inhaled or oral corticosteroids without medical advice even if feeling better; do not exhale into the Diskus&reg;; do not wash the mouthpiece or any part of the diskus; keep it dry; never attempt to take Diskus&reg; apart; may cause dry mouth",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1062008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When salmeterol is initiated in patients previously receiving a short-acting beta agonist, instruct the patient to discontinue the regular use of the short-acting beta agonist and to utilize the shorter-acting agent for symptomatic or acute episodes only.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Meyer JM, Wenzel CL, and Kradjan WA, &ldquo;Salmeterol: A Novel, Long-Acting Beta",
"      <sub>",
"       2",
"      </sub>",
"      -Agonist,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1993, 27(12):1478-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/4/34885/abstract-text/7905757/pubmed\" id=\"7905757\" target=\"_blank\">",
"        7905757",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Asthma Education and Prevention Program (NAEPP), &ldquo;Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma,&rdquo; Clinical Practice Guidelines, National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007. Available at",
"      <a href=\"file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm",
"      </a>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12779 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.131.240.2-B63444C5D6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_4_34885=[""].join("\n");
var outline_f34_4_34885=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709408\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219869\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219870\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061999\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061992\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219849\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219834\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874829\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062003\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061995\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062002\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219922\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219920\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062007\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061991\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061990\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219909\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219843\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219845\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2869570\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061998\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061989\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062005\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062006\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061997\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062008\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12779\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12779|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?33/63/34806?source=related_link\">",
"      Salmeterol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/25/40341?source=related_link\">",
"      Salmeterol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_4_34886="Bone marrow transplantation (stem cell transplantation)";
var content_f34_4_34886=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?34/4/34886/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/4/34886/contributors\" id=\"au5263\">",
"       Robert S Negrin, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?34/4/34886/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/4/34886/contributors\" id=\"se4256\">",
"       Nelson J Chao, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?34/4/34886/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/4/34886/contributors\" id=\"de1889\">",
"       Rebecca F Connor, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?34/4/34886?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      BONE MARROW TRANSPLANTATION OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Bone marrow transplantation (BMT), also called hematopoietic stem cell transplant or hematopoietic cell transplant, is a type of treatment for cancer (and a few other conditions as well). A review of the normal function of the bone marrow will help in the understanding of bone marrow transplantation.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2\">",
"     <span class=\"h2\">",
"      Bone marrow function",
"     </span>",
"     &nbsp;&mdash;&nbsp;Bone marrow is the soft, spongy area in the center of some of the larger bones of the body. The marrow produces all of the different cells that make up the blood, such as red blood cells, white blood cells (of many different types), and platelets. All of these cells develop from a type of precursor cell found in the bone marrow, called a hematopoietic stem cell.",
"    </p>",
"    <p>",
"     The body is able to direct hematopoietic stem cells to develop into the blood components needed at any given moment. This is a very active process, with the bone marrow producing millions of different cells every hour. Most of the stem cells stay in the marrow until they are transformed into the various blood components, which are then released into the blood stream. Small numbers of stem cells, however, can be found in the circulating blood, which allows them to be collected under certain circumstances (see below). Various strategies can be employed to increase the number of hematopoietic stem cells in the blood prior to collection. (See",
"     <a class=\"local\" href=\"#H19\">",
"      'Peripheral blood'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Bone marrow transplantation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some of the most effective treatments for cancer, such as chemotherapy and radiation, are toxic to the bone marrow. In general, the higher the dose, the more toxic the effects on the bone marrow.",
"    </p>",
"    <p>",
"     In bone marrow transplantation, you are given very high doses of chemotherapy or radiation therapy, which is intended to more effectively kill cancer cells and unfortunately also destroy all the normal cells developing in the bone marrow, including the critical stem cells. After the treatment, you must have a healthy supply of stem cells reintroduced, or transplanted. The transplanted cells then reestablish the blood cell production process in the bone marrow. Reduced doses of radiation or chemotherapy that do not completely destroy the bone marrow may be used in some settings. (See",
"     <a class=\"local\" href=\"#H7\">",
"      'Non-myeloablative transplant'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     The cells that will be transplanted can be taken from the bone marrow (called a bone marrow transplant), from the bloodstream (called a peripheral blood stem cell transplant, which requires that you take medication to boost the number of hematopoietic stem cells in the blood), or occasionally from blood obtained from the umbilical cord at the time of birth of a normal newborn (called an umbilical cord blood transplant).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      TYPES OF BONE MARROW TRANSPLANTATION",
"     </span>",
"    </p>",
"    <p>",
"     There are two main types of bone marrow transplantation: autologous and allogeneic.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Autologous transplant",
"     </span>",
"     &nbsp;&mdash;&nbsp;In autologous transplantation, your own hematopoietic stem cells are removed before the high dose chemotherapy or radiation is given and are then frozen for storage and later use. After your chemotherapy or radiation is complete, the harvested cells are thawed and returned to you.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Allogeneic transplant",
"     </span>",
"     &nbsp;&mdash;&nbsp;In allogeneic transplantation, the hematopoietic stem cells come from a donor, ideally a brother or sister with a similar genetic makeup. If you do not have a suitably matched sibling, an unrelated person with a similar genetic makeup may be used. Under some circumstances, a parent or child who is only half-matched can also be used; this is termed a haploidentical transplant.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18872755\">",
"     <span class=\"h2\">",
"      Myeloablative transplant",
"     </span>",
"     &nbsp;&mdash;&nbsp;A myeloablative transplant uses very high doses of chemotherapy or radiation prior to transplantation with autologous or allogeneic hematopoietic stem cells.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Non-myeloablative transplant",
"     </span>",
"     &nbsp;&mdash;&nbsp;A non-myeloablative transplant, sometimes referred to as a \"mini\" or reduced intensity transplant, allows you to have less intensive chemotherapy before transplantation with allogeneic hematopoietic stem cells. This approach may be recommended for a variety of reasons including your age, type of disease, other medical issues, or prior therapies.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Which type of transplant is best?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Your physician will determine whether allogeneic or autologous transplantation is best, based on many factors including the type of cancer, your age and overall health, and the availability of a suitable donor. As a general rule, autologous transplantation is associated with fewer serious side effects, since you are given cells from your own body. However, an autologous transplant may be less effective than an allogeneic transplant in treating certain kinds of cancer.",
"    </p>",
"    <p>",
"     In an allogeneic transplant, the donor's immune system, which is generated from the transplanted hematopoietic stem cells, recognize your cells, including the tumor cells, as foreign and rejects them. This beneficial reaction is called the",
"     <strong>",
"      graft versus tumor",
"     </strong>",
"     effect. In many cancers, the immune response caused by the transplanted cells improves the overall effectiveness of the treatment. This immune response helps kill off any residual cancer cells remaining in your body.",
"    </p>",
"    <p>",
"     A major concern is that you will have an immune response against normal tissues as well, called",
"     <strong>",
"      graft versus host",
"     </strong>",
"     disease. (See",
"     <a class=\"local\" href=\"#H27\">",
"      'Graft versus host disease'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     In a non-myeloablative transplant, it is hoped that the graft versus tumor effect, rather than the high-dose chemotherapy, will help eradicate the cancer, although graft versus host disease is a concern (see",
"     <a class=\"local\" href=\"#H27\">",
"      'Graft versus host disease'",
"     </a>",
"     below).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      CHOOSING A BONE MARROW TRANSPLANT DONOR",
"     </span>",
"    </p>",
"    <p>",
"     There are many possible choices for an allogeneic hematopoietic stem cell donor. These are described below. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/38/26218?source=see_link\">",
"      \"Donor selection for hematopoietic cell transplantation\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Matched donor",
"     </span>",
"     &nbsp;&mdash;&nbsp;To help minimize the problems that can be caused by the expected immune response, a donor who has similar genetic makeup to you is preferred. Your cells will seem \"less foreign\" to the transplanted donor cells. Siblings (ie, brothers and sisters who share the same parents as you) are typically the only members of your family that are tested for being a donor because they have a one in four chance of sharing genetic characteristics with you; these characteristics are critical for your body to accept the graft. In general, parents, children, and relatives are not suitable donors since they do not share the same parents, and therefore do not have the same genetic material.",
"    </p>",
"    <p>",
"     An exception is called a haploidentical transplant, which may be considered under certain circumstances.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Matched unrelated donor",
"     </span>",
"     &nbsp;&mdash;&nbsp;If no siblings are available, or if testing the blood of the siblings does not reveal a match, a matched unrelated donor may be used. The search for an appropriate donor can be accomplished using transplant registries throughout the world.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Mismatched related donor or umbilical cord blood donor",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some patients are offered treatment with cells from a partially matched family member (called mismatched related donor). The hematopoietic stem cell product may be specially prepared to minimize the immune response in the patient. Another alternative is to use umbilical cord blood, collected from a healthy newborn infant at the time of delivery; this blood is a rich source of hematopoietic stem cells.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      PRE-BONE MARROW TRANSPLANTATION PROCEDURES",
"     </span>",
"    </p>",
"    <p>",
"     Bone marrow transplantation regimens vary from one patient to another, and depend upon the type of cancer, the treatment program used by the medical center, the clinical trial protocol (if the patient is enrolled in a clinical trial), as well as other factors. The most common components of the bone marrow transplantation procedure are outlined here. You should talk with your transplant team about specific details of their program. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/34/25130?source=see_link\">",
"      \"Preparative regimens for hematopoietic cell transplantation\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Health evaluation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Before undergoing bone marrow transplantation, you will have a complete evaluation of your health. Your complete health history is reviewed by the transplant team. Most patients also have a number of tests.",
"    </p>",
"    <p>",
"     Your mental health is reviewed because of the stress and demands of bone marrow transplantation; some patients meet with a mental health counselor to discuss concerns and to plan coping strategies.",
"    </p>",
"    <p>",
"     You will also meet with a transplant coordinator or nurse to discuss the transplant process. Because patients who receive donor bone marrow are hospitalized for several weeks to months, it is important that you have a clear understanding of what will happen and what services are available. Some patients prefer to have a friend or family member accompany them, tape record the conversation with the transplant physician, or have this information in writing so that they can review it later.",
"    </p>",
"    <p>",
"     In many cases, patients undergo bone marrow transplantation while they are in remission from their underlying disease. You may feel well going into treatment, but you should be prepared to feel poorly for a period of time. You must understand that you will require intensive treatment and monitoring, but that there are long-term benefits from the treatment.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Life planning",
"     </span>",
"     &nbsp;&mdash;&nbsp;Patients who will be in the hospital for several weeks or months need to make plans regarding their family, home, finances, pets, and employment. The National Marrow Donor Program (",
"     <a class=\"external\" href=\"file://www.marrow.org/PATIENT\">",
"      www.marrow.org/PATIENT",
"     </a>",
"     ) has excellent information about these and other bone marrow transplantation related topics.",
"    </p>",
"    <p>",
"     During the pre-transplant planning process, you should consider completing an advanced directive. This is a legal document that describes the type of care you want in case you are unable to communicate. Advanced directives include a living will, durable power of attorney, and healthcare proxy; a social worker or attorney can provide guidance about what documents are needed. The laws surrounding these documents vary from one state to another, so it is important to be sure the correct guidelines are used.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Central line placement",
"     </span>",
"     &nbsp;&mdash;&nbsp;A number of medications will be required before, during, and after bone marrow transplantation. To avoid the need for multiple intravenous lines and needle sticks, most patients will have a central line placed before treatment begins. This requires a short surgical procedure to insert a thin, flexible plastic tube into a large vein in the chest, above the heart. The line usually has two or three ports, which can be used to infuse medications or blood products (including the hematopoietic stem cell product), as well as to withdraw blood samples.",
"    </p>",
"    <p>",
"     After the central line is placed, you must keep the area clean and watch for signs and symptoms of infection (pain, redness, swelling, or fluid drainage from the site, fever or chills).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Harvesting hematopoietic stem cells",
"     </span>",
"     &nbsp;&mdash;&nbsp;If you are having an autologous transplant, hematopoietic stem cells will be removed from your body before intensive chemotherapy or radiation begins. The most common sources for hematopoietic stem cells are bone marrow and blood.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h3\">",
"      Bone marrow",
"     </span>",
"     &nbsp;&mdash;&nbsp;If your bone marrow has been invaded with cancer cells, hematopoietic stem cell removal may be preceded by one or more courses of chemotherapy. Removal (called harvest) of bone marrow stem cells is done while you are under general or epidural anesthesia. The harvest is done by using a long needle to repeatedly remove a sample of bone marrow fluid from multiple areas in your pelvic and hip bones.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h3\">",
"      Peripheral blood",
"     </span>",
"     &nbsp;&mdash;&nbsp;The harvest of peripheral blood stem cells is similar to the process of platelet donation. It uses an apparatus, called an apheresis device, which removes hematopoietic stem cells from blood by a filtration process. Blood is removed from a vein in one location, filtered, and then returned to a vein in another location. The process does not require anesthesia.",
"    </p>",
"    <p>",
"     In order for there to be sufficient numbers of hematopoietic stem cells in the blood, you (or the donor) must first be treated with either chemotherapy or a growth factor that stimulates the production of hematopoietic stem cells. Healthy donors only receive growth factor; patients with cancer may receive growth factor alone or chemotherapy plus growth factor. The most commonly used growth factor is granulocyte colony-stimulating factor (G-CSF or Neupogen&reg;).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h3\">",
"      Allogeneic bone marrow harvest",
"     </span>",
"     &nbsp;&mdash;&nbsp;People who donate their bone marrow will undergo harvest the day of transplant or one day prior. The donor is usually given general anesthesia to prevent pain.",
"    </p>",
"    <p>",
"     Following the procedure, pain in the donor is usually relatively minor and can be treated with pain medications such as acetaminophen. The donor may be hospitalized overnight following the procedure, and generally returns to his or her prior state of health within the following one to two weeks.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Myeloablative therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;As noted above, many patients receiving bone marrow transplantation will undergo myeloablative therapy, which destroys bone marrow function as part of the intensive treatment for the patient's underlying cancer. The purpose of this treatment is to reduce the amount of cancer in the body and also to suppress the immune system adequately so that the graft will not be rejected. Depending upon the underlying disease and other factors, this phase of treatment may involve intensive chemotherapy, total body irradiation (radiation therapy), or both.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      Preventing infection",
"     </span>",
"     &nbsp;&mdash;&nbsp;When bone marrow function is destroyed, you are at risk for developing life-threatening infections because you have temporarily lost your ability to produce white blood cells (the infection-fighting cells in the blood). You are also at risk for excessive bleeding due to the reduced number of platelets in the blood. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/57/32666?source=see_link\">",
"      \"Prophylaxis of infections in hematopoietic cell transplant recipients\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     It is important to minimize your exposure to bacteria, viruses, and fungi after myeloablative therapy because even a small number of organisms (that are usually encountered every day) can cause serious infection.",
"    </p>",
"    <p>",
"     Patients who undergo allogeneic transplant are often placed in protective isolation in a private room. The room's air is filtered and air from the room is forced out when the door is opened (called a positive-pressure room). This isolation, combined with feeling poorly, can be challenging to some people who may feel depressed",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     anxious. Discussing these issues with your health care team is very important.",
"    </p>",
"    <p>",
"     Special precautions are required for all persons who enter the room to reduce the chance of infection. Hand washing is one of the most important precautions, and has been shown to significantly reduce the chance of transmitting infection. Visitors should",
"     <strong>",
"      NOT",
"     </strong>",
"     bring fresh fruit, plants, or flowers into your room because these can harbor microorganisms that are dangerous.",
"    </p>",
"    <p>",
"     Other measures may be taken to reduce the chance of infection. For example, antibiotics, antifungal,",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     antiparasitic medications may be given to prevent infections, and your diet may be restricted to exclude items that contain potentially infectious organisms. For example, all foods should be cooked until hot, raw fruits and vegetables should be avoided, and drinking water should be sterilized.",
"    </p>",
"    <p>",
"     Most patients can shower. There has been a concern that showers can aerosolize fungal spores, and some centers prefer that patients take a tub or sponge bath. You can wear a hospital gown or your own clean clothing.",
"    </p>",
"    <p>",
"     Different transplant centers use different precautions and your health care team will discuss the precautions and procedures that they expect.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h2\">",
"      Blood product transfusions",
"     </span>",
"     &nbsp;&mdash;&nbsp;During the time that the marrow is not functioning, you will likely require transfusion of blood products, such as red cells, which carry oxygen to the tissues, or platelets, which help prevent bleeding. These blood products have no white blood cells and are irradiated to reduce the risk of an immune response.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H24\">",
"     <span class=\"h1\">",
"      BONE MARROW TRANSPLANTATION PROCEDURE",
"     </span>",
"    </p>",
"    <p>",
"     When the intensive chemotherapy",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     radiation are complete, you will be given an infusion of the harvested bone marrow or peripheral blood stem cells. The infusion is given through an intravenous (IV) line, usually the central line. The infusion usually takes about an hour, and usually causes no pain.",
"    </p>",
"    <p>",
"     The cells find their way to the bone marrow, where they will reestablish normal production of blood cells; this process is called engraftment. Determining when engraftment has occurred is important because it is used to determine when it is safe for you to go home",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     reduce isolation procedures. Medications that stimulate the bone marrow to produce white and red cells may be used when engraftment is slower than expected. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34664?source=see_link\">",
"      \"Hematopoietic support after hematopoietic cell transplantation\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Engraftment is measured by performing daily blood cell counts. Neutrophils are a type of white blood cell that are a marker of engraftment; the absolute neutrophil count (ANC) must be at least 500 for three days in a row to say that engraftment has occurred. This can occur as soon as 10 days after transplant, although 15 to 20 days is common for patients who are given bone marrow or peripheral blood cells. Umbilical cord blood recipients usually require between 21 and 35 days for neutrophil engraftment.",
"    </p>",
"    <p>",
"     Platelet counts are also used to determine when engraftment has occurred. The platelet count must be between 20,000 and 50,000 (without a recent platelet transfusion). This usually occurs at the same time or soon after neutrophil engraftment, but can take as long as eight weeks and even longer in some instances for people who are given umbilical cord blood.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H25\">",
"     <span class=\"h1\">",
"      BONE MARROW TRANSPLANTATION SIDE EFFECTS",
"     </span>",
"    </p>",
"    <p>",
"     The high-dose chemotherapy and total body irradiation required for bone marrow transplantation can have serious side effects. You should discuss the expected side effects, toxicities, and risks associated with bone marrow transplant before deciding to undergo the procedure. You will be asked to sign a consent form indicating that you have received verbal and written information to understand the risks and benefits of the proposed treatment, possible treatment alternatives, and that all your questions have been answered.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H26\">",
"     <span class=\"h2\">",
"      Common side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some of the most common side effects include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Mucositis&nbsp;(mouth sores) and diarrhea &mdash; Mucositis and diarrhea are caused by the damage done to rapidly dividing cells (such as skin cells in the mouth and digestive tract) by chemotherapy and radiation. If mucositis is severe and affects your ability to eat, intravenous nutrition (called TPN, total parenteral nutrition) may be given. Pain medications are usually given as well.",
"      </li>",
"      <li>",
"       Nausea and vomiting &mdash; Nausea and vomiting can be prevented and treated with a combination of medications, usually including a 5-HT3 receptor antagonist (dolasetron, granisetron, ondansetron, tropisetron, or palonosetron), an NK1 receptor antagonist (aprepitant (Emend&reg;)), and a steroid (dexamethasone).",
"      </li>",
"      <li>",
"       Loss of hair &mdash; Loss of hair is temporary, and generally includes hair on the head, face, and body. After high-dose chemotherapy and radiation are completed, hair begins to regrow. No treatment is available to prevent hair loss or speed its regrowth.",
"      </li>",
"      <li>",
"       Infertility &mdash; The risk of permanent infertility after bone marrow transplant depends upon the treatments used (high-dose chemotherapy versus total body irradiation, ablative versus non-ablative regimen) and dosage given. If you are of reproductive age, you should speak with your healthcare provider about options for lowering the risks of infertility and the option of donating eggs or sperm before treatment begins. (See",
"       <a class=\"medical medical_review\" href=\"mobipreview.htm?37/7/38010?source=see_link\">",
"        \"Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Organ toxicity &mdash; The lungs, liver, and bones are at greatest risk of damage as a result of treatments used with bone marrow transplantation. People who have total body irradiation can develop cataracts in the eyes, although this complication is less common with current methods of delivering radiation treatment.",
"      </li>",
"      <li>",
"       Secondary cancers &mdash; There is a small risk of a second cancer developing in patients who undergo bone marrow transplantation, probably as a result of the treatments used for the first cancer as well as the treatments required for transplant. The second cancer usually develops several years (typically three to five) after bone marrow transplantation. (See",
"       <a class=\"medical medical_review\" href=\"mobipreview.htm?27/39/28280?source=see_link\">",
"        \"Malignancy after hematopoietic cell transplantation\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27\">",
"     <span class=\"h2\">",
"      Graft versus host disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;Between 10 and 50 percent of patients who receive an allogeneic transplant experience a side effect known as graft versus host disease (GVHD). GVHD may be acute (developing within the first 100 days) or chronic (developing beyond 100 days). This problem does not occur following autologous transplantation (when the patient is the donor). (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/11/10425?source=see_link\">",
"      \"Prevention and treatment of acute graft-versus-host disease: Recommendations\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The \"graft\" refers to the transplanted hematopoietic stem cells; the \"host\" refers to the patient. Thus, graft versus host disease refers to a condition in which the donor's immune cells attack some of your organs. GVHD is the biggest single threat, other than the underlying disease, to the success of a bone marrow transplant.",
"    </p>",
"    <p>",
"     Treatments are given to help prevent GVHD, and generally include immunosuppressive medications, antibiotics, and sometimes steroids. If GVHD develops, additional treatment with high-dose steroids may lessen its severity. Symptoms can include skin rash, diarrhea, liver damage, or other problems, depending upon the organ that is affected. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/35/35385?source=see_link\">",
"      \"Treatment of chronic graft-versus-host disease\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H28\">",
"     <span class=\"h2\">",
"      Graft failure",
"     </span>",
"     &nbsp;&mdash;&nbsp;Failure of engraftment is a rare complication that occurs in approximately one percent of cases following bone marrow transplantation. The risk of graft failure can be higher depending upon the type of transplant and the source of hematopoietic stem cells. Discuss these risks with the transplant team prior to treatment. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/58/16298?source=see_link\">",
"      \"Immunotherapy for the prevention and treatment of relapse following hematopoietic cell transplantation\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H29\">",
"     <span class=\"h2\">",
"      Risk of death",
"     </span>",
"     &nbsp;&mdash;&nbsp;Bone marrow transplantation carries a risk of treatment-related death. The risk of death depends upon your age, the nature of the underlying disease, the type of transplant (autologous or allogeneic), and other factors, including the skill and expertise of the institution where treatment is offered. Your risk, as well as the potential benefits of bone marrow transplantation, should be discussed with the treatment team before any decision is made about undergoing a transplant procedure.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H30\">",
"     <span class=\"h1\">",
"      POST-BONE MARROW TRANSPLANTATION CARE",
"     </span>",
"    </p>",
"    <p>",
"     After engraftment occurs, blood cell counts continue to rise and the immune system becomes stronger. You will usually be cared for by the transplant team and monitored closely for complications.",
"    </p>",
"    <p>",
"     Non-myeloablative transplants may be done on an outpatient basis, allowing you to sleep at home. Other types of transplantation require you to stay in the hospital for two to three weeks following transplantation. In all cases, frequent visits to the healthcare provider's office are needed following discharge. If you live a distance from your provider, you should arrange to live in a place within reasonable driving distance to the treatment center until at least 100 days have passed since the transplant.",
"    </p>",
"    <p>",
"     Patients who undergo bone marrow transplantation are at an increased risk of infection for many months following transplantation. You should be aware of these risks and monitor yourself for symptoms of infection, including fever (temperature greater than 100.4&ordm;F or 38&ordm;C), pain, or chills. You may be given antibiotics to prevent infections.",
"    </p>",
"    <p>",
"     Studies have shown that most patients who undergo transplant and remain free of cancer have a good quality of life. Most patients are able to be active, employed, and in reasonably good health. Quality of life usually continues to improve in the months following transplant.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H31\">",
"     <span class=\"h1\">",
"      CLINICAL TRIALS",
"     </span>",
"    </p>",
"    <p>",
"     A clinical trial is a carefully controlled way to study the effectiveness of new treatments or new combinations of known therapies, and patients who will undergo bone marrow transplantation may be asked to participate. Ask a healthcare provider for more information about clinical trials, or read further at the following web sites.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Cancer Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.gov/clinicaltrials/\">",
"      www.cancer.gov/clinicaltrials/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://clinicaltrials.gov/\">",
"      file://clinicaltrials.gov/",
"     </a>",
"     )",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H32\">",
"     <span class=\"h1\">",
"      SUMMARY",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Bone marrow transplantation (BMT) is a treatment used in some types of cancer.",
"      </li>",
"      <li>",
"       Bone marrow is the soft, spongy area in the center of some of the larger bones of the body. The marrow produces all of the different cells that make up the blood, such as red blood cells, white blood cells, and platelets. All of these cells develop from a type of basic cell found in the bone marrow, called a stem cell.",
"      </li>",
"      <li>",
"       In bone marrow transplantation, the patient is given very high doses of chemotherapy or radiation therapy, which kills cancer cells and destroys all the normal cells developing in the bone marrow, including the critical stem cells. After the treatment, the patient must have a healthy supply of hematopoietic stem cells reintroduced, or transplanted.",
"      </li>",
"      <li>",
"       There are two types of bone marrow transplantation, autologous and allogeneic. An autologous bone marrow transplant uses a patient's own bone marrow or blood. An allogeneic bone marrow transplant uses a donor's bone marrow or blood. The donor is usually a relative of the patient (eg, sister), although unrelated donors are sometimes used.",
"      </li>",
"      <li>",
"       Most patients who have bone marrow transplantation must remain in the hospital for several days or weeks during their treatment and recovery. It is important to understand and follow the hospital's bone marrow transplantation treatment plan to minimize the risk of complications (eg, infection) and to know what to expect in advance.",
"      </li>",
"      <li>",
"       The treatments required before and during bone marrow transplantation can have serious side effects. Patients should be aware of the most common side effects (eg, diarrhea, nausea, vomiting, mouth sores) as well as the types of treatments that are available to improve comfort.",
"      </li>",
"      <li>",
"       Following bone marrow transplantation, most people stay in the hospital for several weeks. However, even after going home, frequent visits with a doctor or nurse are needed for 3 to 6 months.",
"      </li>",
"      <li>",
"       Clinical trials are carefully controlled studies of new treatments or new combinations of current treatment. Clinical trials help researchers to learn the best way to treat specific conditions. Some patients who have bone marrow transplantation will be asked to participate in a clinical trial.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H33\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H364378\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H364385\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/47/2802?source=see_link\">",
"      Patient information: Bone marrow transplant (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/13/38098?source=see_link\">",
"      Patient information: Leukemia in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/40/24194?source=see_link\">",
"      Patient information: Leukemia in children (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/28/40386?source=see_link\">",
"      Patient information: Lymphoma (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?15/15/15602?source=see_link\">",
"      Patient information: Acute lymphoblastic leukemia (ALL) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?14/4/14402?source=see_link\">",
"      Patient information: Acute myeloid leukemia (AML) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/39/12914?source=see_link\">",
"      Patient information: Chronic lymphocytic leukemia (CLL) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/58/12194?source=see_link\">",
"      Patient information: Chronic myeloid leukemia (CML) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/19/26930?source=see_link\">",
"      Patient information: Diffuse large B-cell lymphoma (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/23/18802?source=see_link\">",
"      Patient information: Follicular lymphoma (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/10/23714?source=see_link\">",
"      Patient information: Hodgkin lymphoma in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/50/31523?source=see_link\">",
"      Patient information: Hodgkin lymphoma in children (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/1/9234?source=see_link\">",
"      Patient information: Myelodysplastic syndromes (MDS) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/8/4227?source=see_link\">",
"      Patient information: Sickle cell anemia (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/17/29970?source=see_link\">",
"      Patient information: Immune thrombocytopenia (ITP) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/14/7394?source=see_link\">",
"      Patient information: Thalassemia (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/19/8498?source=see_link\">",
"      Patient information: Chronic granulomatous disease (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/23/12658?source=see_link\">",
"      Patient information: Invasive aspergillosis (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H364402\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     This topic currently has no corresponding Beyond the Basics content.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H364419\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/38/26218?source=see_link\">",
"      Donor selection for hematopoietic cell transplantation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34664?source=see_link\">",
"      Hematopoietic support after hematopoietic cell transplantation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/58/16298?source=see_link\">",
"      Immunotherapy for the prevention and treatment of relapse following hematopoietic cell transplantation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/34/25130?source=see_link\">",
"      Preparative regimens for hematopoietic cell transplantation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/11/10425?source=see_link\">",
"      Prevention and treatment of acute graft-versus-host disease: Recommendations",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/49/38682?source=see_link\">",
"      Sources of hematopoietic stem cells",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/35/35385?source=see_link\">",
"      Treatment of chronic graft-versus-host disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/57/32666?source=see_link\">",
"      Prophylaxis of infections in hematopoietic cell transplant recipients",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/7/38010?source=see_link\">",
"      Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/39/28280?source=see_link\">",
"      Malignancy after hematopoietic cell transplantation",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Marrow Donor Program",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.marrow.org/\">",
"      www.marrow.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Cancer Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.gov/\">",
"      www.cancer.gov/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Cancer Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.org/\">",
"      www.cancer.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Leukemia &amp; Lymphoma Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.leukemia-lymphoma.org/\">",
"      www.leukemia-lymphoma.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Bone Marrow Transplant Link",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nbmtlink.org/\">",
"      www.nbmtlink.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The American Society of Clinical Oncology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.net/portal/site/patient\">",
"      www.cancer.net/portal/site/patient",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?34/4/34886/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 3, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?34/4/34886?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34886/abstract/1\">",
"      Soci&eacute; G, Mary JY, Esperou H, et al. Health and functional status of adult recipients 1 year after allogeneic haematopoietic stem cell transplantation. Br J Haematol 2001; 113:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34886/abstract/2\">",
"      Chiodi S, Spinelli S, Ravera G, et al. Quality of life in 244 recipients of allogeneic bone marrow transplantation. Br J Haematol 2000; 110:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34886/abstract/3\">",
"      Dominietto A, Raiola AM, van Lint MT, et al. Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft-versus-host disease, donor type, cytomegalovirus infections and cell dose. Br J Haematol 2001; 112:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34886/abstract/4\">",
"      L&eacute;ger CS, Nevill TJ. Hematopoietic stem cell transplantation: a primer for the primary care physician. CMAJ 2004; 170:1569.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f34_4_34886=[""].join("\n");
var outline_f34_4_34886=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           BONE MARROW TRANSPLANTATION OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           TYPES OF BONE MARROW TRANSPLANTATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           CHOOSING A BONE MARROW TRANSPLANT DONOR",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           PRE-BONE MARROW TRANSPLANTATION PROCEDURES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H24\">",
"           BONE MARROW TRANSPLANTATION PROCEDURE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H25\">",
"           BONE MARROW TRANSPLANTATION SIDE EFFECTS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H30\">",
"           POST-BONE MARROW TRANSPLANTATION CARE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H31\">",
"           CLINICAL TRIALS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H32\">",
"           SUMMARY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H33\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f34_4_34887="Nicotine: Drug information";
var content_f34_4_34887=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nicotine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?24/29/25046?source=see_link\">",
"    see \"Nicotine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F201268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Commit&reg; [OTC];",
"     </li>",
"     <li>",
"      NicoDerm&reg; CQ&reg; [OTC];",
"     </li>",
"     <li>",
"      Nicorelief&reg; [OTC];",
"     </li>",
"     <li>",
"      Nicorette&reg; [OTC];",
"     </li>",
"     <li>",
"      Nicotrol&reg; Inhaler;",
"     </li>",
"     <li>",
"      Nicotrol&reg; NS;",
"     </li>",
"     <li>",
"      Thrive&trade; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F201269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Habitrol&reg;;",
"     </li>",
"     <li>",
"      Nicoderm&reg;;",
"     </li>",
"     <li>",
"      Nicorette&reg;;",
"     </li>",
"     <li>",
"      Nicorette&reg; Plus;",
"     </li>",
"     <li>",
"      Nicotrol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F201309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Smoking Cessation Aid",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F201272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tobacco cessation (patients should be advised to completely stop smoking upon initiation of therapy):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Gum:",
"     </i>",
"     Chew 1 piece of gum when urge to smoke, up to 24 pieces/day. Patients who smoke &lt;25 cigarettes/day should start with 2-mg strength; patients smoking &ge;25 cigarettes/day should start with the 4-mg strength. Use according to the following 12-week dosing schedule:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Weeks 1-6: Chew 1 piece of gum every 1-2 hours; to increase chances of quitting, chew at least 9 pieces/day during the first 6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Weeks 7-9: Chew 1 piece of gum every 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Weeks 10-12: Chew 1 piece of gum every 4-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Inhaler:",
"     </i>",
"     Oral: Usually 6-16 cartridges per day; best effect was achieved by frequent continuous puffing (20 minutes); recommended duration of treatment is 3 months, after which patients may be weaned from the inhaler by gradual reduction of the daily dose over 6-12 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Lozenge:",
"     </i>",
"     Oral: Patients who smoke their first cigarette within 30 minutes of waking should use the 4-mg strength; otherwise the 2-mg strength is recommended. Use according to the following 12-week dosing schedule:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Weeks 1-6: One lozenge every 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Weeks 7-9: One lozenge every 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Weeks 10-12: One lozenge every 4-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Use at least 9 lozenges/day during first 6 weeks to improve chances of quitting; do not use more than one lozenge at a time (maximum: 5 lozenges every 6 hours, 20 lozenges/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Spray:",
"     </i>",
"     Nasal: 1-2 sprays/hour; do not exceed more than 5 doses (10 sprays) per hour [maximum: 40 doses/day (80 sprays); each dose (2 sprays) contains 1 mg of nicotine]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Transdermal patch:",
"     </i>",
"     Topical: Apply new patch every 24 hours to nonhairy, clean, dry skin on the upper body or upper outer arm; each patch should be applied to a different site.",
"     <b>",
"      Note:",
"     </b>",
"     Adjustment may be required during initial treatment (move to higher dose if experiencing withdrawal symptoms; lower dose if side effects are experienced).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     NicoDerm CQ&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Patients smoking &gt;10 cigarettes/day: Begin with step 1 (21 mg/day) for 6 weeks,",
"     <b>",
"      followed by",
"     </b>",
"     step 2 (14 mg/day) for 2 weeks;",
"     <b>",
"      finish with",
"     </b>",
"     step 3 (7 mg/day) for 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Patients smoking &le;10 cigarettes/day: Begin with step 2 (14 mg/day) for 6 weeks,",
"     <b>",
"      followed by",
"     </b>",
"     step 3 (7 mg/day) for 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients who are receiving &gt;600 mg/day of cimetidine: Decrease to the next lower patch size",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Benefits of use of nicotine transdermal patches beyond 3 months have not been demonstrated",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F201273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F201244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gum, chewing, oral, as polacrilex: 2 mg (20s, 40s, 50s, 100s, 110s); 4 mg (20s, 40s, 50s, 100s, 110s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nicorelief&reg;: 2 mg (50s, 110s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nicorelief&reg;: 2 mg (50s, 110s) [mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nicorelief&reg;: 4 mg (50s, 110s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nicorelief&reg;: 4 mg (50s, 110s) [mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nicorette&reg;: 2 mg (40s, 100s) [fresh mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nicorette&reg;: 2 mg (48s, 50s, 108s, 110s, 168s, 170s, 192s, 200s, 216s) [mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nicorette&reg;: 2 mg (48s, 108s) [orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nicorette&reg;: 2 mg (48s, 50s, 108s, 110s, 168s, 170s, 192s, 200s, 216s) [original flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nicorette&reg;: 2 mg (40s, 100s) [contains calcium 94 mg/gum, sodium 11 mg/gum; fruit chill flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nicorette&reg;: 4 mg (40s, 100s) [fresh mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nicorette&reg;: 4 mg (48s, 108s, 110s, 168s, 170s, 192s, 200s, 216s) [mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nicorette&reg;: 4 mg (48s, 108s, 110s) [orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nicorette&reg;: 4 mg (48s, 50s, 108s, 110s, 168s, 170s, 192s, 200s, 216s) [original flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nicorette&reg;: 4 mg (40s, 100s) [contains calcium 94 mg/gum, sodium 13 mg/gum; fruit chill flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Thrive&trade;: 2 mg (40s); 4 mg (40s) [gluten free, sucrose free; mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lozenge, oral, as polacrilex:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Commit&reg;: 2 mg, 4 mg [gluten free, sugar free; contains phenylalanine 3.4 mg/lozenge, sodium 18 mg/lozenge; mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nicorelief&reg;: 2 mg, 4 mg [contains phenylalanine 5.1 mg/lozenge, sodium 16 mg/lozenge; mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nicorette&reg;: 4 mg [mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral inhalation system, for oral inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nicotrol&reg; Inhaler: 10 mg (10 mL) [contains menthol; delivering 4 mg nicotine]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patch, transdermal: 7 mg/24 hours (7s, 14s); 14 mg/24 hours (7s, 14s); 21 mg/24 hours (7s, 14s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NicoDerm&reg; CQ&reg;: 7 mg/24 hours (14s) [contains metal; step 3; clear patch]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NicoDerm&reg; CQ&reg;: 7 mg/24 hours (14s) [contains metal; step 3; tan patch]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NicoDerm&reg; CQ&reg;: 14 mg/24 hours (14s) [contains metal; step 2; clear patch]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NicoDerm&reg; CQ&reg;: 14 mg/24 hours (14s) [contains metal; step 2; tan patch]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NicoDerm&reg; CQ&reg;: 21 mg/24 hours (7s, 14s) [contains metal; step 1; clear patch]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NicoDerm&reg; CQ&reg;: 21 mg/24 hours (7s, 14s) [contains metal; step 1; tan patch]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal [spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nicotrol&reg; NS: 10 mg/mL (10 mL) [chlorofluorocarbon free; delivers ~0.5 mg/spray; ~200 sprays]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F201229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Transdermal patch and gum",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F201248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gum: Should be chewed slowly to avoid jaw ache and to maximize benefit. Chew slowly until it tingles, then park gum between cheek and gum until tingle is gone; repeat process until most of tingle is gone (~30 minutes).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lozenge: Should not be chewed or swallowed; allow to dissolve slowly (~20-30 minutes)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Nasal spray: Prime pump prior to first use (pump 6-8 times until fine spray appears) or if it has not been used for 24 hours (pump 1-2 times). Blow nose prior to use. Tilt head back slightly and insert tip of bottle into nostril. Breathe through mouth and spray once in each nostril. Do not sniff, swallow, or inhale through the nose during administration. After administration, wait 2-3 minutes before blowing nose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral Inhalant: Insert cartridge into inhaler and push hard until it pops into place.  Replace mouthpiece and twist the top and bottom so that markings do not line up. Inhale deeply into the back of the throat or puff in short breaths. Nicotine in cartridge is used up after about 20 minutes of active puffing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Transdermal patch: Do not cut patch; causes rapid evaporation, rendering the patch useless",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F201247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment to aid smoking cessation for the relief of nicotine withdrawal symptoms (including nicotine craving)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F201305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of ulcerative colitis (transdermal)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F201316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       NicoDerm&reg; may be confused with Nitroderm",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Nicorette&reg; may be confused with Nordette&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Transdermal patch may contain conducting metal (eg, aluminum); remove patch prior to MRI.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F201307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nasal spray/inhaler:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Central nervous system: Headache (18% to 26%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Gastrointestinal: Inhaler: Mouth/throat irritation (66%), dyspepsia (18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Respiratory: Inhaler: Cough (32%), rhinitis (23%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Dermatologic: Acne (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dysmenorrhea (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Gastrointestinal: Flatulence (4%), gum problems (4%), diarrhea, hiccup, nausea, taste disturbance, tooth abrasions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (6%), arthralgia (5%), jaw/neck pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Respiratory: Nasal burning (nasal spray), sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Miscellaneous: Withdrawal symptoms",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Allergy, amnesia, aphasia, bronchitis, bronchospasm, edema, migraine, numbness, pain, purpura, rash, sputum increased, vision abnormalities, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Adverse events previously reported in prescription labeling for chewing gum, lozenge and/or transdermal systems. Frequency not defined; may be product or dose specific:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Concentration impaired, depression, dizziness, headache, insomnia, nervousness, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Aphthous stomatitis, constipation, cough, diarrhea, dyspepsia, flatulence, gingival bleeding, glossitis, hiccups, jaw pain, nausea, salivation increased, stomatitis, taste perversion, tooth abrasions, ulcerative stomatitis, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Application site reaction, local edema, local erythema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, myalgia, paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F201251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to nicotine or any component of the formulation; patients who are smoking during the postmyocardial infarction period; patients with life-threatening arrhythmias, or severe or worsening angina pectoris; active temporomandibular joint disease (gum); pregnancy; not for use in nonsmokers",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F201233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: The risk versus the benefits should be weighed in patients with CAD, serious cardiac arrhythmias, or vasospastic disease; use caution in patients with angina, hypertension, or recent MI.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with insulin-dependent diabetes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal disease: Use with caution in patients with oropharyngeal inflammation, history of esophagitis, or  peptic ulcer disease; healing may be delayed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment; effects on metabolism unknown.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperthyroidism: Use with caution in patients with hyperthyroidism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pheochromocytoma: Use with caution in patients with pheochromocytoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment; effects on elimination unknown.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Chewing gum: Dental problems may be worsened by chewing gum.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Inhaler: Use with caution in patients with bronchospastic disease due to potential airway irritation (other forms of nicotine replacement may be preferred).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nasal products: Use of nasal product is not recommended with chronic nasal disorders (eg, allergy, rhinitis, nasal polyps, and sinusitis). Exacerbations of bronchospasm has been reported in patients with pre-existing asthma; use in patients with severe reactive airway disease is not recommended. Nasal mucosa irritation may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Topical products:  Cautious use of topical nicotine in patients with certain skin diseases. Hypersensitivity to the topical products can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Transdermal patch: May contain conducting metal (eg, aluminum); remove patch prior to MRI.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use:  Urge patients to stop smoking completely when initiating therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F201303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2A6 (minor), CYP2B6 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2A6 (weak), CYP2E1 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F201238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adenosine: Nicotine may enhance the AV-blocking effect of Adenosine. Nicotine may enhance the tachycardic effect of Adenosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of Nicotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F201265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Lozenge: Acidic foods/beverages decrease absorption of nicotine.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F201240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (nasal) (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2725078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nicotine is teratogenic in animal studies. Nicotine exposure via cigarette smoke may cause increased ectopic pregnancy, low birth weight, increased risk of spontaneous abortion, increased perinatal mortality; increased aortic blood flow, increased heart rate, decreased uterine blood flow, and decreased breathing have been reported in the fetus. Smoking during pregnancy is associated with sudden infant death syndrome (SIDS), an increased risk of asthma, infantile colic, and childhood obesity. Women who are pregnant should be encouraged not to smoke. The use of nicotine replacement products to aid in smoking cessation has not been adequately studied in pregnant women (amount of nicotine exposure is varied). Nonpharmacologic treatments are recommended. If the benefits of nicotine replacement therapy outweigh the unknown risks, products with intermittent dosing are suggested to be tried first. If a patch is used, it is suggested to remove it overnight while sleeping to decrease fetal exposure.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F201276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F2725080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nicotine from cigarette smoke is found in breast milk at 1.5-3 times the maternal plasma concentrations. The amount from nicotine replacement products is not known. Women who are breast-feeding are encouraged not to smoke.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F201255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Some products may contain phenylalanine and/or sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F201254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gum",
"     </b>",
"     (Nicorelief Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (50): $29.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (50): $29.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gum",
"     </b>",
"     (Nicorette Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (100): $49.43",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (100): $49.43",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gum",
"     </b>",
"     (Nicorette Refill Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (192): $70.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (192): $70.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gum",
"     </b>",
"     (Nicorette Starter Kit Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (100): $49.43",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (110): $49.43",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gum",
"     </b>",
"     (Nicotine Polacrilex Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (110): $30.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (110): $41.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Inhalation",
"     </b>",
"     (Nicotrol Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (168): $259.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Nicotine Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     21-14-7 mg/24 hrs (56): $102.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lozenge",
"     </b>",
"     (Commit Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (48): $28.03",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (48): $28.03",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lozenge",
"     </b>",
"     (NICOrelief Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (72): $51.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (72): $51.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lozenge",
"     </b>",
"     (Nicorette Mini Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (81): $42.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (81): $42.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lozenge",
"     </b>",
"     (Nicorette Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (72): $39.37",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (72): $39.37",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lozenge",
"     </b>",
"     (Nicotine Polacrilex Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (72): $38.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (108): $54.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Patch, 24-hour",
"     </b>",
"     (Nicoderm CQ Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7 mg/24 hrs (7): $27.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     14 mg/24 hrs (14): $49.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     21 mg/24 hrs (7): $28.57",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Patch, 24-hour",
"     </b>",
"     (Nicotine Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7 mg/24 hrs (14): $39.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     14 mg/24 hrs (14): $38.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     21 mg/24 hrs (14): $38.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Nicotrol NS Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (10 mL): $64.87",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F201242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Heart rate and blood pressure periodically during therapy; discontinue therapy if signs of nicotine toxicity occur (eg, severe headache, dizziness, mental confusion, disturbed hearing and vision, abdominal pain; rapid, weak and irregular pulse; salivation, nausea, vomiting, diarrhea, cold sweat, weakness); therapy should be discontinued if rash develops; discontinuation may be considered if other adverse effects of patch occur such as myalgia, arthralgia, abnormal dreams, insomnia, nervousness, dry mouth, sweating",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F201256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Habitrol Gum (NZ);",
"     </li>",
"     <li>",
"      Nicabate (AU);",
"     </li>",
"     <li>",
"      Nicabate Clear (AU);",
"     </li>",
"     <li>",
"      Nicabate CQ (NZ);",
"     </li>",
"     <li>",
"      Nicabate Lozenges (AU);",
"     </li>",
"     <li>",
"      Nicabate Soft Gum (AU);",
"     </li>",
"     <li>",
"      Nicoman (KP);",
"     </li>",
"     <li>",
"      Nicomild (TH);",
"     </li>",
"     <li>",
"      Nicopass sans sucre menthe fraicheur (FR);",
"     </li>",
"     <li>",
"      Nicopass sans sucre reghsse menthe (FR);",
"     </li>",
"     <li>",
"      Nicopatch (FR);",
"     </li>",
"     <li>",
"      Nicorest (FR);",
"     </li>",
"     <li>",
"      Nicorette (AE, AT, AU, BE, BF, BG, BH, BJ, BR, CH, CI, CL, CN, CO, CR, CY, CZ, DE, DK, EC, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, GT, HK, HN, HU, IL, IQ, IR, IT, JO, JP, KE, KW, LB, LR, LU, LY, MA, ML, MR, MT, MU, MW, MY, NE, NG, NI, NL, NO, NZ, OM, PA, PL, QA, RU, SA, SC, SD, SE, SG, SK, SL, SN, SV, SY, TH, TN, TW, TZ, UG, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Nicorette Fruit (FR);",
"     </li>",
"     <li>",
"      Nicorette Inhaler (AU);",
"     </li>",
"     <li>",
"      Nicorette Menthe (AE, BH, CY, EG, FR, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Nicorette Menthe Fraiche (FR);",
"     </li>",
"     <li>",
"      Nicorette Orange (FR);",
"     </li>",
"     <li>",
"      Nicorette Orange sans sucre (FR);",
"     </li>",
"     <li>",
"      Nicostop (PT);",
"     </li>",
"     <li>",
"      Nicotab (SE);",
"     </li>",
"     <li>",
"      Nicotinell (AT, AU, BE, BG, CH, DE, DK, FI, FR, GB, GR, IE, IT, NL, NO, PL, PT, SE, TR);",
"     </li>",
"     <li>",
"      Nicotinell Chewing Gum (HK);",
"     </li>",
"     <li>",
"      Nicotinell Fruit sans sucre (FR);",
"     </li>",
"     <li>",
"      Nicotinell Menthe sans sucre (FR);",
"     </li>",
"     <li>",
"      Nicotinell Mint Lozenge (KP);",
"     </li>",
"     <li>",
"      Nicotinell TTS (AE, AR, BB, BF, BH, BJ, BM, BS, BZ, CI, CN, CY, EE, EG, ET, FR, GH, GM, GN, GY, HK, HR, HU, IL, IQ, IR, JM, JO, KE, KP, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, MX, MY, NE, NG, NZ, OM, PH, PR, PY, QA, SA, SC, SD, SL, SN, SR, SY, TH, TN, TT, TW, TZ, UG, UY, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Nicotrans (IT);",
"     </li>",
"     <li>",
"      Nicotrol Gum (NZ);",
"     </li>",
"     <li>",
"      Nikofrenon (DE);",
"     </li>",
"     <li>",
"      Niquitin (BR, CO, MX);",
"     </li>",
"     <li>",
"      Niquitin CQ (IL, SG);",
"     </li>",
"     <li>",
"      Niquitin CQ Clear (IL);",
"     </li>",
"     <li>",
"      Niquitin Mint (TW);",
"     </li>",
"     <li>",
"      Niquitin sans sucre (FR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F201232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nicotine is one of two naturally-occurring alkaloids which exhibit their primary effects via autonomic ganglia stimulation. The other alkaloid is lobeline which has many actions similar to those of nicotine but is less potent. Nicotine is a potent ganglionic and central nervous system stimulant, the actions of which are mediated via nicotine-specific receptors. Biphasic actions are observed depending upon the dose administered. The main effect of nicotine in small doses is stimulation of all autonomic ganglia; with larger doses, initial stimulation is followed by blockade of transmission. Biphasic effects are also evident in the adrenal medulla; discharge of catecholamines occurs with small doses, whereas prevention of catecholamines release is seen with higher doses as a response to splanchnic nerve stimulation. Stimulation of the central nervous system (CNS) is characterized by tremors and respiratory excitation. However, convulsions may occur with higher doses, along with respiratory failure secondary to both central paralysis and peripheral blockade to respiratory muscles.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F201250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Intranasal: More closely approximate the time course of plasma nicotine levels observed after cigarette smoking than other dosage forms",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Transdermal: 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Transdermal: Slow",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic, primarily to cotinine (",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      5",
"     </sub>",
"     as active)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 4 hours; Nasal spray: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Transdermal: 8-9 hours; Nasal spray: 10-20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Renal: pH dependent",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ACOG Committee Opinion, Number 316, October 2005, &ldquo;Smoking Cessation During Pregnancy,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2005, 106(4):883-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/4/34887/abstract-text/16199654/pubmed\" id=\"16199654\" target=\"_blank\">",
"        16199654",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;American Academy of Pediatrics Committee on Drugs. The Transfer of Drugs and Other Chemicals Into Human Milk,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/4/34887/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Benowitz NL, &ldquo;Pharmacologic Aspects of Cigarette Smoking and Nicotine Addiction,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1988, 319(20):1318-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/4/34887/abstract-text/3054551/pubmed\" id=\"3054551\" target=\"_blank\">",
"        3054551",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Benowitz NL, Jacob P 3rd, and Sachs DP, &ldquo;Deficient C-oxidation of Nicotine,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1995, 57(5):590-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/4/34887/abstract-text/7768082/pubmed\" id=\"7768082\" target=\"_blank\">",
"        7768082",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blanchard J, &ldquo;Nicotine,&rdquo;",
"      <i>",
"       Clin Toxicol Rev",
"      </i>",
"      , 1993, 15:11-2.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guslandi M, &ldquo;Long-Term Effects of a Single Course of Nicotine Treatment in Acute Ulcerative Colitis: Remission Maintenance in a 12-month Follow-up Study,&rdquo;",
"      <i>",
"       Int J Colorectal Dis",
"      </i>",
"      , 1999, 14(4-5):261-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/4/34887/abstract-text/10647637/pubmed\" id=\"10647637\" target=\"_blank\">",
"        10647637",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Harchelroad F, Potts K, Burdick J, et al, &ldquo;Oral Absorption of Nicotine From Transdermal Therapeutic Systems,&rdquo;",
"      <i>",
"       Vet Hum Toxicol",
"      </i>",
"      , 1992, 34:332.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Landesman-Dwyer S and Emanuel I, &ldquo;Smoking During Pregnancy,&rdquo;",
"      <i>",
"       Teratology",
"      </i>",
"      , 1979, 19(1):119-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/4/34887/abstract-text/377552/pubmed\" id=\"377552\" target=\"_blank\">",
"        377552",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Li Wan Po A, &ldquo;Transdermal Nicotine in Smoking Cessation. A Meta-Analysis,&rdquo;",
"      <i>",
"       Eur J Clin Pharmacol",
"      </i>",
"      , 1993, 45(6):519-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/4/34887/abstract-text/8157037/pubmed\" id=\"8157037\" target=\"_blank\">",
"        8157037",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Luck W and Nau H, &ldquo;Nicotine and Cotinine Concentrations in Serum and Urine of Infants Exposed Via Passive Smoking or Milk From Smoking Mothers,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1985, 107(5):816-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/4/34887/abstract-text/4056988/pubmed\" id=\"4056988\" target=\"_blank\">",
"        4056988",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McGee D, Brabson T, McCarthy J, et al, &ldquo;Four-Year Review of Cigarette Ingestions in Children,&rdquo;",
"      <i>",
"       Pediatr Emerg Care",
"      </i>",
"      , 1995, 11(1):13-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/4/34887/abstract-text/7739954/pubmed\" id=\"7739954\" target=\"_blank\">",
"        7739954",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ottervanger JP, Festen JM, de Vries AG, et al, &ldquo;Acute Myocardial Infarction While Using The Nicotine,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 1995, 107(6):1765-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/4/34887/abstract-text/7781384/pubmed\" id=\"7781384\" target=\"_blank\">",
"        7781384",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pattishall EN, Strope GL, Etzel RA, et al, &ldquo;Serum Cotinine as a Measure of Tobacco Smoke Exposure in Children,&rdquo;",
"      <i>",
"       Am J Dis Child",
"      </i>",
"      , 1985, 139(11):1101-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/4/34887/abstract-text/4061405/pubmed\" id=\"4061405\" target=\"_blank\">",
"        4061405",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ross MP, Revolinski D, and Taurman L, &ldquo;Green Tobacco Sickness Among Adults in Kentucky,&rdquo;",
"      <i>",
"       Vet Hum Toxicol",
"      </i>",
"      , 1994, 36:360.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sandborn WJ, &ldquo;Nicotine Therapy for Ulcerative Colitis: A Review of Rationale, Mechanisms, Pharmacology, and Clinical Results,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 1999, 94(5):1161-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/4/34887/abstract-text/10235187/pubmed\" id=\"10235187\" target=\"_blank\">",
"        10235187",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sandborn WJ, Tremaine WJ, Offord KP, et al, &ldquo;Transdermal Nicotine for Mildly to Moderately Active Ulcerative Colitis. A Randomized, Double-blind, Placebo-Controlled Trial,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1997, 126(5):364-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/4/34887/abstract-text/9054280/pubmed\" id=\"9054280\" target=\"_blank\">",
"        9054280",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smolinske SC, Spoerke DG, Spiller SK, et al, &ldquo;Cigarette and Nicotine Chewing Gum Toxicity in Children,&rdquo;",
"      <i>",
"       Hum Toxicol",
"      </i>",
"      , 1988, 7(1):27-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/4/34887/abstract-text/3346035/pubmed\" id=\"3346035\" target=\"_blank\">",
"        3346035",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Svensson CK, &ldquo;Clinical Pharmacokinetics of Nicotine,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1987, 12(1):30-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/4/34887/abstract-text/3545615/pubmed\" id=\"3545615\" target=\"_blank\">",
"        3545615",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thomas GA, Rhodes J, Mani V, et al, &ldquo;Transdermal Nicotine as Maintenance Therapy for Ulcerative Colitis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1995, 332(15):988-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/4/34887/abstract-text/7885427/pubmed\" id=\"7885427\" target=\"_blank\">",
"        7885427",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Transdermal Nicotine Study Group, &ldquo;Transdermal Nicotine for Smoking Cessation. Six-month Results from Two Multicenter Controlled Clinical Trials,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1991, 266(22):3133-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/4/34887/abstract-text/1956099/pubmed\" id=\"1956099\" target=\"_blank\">",
"        1956099",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Westman EC, Levin ED, and Rose JE, &ldquo;The Nicotine Patch in Smoking Cessation,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1993, 153(16):1917-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/4/34887/abstract-text/8250653/pubmed\" id=\"8250653\" target=\"_blank\">",
"        8250653",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wynn RL, &ldquo;Nicotine Patches in Smoking Cessation,&rdquo;",
"      <i>",
"       AGD Impact",
"      </i>",
"      , 1994, 22:14.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9698 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.66.252.144-2A34E2F131-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_4_34887=[""].join("\n");
var outline_f34_4_34887=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201268\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201269\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201309\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201272\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201273\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201244\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201229\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201248\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201247\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201305\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201316\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201307\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201251\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201233\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201303\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201238\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201265\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201240\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2725078\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201276\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2725080\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201255\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201254\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201242\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201256\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201232\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201250\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9698\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9698|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?24/29/25046?source=related_link\">",
"      Nicotine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_4_34888="Cerebrotendinous xanthomatosis";
var content_f34_4_34888=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cerebrotendinous xanthomatosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/4/34888/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/4/34888/contributors\">",
"     Amy T Waldman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/4/34888/contributors\">",
"     Alan K Percy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/4/34888/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/4/34888/contributors\">",
"     Francisco Gonzalez-Scarano, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/4/34888/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/4/34888/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/4/34888/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/4/34888/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebrotendinous xanthomatosis (CTX; MIM 213700) is an autosomal recessive lipid storage disease caused by disruption of bile acid synthesis that was first described in 1937 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/1\">",
"     1",
"    </a>",
"    ]. A deficiency of the enzyme sterol 27-hydroxylase causes the accumulation of cholesterol and cholestanol in virtually all tissues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/2\">",
"     2",
"    </a>",
"    ]. As its name suggests, xanthomas, nodules, or plaques caused by fat deposition form in the central nervous system, tendons, skin, lungs, and bones.",
"   </p>",
"   <p>",
"    CTX is one of a group of neurologic disorders, collectively referred to as leukodystrophies, which predominantly affect the central nervous system (CNS) white matter. These disorders are caused by defects in the synthesis or maintenance of the myelin sheath that insulates the nerves.",
"   </p>",
"   <p>",
"    The main neurologic features of CTX are cerebellar ataxia, pyramidal tract signs, and intellectual decline. One or more of these is usually apparent by late childhood or early adulthood. The syndrome is slowly progressive, and while there is no cure, its course can be altered with treatment.",
"   </p>",
"   <p>",
"    This topic will review the pathogenesis, clinical features, diagnosis, and treatment of CTX.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of cerebrotendinous xanthomatosis (CTX) involves a genetic defect in the CYP27A1 gene that causes derangements of lipid metabolism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;CTX is caused by mutations in the CYP27A1 gene on chromosome 2q33-qter that encodes the mitochondrial enzyme sterol 27-hydroxylase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Deficiency of this enzyme, a member of the cytochrome P-450 enzyme family, results in increased cholestanol and cholesterol.",
"   </p>",
"   <p>",
"    Fifty-four different mutations have been described in CYP27A1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. No correlation between genotype and phenotype has been established. The same missense mutation has been found in both spinal xanthomatosis and the classic form of CTX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inheritance of CTX is autosomal recessive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Lipid derangements",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal catabolism of cholesterol depends on the formation of primary bile acids (cholic acid and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33076?source=see_link\">",
"     chenodeoxycholic acid",
"    </a>",
"    ) through various sterol intermediates. Ten different enzymes are required for the hydroxylation of the four-membered cholesterol ring structure in the endoplasmic reticulum and cytosol, and oxidation of its eight-carbon side chain in the mitochondria and peroxisomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/7-9\">",
"     7-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sterol 27-hydroxylase, in the presence of co-factors ferredoxin and NADPH-ferredoxin reductase, catalyzes the hydroxylation of 5 beta-cholestane-3 alpha,7 alpha,12 alpha-triol at C27 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/3\">",
"     3",
"    </a>",
"    ]. The deficiency of sterol 27-hydroxylase leads to the accumulation of cholestanol and cholesterol.",
"   </p>",
"   <p>",
"    The disruption of bile acid synthesis in CTX leads to the upregulation of CYP7A, the gene encoding cholesterol 7 alpha-hydroxylase, which catalyzes the rate-limiting step of bile acid synthesis, the conversion of cholesterol and 7 alpha-hydroxycholesterol to cholestanol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hydrophobic bile acids are required to activate heterodimers that, in turn, reduce CYP7A transcription. However, in CTX, levels of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33076?source=see_link\">",
"     chenodeoxycholic acid",
"    </a>",
"    , which is highly hydrophobic, are decreased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. Nevertheless, the exogenous administration of chenodeoxycholic acid has been shown to downregulate CYP7A transcription [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bile acids are also necessary for feedback inhibition of hepatic hydroxymethylglutaryl coenzyme A (HMG-CoA), which is involved in regulating cholesterol production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/12\">",
"     12",
"    </a>",
"    ]. In CTX, increased activity of hepatic HMG-CoA reductase causes elevated synthesis of cholesterol, thereby enhancing hepatic secretion of apoB-containing lipoproteins. Low-density lipoprotein (LDL) receptors are upregulated, resulting in normal serum cholesterol levels in CTX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Neurologic injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the pathogenesis remains unknown, one hypothesis is that a membrane defect causes the accumulation of sterols in the eyes (blood-lens barrier), central nervous system (CNS) (blood-brain barrier), peripheral nerves (blood-nerve barrier), and vessel walls (endothelial cell membrane) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In human aortic and pulmonary endothelium, sterol 27-hydroxylase may provide local defense against the accumulation of cholesterol in the arterial wall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/18\">",
"     18",
"    </a>",
"    ]. Cholesterol is a major constituent of the myelin sheath, and its availability in oligodendrocytes is a rate-limiting factor for brain maturation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/19\">",
"     19",
"    </a>",
"    ]. Cholesterol is also present in the plasma membranes of astrocytes and neurons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/20\">",
"     20",
"    </a>",
"    ]. Furthermore, sterols are important in membrane permeability. Minor changes in sterol structure, such as the incorporation of cholestanol instead of cholesterol, can have deleterious effects on cell membrane integrity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cholestanol is thought to be responsible for the neurologic toxicity in CTX. Evidence of a neurotoxic mechanism is supported by the finding of cholestanol deposition in neuronal cells, most notably Purkinje cells, in the cerebellum of rats fed a 1 percent cholestanol diet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/21\">",
"     21",
"    </a>",
"    ]. Furthermore, in vitro study of cerebellar neuronal cells cultured with cholestanol revealed increased apoptosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional evidence supporting a neurotoxic mechanism comes from a study of 12 patients with CTX who had magnetic resonance spectroscopy (MRS), which revealed decreased N-acetylaspartate (NAA), increased lactate, and normal choline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/11\">",
"     11",
"    </a>",
"    ]. Decreased NAA is thought to be due to neuronal or axonal damage, and increased lactate is a marker for a defect in mitochondrial metabolism or infiltration of inflammatory cells. The normal choline levels argue against processes that cause membrane breakdown, such as active demyelination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Mitochondrial dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;As just discussed, the finding of increased lactate on MRS suggests diffuse brain mitochondrial dysfunction in patients with CTX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/11\">",
"     11",
"    </a>",
"    ]. In addition, abnormal aggregates of mitochondria were observed in muscle biopsies performed in eight patients with CTX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/22\">",
"     22",
"    </a>",
"    ]. An additional case had decreased activity of respiratory chain enzymes, including cytochrome c oxidase, as well as significantly elevated pyruvate and lactate in the serum and cerebrospinal fluid (CSF) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/23\">",
"     23",
"    </a>",
"    ]. Clinically, the patient had a myopathic facies (ie, expressionless with drooping cheeks and inability to smile or frown due to weakness) and generalized muscle weakness, consistent with mitochondrial dysfunction.",
"   </p>",
"   <p>",
"    The cause of the mitochondrial dysfunction remains unknown, but one hypothesis is that toxic effects of elevated cholestanol or bile acids or membrane alteration may play a role.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiologic data are limited, but cerebrotendinous xanthomatosis (CTX) is a rare disease. Based upon an analysis of a single CYP27A1 mutation (R362C), the estimated prevalence of CTX was 1.9 per 100,000 in Caucasians of European ancestry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/24\">",
"     24",
"    </a>",
"    ]. The disease has been reported in numerous countries around the world [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/6,11,25-30\">",
"     6,11,25-30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many systemic and neurologic symptoms have been identified in patients with cerebrotendinous xanthomatosis (CTX), including intractable diarrhea, premature cataracts, tendon xanthomas, and progressive neurologic signs and symptoms. The systemic features typically present earlier than the neurologic manifestations.",
"   </p>",
"   <p>",
"    Neurologic dysfunction involving cerebral, cerebellar, neuropsychiatric, myelopathic, or peripheral manifestations is usually apparent by late childhood or early adulthood, and progresses during adulthood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Systemic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal cholestatic jaundice is often the earliest symptom of CTX, but does not occur in every patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/31\">",
"     31",
"    </a>",
"    ]. There is significant clinical heterogeneity, even among siblings with the same mutation. For some, the jaundice self-resolves; others require treatment with bile acids (see",
"    <a class=\"local\" href=\"#H21\">",
"     'Treatment'",
"    </a>",
"    below). Fetal demise and death in infancy have occurred in siblings of CTX patients, including one child with jaundice from birth until his death at 13 months, suggesting that CYP27A mutations may be fatal in some patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/31\">",
"     31",
"    </a>",
"    ]. Chronic infantile diarrhea, which is due to a defect in bile acid synthesis, is another early symptom of CTX. However, hepatitis of infancy and chronic diarrhea are rarely identified as symptoms of CTX until other manifestations of the disease appear. Most patients (75 percent) present to medical attention in the first decade of life because of cataracts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/2,32\">",
"     2,32",
"    </a>",
"    ], and the overall incidence of cataracts may be as high as 92 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Xanthomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Xanthomas develop in approximately 70 percent of patients with CTX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/33\">",
"     33",
"    </a>",
"    ]. They typically form in the second or third decade on the Achilles, extensor elbow, extensor hand, patellar, and neck tendons. Xanthomas can also develop in the brain, lungs, and bones.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Skeletal abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although serum calcium is normal, patients with CTX have skeletal abnormalities due to impaired calcium absorption (demonstrated by impaired radiocalcium uptake) that leads to decreased bone",
"    <span class=\"nowrap\">",
"     density/osteopenia,",
"    </span>",
"    osteoporosis, and fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Cardiovascular",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atherosclerosis and cardiovascular disease have been associated with CTX, including reports of premature coronary atheroma, angina pectoris, myocardial infarction, aneurysmal coronary artery disease, mitral valve insufficiency, and lipomatous hypertrophy of the atrial septum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. The true prevalence of cardiac disease in CTX is unknown, but in one review of 144 patients with CTX, cardiac abnormalities were found in 15 patients (10.4 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/25\">",
"     25",
"    </a>",
"    ]. In a series of seven patients who were studied with myocardial scintigram and coronary angiography, asymptomatic coronary artery disease was present in four [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most likely mechanism of cardiac disease and atherosclerosis in CTX is the accumulation of cholesterol and cholestanol in various tissues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/37\">",
"     37",
"    </a>",
"    ]. However, this relationship is controversial, in part because patients with CTX are more likely to have what looks like an \"antiatherogenic\" lipid profile, with lower total cholesterol and low-density lipoprotein (LDL) levels and increased HDL levels, than controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Premature aging and hypothyroidism have also been reported in patients with CTX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Neurologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although mental retardation can present in infancy, most patients with CTX have borderline or normal intelligence until puberty. Intellectual functioning worsens with age, and over 50 percent of individuals with CTX have dementia and intellectual decline in their 20s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neuropsychiatric manifestations of CTX include paranoid delusions, hallucinations, agitation, aggression, and depression. The latter may lead to suicide attempts.",
"     </li>",
"     <li>",
"      Many patients develop spasticity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/39\">",
"       39",
"      </a>",
"      ], which is especially prominent in spinal xanthomatosis. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Spinal variant'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Seizures occur in approximately 50 percent of patients with CTX [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/2\">",
"       2",
"      </a>",
"      ], and can be the presenting symptom [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Extrapyramidal symptoms, such as dystonia and parkinsonism, are observed in approximately 20 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/41-45\">",
"       41-45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Both demyelinating and axonal neuropathies have been described [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/46\">",
"       46",
"      </a>",
"      ], leading to distal muscle atrophy and pes cavus. Sensory symptoms are typically absent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Spinal variant",
"    </span>",
"    &nbsp;&mdash;&nbsp;A rare spinal variant of CTX is characterized by a slowly progressive myelopathy and corticospinal and dorsal column demyelination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. In the largest series, with seven patients, the age at presentation ranged from 20 to 35 years old, and all had juvenile bilateral cataracts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/47\">",
"     47",
"    </a>",
"    ]. Other typical features of CTX, such as diarrhea, xanthomas, dementia, ataxia, and polyneuropathies, were less frequent than cataracts. Only two patients developed the classic symptoms; these were detected five to eight years after the onset of the myelopathy. In general, patients with spinal xanthomatosis have a milder clinical course than those with classic CTX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Head computed tomography (CT) and brain magnetic resonance imaging (MRI) reveal diffuse atrophy, white matter signal alterations affecting cerebellum more than cerebrum, and bilateral focal cerebellar lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On CT, white matter changes are hypodense, while cerebellar xanthomas are hyperdense.",
"   </p>",
"   <p>",
"    In adults, hyperintense lesions on T2-weighted MRI are observed in the dentate nucleus, globus pallidus, substantia nigra, and inferior olive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/51\">",
"     51",
"    </a>",
"    ]. With disease progression, these lesions typically extend into adjacent white matter. On MRI, fluid-attenuated inversion recovery (FLAIR) sequences may be more sensitive than T2-weighted sequences, as suggested by a study of 12 patients with CTX that found bilateral hyperintensities in the dentate nuclei on T2 and FLAIR sequences in 9 and 12 patients, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both dentate hyperintensity (common) and hypointensity (less common) on T2 MRI have been reported in CTX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/51\">",
"     51",
"    </a>",
"    ]. This discrepancy is explained by the presence of hemosiderin deposits and calcifications in the dentate, which lowers the T2 signal intensity.",
"   </p>",
"   <p>",
"    The presence of bilateral focal cerebellar lesions and the predominance of cerebellar white matter involvement helps distinguish the radiographic features of CTX from other leukodystrophies (",
"    <a class=\"graphic graphic_algorithm graphicRef65871 \" href=\"mobipreview.htm?23/14/23785\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the spinal variant of CTX, abnormal signal on T2-weighted images was observed in the lateral and dorsal columns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Laboratory",
"    </span>",
"    &nbsp;&mdash;&nbsp;The disruption of bile acid synthesis in CTX results in a number of laboratory abnormalities. Serum and tissue levels of cholestanol are elevated to 5 to 10 times normal levels, whereas serum cholesterol levels are normal or decreased. The formation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33076?source=see_link\">",
"     chenodeoxycholic acid",
"    </a>",
"    is markedly decreased, and the bile, urine, and serum concentrations of bile alcohols and their glycoconjugates are increased.",
"   </p>",
"   <p>",
"    Increased serum lactate is also seen, but this finding is nonspecific. Changes in the blood-brain barrier result in increased concentrations of cholestanol and apolipoprotein B in the cerebrospinal fluid.",
"   </p>",
"   <p>",
"    While not routinely evaluated, the enzymatic activity of sterol 27-hydroxylase is markedly reduced in fibroblasts, liver, and leukocytes in patients with CTX.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sections of gross brain from patients with CTX reveal symmetric lesions in the cerebellar white matter, globus pallidus, midbrain, posterior part of the internal capsule, and dentate nuclei [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/51\">",
"     51",
"    </a>",
"    ]. Granulomatous and xanthomatous lesions are seen in the cerebellar hemispheres, globus pallidus, and cerebellar peduncles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Microscopic examination reveals extensive rarefaction, with severe neuronal loss, demyelination, hemosiderin deposits, lipid crystal clefts, fibrosis, infiltration of foamy macrophages, and reactive astrocytosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/51\">",
"     51",
"    </a>",
"    ]. The cerebellar findings of lipid crystal clefts, xanthomatous lesions, fibrosis, and hemosiderin deposits, especially around the dentate nuclei, are pathognomonic for cerebrotendinous xanthomatosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/47,51\">",
"     47,51",
"    </a>",
"    ]. In addition to the typical brain pathology, patients with significant spinal cord involvement have extensive demyelination, axonal loss, gliosis, and macrophagic infiltrates in the corticospinal tracts and gracile tracts.",
"   </p>",
"   <p>",
"    Microscopically, xanthomas have shown birefringent crystalline storage material surrounded by multinucleated giant cells with foamy cytoplasm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of CTX is suggested when the typical symptoms are present. Laboratory studies showing elevated levels of serum cholestanol and serum and urine bile alcohols are supportive of the diagnosis, and genetic testing can confirm the diagnosis. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Clinical features'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Suspicion for CTX is highest in patients with the following symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/2,31\">",
"     2,31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Neonatal cholestatic jaundice",
"     </li>",
"     <li>",
"      Infantile diarrhea",
"     </li>",
"     <li>",
"      Premature cataracts presenting in childhood",
"     </li>",
"     <li>",
"      Tendon xanthomas presenting during adolescence or early adulthood",
"     </li>",
"     <li>",
"      Progressive neurologic dysfunction beginning in late childhood or early adulthood",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, CTX should be considered if a child has prolonged neonatal jaundice or infantile diarrhea of unclear etiology, especially if there is a family history of similar symptoms or fetal demise. However, as noted earlier, hepatitis of infancy and chronic diarrhea are rarely identified as symptoms of CTX until other manifestations of the disease appear. In patients with mental retardation who have a component of progressive neurologic disease, CTX deserves special consideration because of its response to treatment.",
"   </p>",
"   <p>",
"    While CTX is suggested by the presence of xanthomas and cholesterol abnormalities, it may not be considered in patients lacking these systemic findings. However, this may lead to diagnostic error, as one review found that xanthomas were not present in 29 percent of patients with CTX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/33\">",
"     33",
"    </a>",
"    ]. In addition, children with early-stage CTX may present with bile disorders, diarrhea, or cataracts, but may lack overt neurologic symptoms or signs. In such cases, laboratory testing for serum cholestanol and serum and urine bile alcohols should be performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of bilateral neuroimaging abnormalities in the dentate nuclei of the cerebellum strongly supports the diagnosis of CTX in patients who have clinical features that raise suspicion for the disorder.",
"   </p>",
"   <p>",
"    Molecular genetic testing including sequence analysis can detect CYP27A1 mutations in up to 99 percent of affected individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/2\">",
"     2",
"    </a>",
"    ]. Genetic testing with sequence analysis is clinically available and is suggested to confirm the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with neurologic disease, myotonic dystrophy is the number one cause of early-onset cataracts, followed by CTX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/53\">",
"     53",
"    </a>",
"    ]. Distal myotonic dystrophy, as opposed to the proximal and neonatal forms, presents as early as adolescence with impaired muscle relaxation after contraction, facial and distal limb weakness, cataracts, frontal baldness, and endocrine abnormalities. The characteristic myotonia of myotonic dystrophy&mdash;which may be confirmed by clinical examination",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    by electromyography&mdash;should readily differentiate myotonic dystrophy from CTX. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/26/19882?source=see_link\">",
"     \"Myotonic dystrophy: Etiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tendon xanthomas are also present in sitosterolemia, an inherited sterol storage disease. However, neurologic signs and cataracts are absent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37274?source=see_link\">",
"     \"Inherited disorders of LDL-cholesterol metabolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similarly, xanthomas affecting the spinal cord may lead to spastic paraparesis in the absence of other features of CTX. While hypercholesterolemia and hyperlipidemia cause xanthomas, serum concentrations of cholestanol are normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mainstay of treatment for cerebrotendinous xanthomatosis (CTX) is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33076?source=see_link\">",
"     chenodeoxycholic acid",
"    </a>",
"    . Although unproven, treatment with statins may be beneficial, but only when combined with chenodeoxycholic acid.",
"   </p>",
"   <p>",
"    There are limited and conflicting data regarding the clinical benefit with low-density lipoprotein (LDL) apheresis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/55-58\">",
"     55-58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptomatic therapies are also important.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Chenodeoxycholic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1975,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33076?source=see_link\">",
"     chenodeoxycholic acid",
"    </a>",
"    (CDCA) was shown to decrease cholesterol synthesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/15\">",
"     15",
"    </a>",
"    ]. In the decades since, CDCA has remained the treatment of choice for CTX because it can stabilize or possibly reverse some of the associated symptoms.",
"   </p>",
"   <p>",
"    We recommend treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33076?source=see_link\">",
"     chenodeoxycholic acid",
"    </a>",
"    for children and adults with CTX. The usual dose of CDCA is 250 mg three times a day for adults and 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in three divided doses for children.",
"   </p>",
"   <p>",
"    One of the largest studies showing the benefit of this treatment involved 17 symptomatic patients with CTX who were given CDCA, 750 mg daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/26\">",
"     26",
"    </a>",
"    ]. After at least one year of treatment, the following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dementia cleared in 10 of 13 patients",
"     </li>",
"     <li>",
"      Pyramidal tract and cerebellar signs disappeared in five",
"     </li>",
"     <li>",
"      Electroencephalographic abnormalities resolved in 5 of 10 patients",
"     </li>",
"     <li>",
"      Cerebral CT scans improved in seven patients, and one cerebellar xanthoma disappeared",
"     </li>",
"     <li>",
"      Mean serum cholestanol levels declined by a factor of three, and abnormal bile acid synthesis was suppressed",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In adults with CTX, long-term treatment with CDCA (250 mg orally three times daily) corrects the defect of bile acid metabolism and normalizes the serum, urine, and cerebrospinal fluid lipid concentrations. Despite these data, the neurologic and psychiatric symptoms are often the most difficult to treat, and may not improve with CDCA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/59,60\">",
"     59,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Starting CDCA during childhood or earlier may be associated with greater benefit than starting treatment in adults, when irreversible neurologic injury may be present.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of five symptomatic children (ages 7 to 20 years) treated with CDCA (15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in three divided doses), diarrhea resolved immediately with the start of treatment, and biochemical abnormalities normalized [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/61\">",
"       61",
"      </a>",
"      ]. At one year, no further motor development delays were observed, and the intelligence quotient improved in three children. At five years after the start of CDCA, the children were reported as in stable clinical condition.",
"     </li>",
"     <li>",
"      Another report described four patients with CTX within one family who were treated with CDCA for 14 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/62\">",
"       62",
"      </a>",
"      ]. At the time treatment was started, two young sisters had minimal symptoms and two older brothers (uncles of the sisters) were already severely affected. After 14 years of follow-up, the two sisters remained free of symptoms, whereas the two uncles experienced only moderate improvement in symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Unfortunately, CDCA is not commercially available in the United States or Canada. However, patients with CTX may obtain CDCA from the University of Medicine and Dentistry of New Jersey [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few data regarding side effects of CDCA in patients with CTX. However, in patients with gallstones who are treated with CDCA, dose-related diarrhea is seen in approximately 50 percent, and hypercholesterolemia and increased serum aminotransferases are observed in a substantial proportion. Since diarrhea is a common feature of CTX, it is not clear whether CDCA causes or exacerbates diarrhea in patients with CTX.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Statins lower cholesterol and have been studied as a treatment for CTX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/23,52\">",
"     23,52",
"    </a>",
"    ]. However, statins deplete CoQ10 and thereby alter mitochondrial function, which is a theoretical concern because abnormal mitochondrial metabolism has been reported in CTX. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Mitochondrial dysfunction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although data are limited, there is no evidence that statin monotherapy is beneficial for CTX. In addition, while statins may be useful for lowering cholestanol levels when combined with CDCA, there is no evidence that they provide additional clinical benefit over CDCA treatment alone in the relatively short time periods that have been evaluated.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One patient who previously responded to CDCA showed further reduction of cholestanol levels when",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"       pravastatin",
"      </a>",
"      (10 mg daily) was added to CDCA treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/64\">",
"       64",
"      </a>",
"      ]. However, on pravastatin alone, cholestanol levels returned to pre-CDCA treatment levels, tendon xanthomas enlarged, and electroencephalographic slow waves reappeared on pravastatin monotherapy.",
"     </li>",
"     <li>",
"      In seven patients on long-term CDCA treatment, the addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      [10 to 40 mg daily] to CDCA was well tolerated during a six-month study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/65\">",
"       65",
"      </a>",
"      ]. There was a significant reduction in serum cholestanol, LDL cholesterol, and lathosterol levels. Despite this reduction, there was no clinically significant change in the clinical, radiographic, or electrographic data, measured by xanthoma size, cerebral MRI, electroencephalogram, and visual evoked potentials.",
"     </li>",
"     <li>",
"      Another study of four previously untreated patients with CTX found no benefit for treatment with hydrophilic bile acids (ursodeoxycholic and ursocholic acids),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/33/36374?source=see_link\">",
"       cholestyramine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42312?source=see_link\">",
"       lovastatin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Symptomatic therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of CTX may require interventions for cataracts, epilepsy, parkinsonism, and spasticity. Patients often require cataract surgery before the age of 50 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/2,32\">",
"     2,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Management of seizures and epilepsy is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40570?source=see_link\">",
"     \"Overview of the management of epilepsy in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/32/37386?source=see_link\">",
"     \"Overview of the treatment of seizures and epileptic syndromes in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     Levodopa/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?3/9/3221?source=see_link\">",
"      carbidopa",
"     </a>",
"    </span>",
"    has been used to treat the parkinsonian symptoms of CTX with variable success [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34888/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cerebrotendinous xanthomatosis (CTX) is a rare disease caused by a genetic defect in the CYP27A1 gene, which results in a deficiency of sterol 27-hydroxylase, with accumulation of cholesterol and cholestanol in virtually all tissues. Cholestanol is thought to be responsible for the neurologic toxicity in CTX. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Systemic symptoms associated with CTX include intractable diarrhea, premature cataracts, tendon xanthomas, premature atherosclerosis, and cardiovascular disease. The systemic features typically present earlier than the neurologic manifestations. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neurologic dysfunction, including mental retardation, dementia, epilepsy, parkinsonism, myelopathy, and neuropathy, is usually apparent by late childhood or early adulthood, and progresses during adulthood. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Neurologic'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Head CT and brain MRI reveal diffuse atrophy, white matter signal alterations affecting cerebellum more than cerebrum, and bilateral focal cerebellar lesions. Hyperintense lesions on T2-weighted and FLAIR MRI are observed in the dentate nucleus, globus pallidus, substantia nigra, and inferior olive. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Neuroimaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serum and tissue levels of cholestanol are elevated to 5 to 10 times normal levels, whereas serum cholesterol levels are normal or decreased. The formation of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33076?source=see_link\">",
"       chenodeoxycholic acid",
"      </a>",
"      is markedly decreased, and the bile, urine, and serum concentrations of bile alcohols and their glycoconjugates are increased. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Laboratory'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of CTX is suggested by the typical constellation of CTX symptoms, which are seen in most patients with the disorder. These symptoms are (see",
"      <a class=\"local\" href=\"#H19\">",
"       'Diagnosis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Neonatal cholestatic jaundice",
"     </li>",
"     <li>",
"      Infantile diarrhea",
"     </li>",
"     <li>",
"      Premature cataracts presenting in childhood",
"     </li>",
"     <li>",
"      Tendon xanthomas presenting during adolescence or early adulthood",
"     </li>",
"     <li>",
"      Progressive neurologic dysfunction beginning in late childhood or early adulthood",
"      <br/>",
"      <br/>",
"      Elevated levels of serum cholestanol and serum and urine bile alcohols are supportive of the diagnosis, which can be confirmed with genetic testing. Laboratory testing for serum cholestanol and serum and urine bile alcohols should be performed for children with bile disorders, diarrhea, or cataracts.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For children and adults with CTX, we recommend treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33076?source=see_link\">",
"       chenodeoxycholic acid",
"      </a>",
"      (CDCA) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The suggested dose of CDCA is 250 mg three times a day for adults, and 15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in three divided doses for children. It is important to begin treatment before the onset of neurologic dysfunction in order to prevent irreversible neuronal injury; clinical improvement in established disease is uncommon. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Chenodeoxycholic acid'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     van Bogaert L, Schere H, Epstein E. Une forme c&eacute;r&eacute;brale de la cholest&eacute;rinose g&eacute;n&eacute;ralis&eacute;e, Masson et Cie, Paris 1937.",
"    </li>",
"    <li>",
"     Federico A, Dotti MT, Gallus GN. Cerebrotendinous xanthomatosis. GeneReviews. www.ncbi.nlm.nih.gov/books/NBK1409/ (Accessed on January 18, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/3\">",
"      Leitersdorf E, Reshef A, Meiner V, et al. Frameshift and splice-junction mutations in the sterol 27-hydroxylase gene cause cerebrotendinous xanthomatosis in Jews or Moroccan origin. J Clin Invest 1993; 91:2488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/4\">",
"      Cali JJ, Hsieh CL, Francke U, Russell DW. Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. J Biol Chem 1991; 266:7779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/5\">",
"      Gallus GN, Dotti MT, Federico A. Clinical and molecular diagnosis of cerebrotendinous xanthomatosis with a review of the mutations in the CYP27A1 gene. Neurol Sci 2006; 27:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/6\">",
"      Verrips A, Hoefsloot LH, Steenbergen GC, et al. Clinical and molecular genetic characteristics of patients with cerebrotendinous xanthomatosis. Brain 2000; 123 ( Pt 5):908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/7\">",
"      Ohno T, Kobayashi S, Hayashi M, et al. Diphenylpyraline-responsive parkinsonism in cerebrotendinous xanthomatosis: long-term follow up of three patients. J Neurol Sci 2001; 182:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/8\">",
"      Andersson S, Davis DL, Dahlb&auml;ck H, et al. Cloning, structure, and expression of the mitochondrial cytochrome P-450 sterol 26-hydroxylase, a bile acid biosynthetic enzyme. J Biol Chem 1989; 264:8222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/9\">",
"      Cali JJ, Russell DW. Characterization of human sterol 27-hydroxylase. A mitochondrial cytochrome P-450 that catalyzes multiple oxidation reaction in bile acid biosynthesis. J Biol Chem 1991; 266:7774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/10\">",
"      Crestani M, Sadeghpour A, Stroup D, et al. Transcriptional activation of the cholesterol 7alpha-hydroxylase gene (CYP7A) by nuclear hormone receptors. J Lipid Res 1998; 39:2192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/11\">",
"      De Stefano N, Dotti MT, Mortilla M, Federico A. Magnetic resonance imaging and spectroscopic changes in brains of patients with cerebrotendinous xanthomatosis. Brain 2001; 124:121.",
"     </a>",
"    </li>",
"    <li>",
"     Bj&ouml;rkhem, I, Boberg, KM. Inborn errors in bile acid biosynthesis and storage of sterols other than cholesterol. In: The metabolic and molecular basis of inherited disease, Vol 7, Scriver, C, Beaudet, AL, Sly, WS, et al (Eds), McGraw-Hill, New York 1995. p.2273.",
"    </li>",
"    <li>",
"     Federico, A, Dotti, MT. Cerebrotendinous xanthomatosis. In: Handbook of clinical neurology, Vol 66, Vinken, PJ, Bruyn, GW, Moser, HW (Eds), Elsevier Science, Amsterdam 1996. p.599.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/14\">",
"      Batta AK, Salen G, Tint GS. Hydrophilic 7 beta-hydroxy bile acids, lovastatin, and cholestyramine are ineffective in the treatment of cerebrotendinous xanthomatosis. Metabolism 2004; 53:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/15\">",
"      Salen G, Meriwether TW, Nicolau G. Chenodeoxycholic acid inhibits increased cholesterol and cholestanol synthesis in patients with cerebrotendinous xanthomatosis. Biochem Med 1975; 14:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/16\">",
"      Ballantyne CM, Vega GL, East C, et al. Low-density lipoprotein metabolism in cerebrotendinous xanthomatosis. Metabolism 1987; 36:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/17\">",
"      Tint GS, Ginsberg H, Salen G, et al. Chenodeoxycholic acid normalizes elevated lipoprotein secretion and catabolism in cerebrotendinous xanthomatosis. J Lipid Res 1989; 30:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/18\">",
"      Reiss AB, Martin KO, Rojer DE, et al. Sterol 27-hydroxylase: expression in human arterial endothelium. J Lipid Res 1997; 38:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/19\">",
"      Saher G, Br&uuml;gger B, Lappe-Siefke C, et al. High cholesterol level is essential for myelin membrane growth. Nat Neurosci 2005; 8:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/20\">",
"      Bj&ouml;rkhem I, Meaney S. Brain cholesterol: long secret life behind a barrier. Arterioscler Thromb Vasc Biol 2004; 24:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/21\">",
"      Inoue K, Kubota S, Seyama Y. Cholestanol induces apoptosis of cerebellar neuronal cells. Biochem Biophys Res Commun 1999; 256:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/22\">",
"      Federico A, Dotti MT, Volpi N. Muscle mitochondrial changes in cerebrotendinous xanthomatosis. Ann Neurol 1991; 30:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/23\">",
"      Dotti MT, Manneschi L, Federico A. Mitochondrial enzyme deficiency in cerebrotendinous xanthomatosis. J Neurol Sci 1995; 129:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/24\">",
"      Lorincz MT, Rainier S, Thomas D, Fink JK. Cerebrotendinous xanthomatosis: possible higher prevalence than previously recognized. Arch Neurol 2005; 62:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/25\">",
"      Kuriyama M, Fujiyama J, Yoshidome H, et al. Cerebrotendinous xanthomatosis: clinical and biochemical evaluation of eight patients and review of the literature. J Neurol Sci 1991; 102:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/26\">",
"      Berginer VM, Salen G, Shefer S. Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid. N Engl J Med 1984; 311:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/27\">",
"      Waterreus RJ, Koopman BJ, Wolthers BG, Oosterhuis HJ. Cerebrotendinous xanthomatosis (CTX): a clinical survey of the patient population in The Netherlands. Clin Neurol Neurosurg 1987; 89:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/28\">",
"      Farpour H, Mahloudji M. Familial cerebrotendinous xanthomatosis. Report of a new family and review of the literature. Arch Neurol 1975; 32:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/29\">",
"      Ben Hamida M, Chabbi N, Ben Hamida C, et al. [Peripheral neuropathy in a sporadic case of cerebrotendinous xanthomatosis]. Rev Neurol (Paris) 1991; 147:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/30\">",
"      Ko KF, Lee KW. Cerebrotendinous xanthomatosis in three siblings from a Chinese family. Singapore Med J 2001; 42:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/31\">",
"      Clayton PT, Verrips A, Sistermans E, et al. Mutations in the sterol 27-hydroxylase gene (CYP27A) cause hepatitis of infancy as well as cerebrotendinous xanthomatosis. J Inherit Metab Dis 2002; 25:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/32\">",
"      Cruysberg JR, Wevers RA, van Engelen BG, et al. Ocular and systemic manifestations of cerebrotendinous xanthomatosis. Am J Ophthalmol 1995; 120:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/33\">",
"      Moghadasian MH. Cerebrotendinous xanthomatosis: clinical course, genotypes and metabolic backgrounds. Clin Invest Med 2004; 27:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/34\">",
"      Berginer VM, Shany S, Alkalay D, et al. Osteoporosis and increased bone fractures in cerebrotendinous xanthomatosis. Metabolism 1993; 42:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/35\">",
"      Federico A, Dotti MT, Lor&eacute; F, Nuti R. Cerebrotendinous xanthomatosis: pathophysiological study on bone metabolism. J Neurol Sci 1993; 115:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/36\">",
"      Fujiyama J, Kuriyama M, Arima S, et al. Atherogenic risk factors in cerebrotendinous xanthomatosis. Clin Chim Acta 1991; 200:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/37\">",
"      Dotti MT, Mondillo S, Plewnia K, et al. Cerebrotendinous xanthomatosis: evidence of lipomatous hypertrophy of the atrial septum. J Neurol 1998; 245:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/38\">",
"      Valdivielso P, Calandra S, Dur&aacute;n JC, et al. Coronary heart disease in a patient with cerebrotendinous xanthomatosis. J Intern Med 2004; 255:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/39\">",
"      Mignarri A, Rossi S, Ballerini M, et al. Clinical relevance and neurophysiological correlates of spasticity in cerebrotendinous xanthomatosis. J Neurol 2011; 258:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/40\">",
"      Arlazoroff A, Roitberg B, Werber E, et al. Epileptic seizure as a presenting symptom of cerebrotendinous xanthomatosis. Epilepsia 1991; 32:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/41\">",
"      Grandas F, Mart&iacute;n-Moro M, Garcia-Mu&ntilde;ozguren S, Anaya F. Early-onset parkinsonism in cerebrotendinous xanthomatosis. Mov Disord 2002; 17:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/42\">",
"      Alcalay R, Wu S, Patel S, Frucht S. Oromandibular dystonia as a complication of cerebrotendinous xanthomatosis. Mov Disord 2009; 24:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/43\">",
"      Posada IJ, Ramos A. Botulinum toxin-responsive oromandibular dystonia in cerebrotendinous xanthomatosis. Parkinsonism Relat Disord 2011; 17:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/44\">",
"      Rubio-Agusti I, Kojovic M, Edwards MJ, et al. Atypical parkinsonism and cerebrotendinous xanthomatosis: report of a family with corticobasal syndrome and a literature review. Mov Disord 2012; 27:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/45\">",
"      Pilo-de-la-Fuente B, Jimenez-Escrig A, Lorenzo JR, et al. Cerebrotendinous xanthomatosis in Spain: clinical, prognostic, and genetic survey. Eur J Neurol 2011; 18:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/46\">",
"      Chen SF, Tsai NW, Chang CC, et al. Neuromuscular abnormality and autonomic dysfunction in patients with cerebrotendinous xanthomatosis. BMC Neurol 2011; 11:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/47\">",
"      Verrips A, Nijeholt GJ, Barkhof F, et al. Spinal xanthomatosis: a variant of cerebrotendinous xanthomatosis. Brain 1999; 122 ( Pt 8):1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/48\">",
"      Bartholdi D, Zumsteg D, Verrips A, et al. Spinal phenotype of cerebrotendinous xanthomatosis--a pitfall in the diagnosis of multiple sclerosis. J Neurol 2004; 251:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/49\">",
"      McKinnon JH, Bosch EP. Clinical reasoning: a case of treatable spastic paraparesis. Neurology 2012; 79:e50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/50\">",
"      Schiffmann R, van der Knaap MS. Invited article: an MRI-based approach to the diagnosis of white matter disorders. Neurology 2009; 72:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/51\">",
"      Barkhof F, Verrips A, Wesseling P, et al. Cerebrotendinous xanthomatosis: the spectrum of imaging findings and the correlation with neuropathologic findings. Radiology 2000; 217:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/52\">",
"      Federico A, Dotti MT. Cerebrotendinous xanthomatosis: clinical manifestations, diagnostic criteria, pathogenesis, and therapy. J Child Neurol 2003; 18:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/53\">",
"      Cruysberg JR. Cerebrotendinous xanthomatosis: juvenile cataract and chronic diarrhea before the onset of neurologic disease. Arch Neurol 2002; 59:1975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/54\">",
"      Moghadasian MH, Salen G, Frohlich JJ, Scudamore CH. Cerebrotendinous xanthomatosis: a rare disease with diverse manifestations. Arch Neurol 2002; 59:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/55\">",
"      Mimura Y, Kuriyama M, Tokimura Y, et al. Treatment of cerebrotendinous xanthomatosis with low-density lipoprotein (LDL)-apheresis. J Neurol Sci 1993; 114:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/56\">",
"      Berginer VM, Salen G. LDL-apheresis cannot be recommended for treatment of cerebrotendinous xanthomatosis. J Neurol Sci 1994; 121:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/57\">",
"      Ito S, Kuwabara S, Sakakibara R, et al. Combined treatment with LDL-apheresis, chenodeoxycholic acid and HMG-CoA reductase inhibitor for cerebrotendinous xanthomatosis. J Neurol Sci 2003; 216:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/58\">",
"      Dotti MT, L&uuml;tjohann D, von Bergmann K, Federico A. Normalisation of serum cholestanol concentration in a patient with cerebrotendinous xanthomatosis by combined treatment with chenodeoxycholic acid, simvastatin and LDL apheresis. Neurol Sci 2004; 25:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/59\">",
"      Mondelli M, Sicurelli F, Scarpini C, et al. Cerebrotendinous xanthomatosis: 11-year treatment with chenodeoxycholic acid in five patients. An electrophysiological study. J Neurol Sci 2001; 190:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/60\">",
"      Federico A, Dotti MT. Cerebrotendinous xanthomatosis. Neurology 2001; 57:1743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/61\">",
"      van Heijst AF, Verrips A, Wevers RA, et al. Treatment and follow-up of children with cerebrotendinous xanthomatosis. Eur J Pediatr 1998; 157:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/62\">",
"      Berginer VM, Gross B, Morad K, et al. Chronic diarrhea and juvenile cataracts: think cerebrotendinous xanthomatosis and treat. Pediatrics 2009; 123:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/63\">",
"      Samenuk P, Koffman BM. Chenodeoxycholic treatment of cerebrotendinous xanthomatosis. Neurology 2001; 56:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/64\">",
"      Nakamura T, Matsuzawa Y, Takemura K, et al. Combined treatment with chenodeoxycholic acid and pravastatin improves plasma cholestanol levels associated with marked regression of tendon xanthomas in cerebrotendinous xanthomatosis. Metabolism 1991; 40:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34888/abstract/65\">",
"      Verrips A, Wevers RA, Van Engelen BG, et al. Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis. Metabolism 1999; 48:233.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1692 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-340D2F8564-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_4_34888=[""].join("\n");
var outline_f34_4_34888=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Lipid derangements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Neurologic injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Mitochondrial dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Systemic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Xanthomas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Skeletal abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Cardiovascular",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Neurologic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Spinal variant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Laboratory",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Chenodeoxycholic acid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Statins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Symptomatic therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1692\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1692|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?23/14/23785\" title=\"algorithm 1\">",
"      MRI algorithm white matter disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37274?source=related_link\">",
"      Inherited disorders of LDL-cholesterol metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/26/19882?source=related_link\">",
"      Myotonic dystrophy: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40570?source=related_link\">",
"      Overview of the management of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/32/37386?source=related_link\">",
"      Overview of the treatment of seizures and epileptic syndromes in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_4_34889="Clinical features and diagnosis of fragile X syndrome in children and adolescents";
var content_f34_4_34889=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features and diagnosis of fragile X syndrome in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/4/34889/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/4/34889/contributors\">",
"     Hilde Van Esch, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/4/34889/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/4/34889/contributors\">",
"     Helen V Firth, DM, FRCP, DCH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/4/34889/contributors\">",
"     Carolyn Bridgemohan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/4/34889/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/4/34889/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/4/34889/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features and diagnosis of fragile X syndrome (previously called fragile X mental retardation syndrome, X-linked mental retardation and macroorchidism, and Martin-Bell syndrome) in children and adolescents will be discussed here. Prenatal screening and the management of fragile X syndrome in children and adolescents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/54/23399?source=see_link\">",
"     \"Prenatal screening and diagnosis for fragile X syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/30/17896?source=see_link\">",
"     \"Management of children and adolescents with fragile X syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fragile X syndrome (FXS, MIM #300624) is the most frequent form of inherited intellectual disability, with a prevalence between 1 in 4000 and 1 in 6000 in males [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The prevalence in females is approximately one-half of that in males [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/2\">",
"     2",
"    </a>",
"    ]. The carrier rate is approximately 1 in 750 men and 1 in 250 women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/1,3,4\">",
"     1,3,4",
"    </a>",
"    ]. FXS has been diagnosed in up to 3 percent of boys with special needs (eg, autism, nonsyndromic intellectual disability) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENETICS AND ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genetics and molecular biology of fragile X syndrome (FXS) are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/54/23399?source=see_link&amp;anchor=H2#H2\">",
"     \"Prenatal screening and diagnosis for fragile X syndrome\", section on 'Genotype and inheritance'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/13/7386?source=see_link&amp;anchor=H16#H16\">",
"     \"Genetic and environmental causes of birth defects\", section on 'Unstable DNA and fragile X syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    FXS is an X-linked disorder. It is caused by decreased or absent levels of fragile X mental retardation protein (FMRP) due to a loss of function mutation in the fragile X mental retardation 1 (FMR1) gene, located at Xq27.3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. In more than 99 percent of cases, loss of function is caused by an unstable expansion of a trinucleotide (CGG) repeat at the 5' untranslated region [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/2,8\">",
"     2,8",
"    </a>",
"    ]. Deletions, point mutations, and missense mutation in FMR1 also may cause FXS, but are extremely rare (&lt;1 percent of cases) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/2,9,10\">",
"     2,9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are two clinically significant levels of CGG expansion:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Expansion of &gt;200 repeats is known as full mutation and leads to methylation-coupled silencing of the FMR1 gene and absence of FMRP, causing the classical FXS phenotype. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Full mutation in boys'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H13\">",
"       'Full mutation in girls'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Expansion between approximately 50 to 55 and 200 repeats is known as premutation. The FMR1 gene remains transcriptionally active, FMRP is produced, and the classic FXS phenotype does not occur. However, a spectrum of clinical findings is associated with the premutation. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Premutation'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     NEUROANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with fragile X syndrome (FXS) have relative macrocephaly (head circumference &gt;50th percentile for age and sex) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/2\">",
"     2",
"    </a>",
"    ]. Macrocephaly is related to underlying structural anomalies. Magnetic resonance imaging and quantitative morphometry demonstrate that individuals with an FMR1 full mutation have increased total brain volume, relatively increased caudate nucleus volume, decreased cerebellar vermis, increased fourth-ventricle volume, and increased hippocampal volume [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. In addition, boys with FXS have decreased lateral ventricle volume [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/11\">",
"     11",
"    </a>",
"    ]. Caudate nucleus volume correlates with the methylation status of the FMR1 gene, and both caudate nucleus and lateral ventricular volumes correlate with IQ.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of fragile X syndrome (FXS) vary depending upon the mutation state (full mutation versus premutation), degree of methylation, sex, tissue variation, and possibly magnitude of the fragile X mental retardation protein (FMRP) deficit (",
"    <a class=\"graphic graphic_table graphicRef73067 \" href=\"mobipreview.htm?41/36/42572\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/2,5,8,14-16\">",
"     2,5,8,14-16",
"    </a>",
"    ]. Males with the full mutation are usually significantly affected. In females with the full mutation, the degree of impairment varies widely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Full mutation in boys",
"    </span>",
"    &nbsp;&mdash;&nbsp;All males with full mutation fragile X syndrome (FXS) have manifestations of FXS, but there is a wide range of physical, cognitive, and behavioral features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/17\">",
"     17",
"    </a>",
"    ]. The physical features may be subtle. The diagnosis in young boys often is suspected because of global developmental delay and typical behavioral characteristics, described below. Approximately 15 percent present with symptoms of attention deficit hyperactivity disorder or specific learning disability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Physical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical features of fragile X syndrome (FXS) in males vary depending upon age. The classic physical manifestations are more obvious in adolescents: long and narrow face with prominent forehead and chin (prognathism), large ears, and testicular enlargement (volume &gt;25 mL after puberty) with normal testicular function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/5,19-23\">",
"     5,19-23",
"    </a>",
"    ]. Testicular enlargement is not a useful clinical sign until the child is at least eight years old [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/20,24\">",
"     20,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Physical manifestations are subtle in infants and young boys. Nonetheless, some craniofacial and connective tissue findings may be present from a young age (",
"    <a class=\"graphic graphic_picture graphicRef60035 \" href=\"mobipreview.htm?11/9/11412\">",
"     picture 1",
"    </a>",
"    ) . These include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/5,17,21,25-27\">",
"     5,17,21,25-27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Relative macrocephaly (head circumference &gt;50th percentile for age and sex)",
"     </li>",
"     <li>",
"      Strabismus",
"     </li>",
"     <li>",
"      Pale blue irises",
"     </li>",
"     <li>",
"      Midface hypoplasia with sunken eyes",
"     </li>",
"     <li>",
"      Arched palate",
"     </li>",
"     <li>",
"      Mitral valve prolapse (seemingly benign)",
"     </li>",
"     <li>",
"      Joint hyperlaxity (particularly of the thumbs, fingers, and wrists)",
"     </li>",
"     <li>",
"      Hypotonia",
"     </li>",
"     <li>",
"      Soft skin over the dorsum of hands",
"     </li>",
"     <li>",
"      Flexible flat feet",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Cognitive function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Developmental delay (including delayed attainment of motor and language milestones), intellectual disability (previously termed mental retardation), and learning disabilities are the most salient clinical features of fragile X syndrome (FXS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/28\">",
"     28",
"    </a>",
"    ]. Boys with FXS typically sit alone at 10 months, walk at 20.6 months, and say their first clear words at 20 months (compared with approximately 7 months, 13 months, and 11 months, respectively, in typically developing children) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adult males typically have an intelligence quotient (IQ) in the moderate intellectual disability range, but intellectual disability ranges from mild to severe. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/10/26793?source=see_link\">",
"     \"Intellectual disability (mental retardation) in children: Definition; causes; and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although individual strengths and weaknesses may vary from patient to patient, consistent strengths among boys with FXS include verbal skills (verbal reasoning, simple labeling, vocabulary, verbal comprehension) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/17\">",
"     17",
"    </a>",
"    ]. Consistent weaknesses include mathematics abilities, visuospatial abilities, attention and executive function (eg, the ability to organize information, plan ahead, problem solve), and visual-motor coordination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/17,29-32\">",
"     17,29-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Longitudinal analysis indicates that cognitive level and adaptive behavior skills decline after early childhood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Prepubertal boys, and in particular preschool boys with FXS, generally have higher IQs than adolescents and adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/35\">",
"     35",
"    </a>",
"    ]. The decline occurs in all areas: quantitative skills, verbal reasoning,",
"    <span class=\"nowrap\">",
"     visual/abstract",
"    </span>",
"    abilities, and short-term memory [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/34\">",
"     34",
"    </a>",
"    ]. Declines in cognitive and adaptive skills reflect the slow acquisition of skills compared with other children of the same age, rather than a regression of skills [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/17,32,36\">",
"     17,32,36",
"    </a>",
"    ]. These observations highlight the importance of early intervention to facilitate cognitive abilities and adaptive behavior skills [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Diagnosis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/30/17896?source=see_link\">",
"     \"Management of children and adolescents with fragile X syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Language and speech",
"    </span>",
"    &nbsp;&mdash;&nbsp;Boys with fragile X syndrome (FXS) have delayed language development. Expressive language skills are achieved more slowly than receptive language skills, and the discrepancy between expressive and receptive skills increases with age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/28,37\">",
"     28,37",
"    </a>",
"    ]. Approximately 10 percent of boys with FXS are nonverbal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Expressive language is often tangential (eg, responses or comments that do not relate to the topic of conversation) and perseverative, with inappropriate self-repetition, echolalia (involuntary parrot-like repetition), and pragmatic errors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/17,28,38\">",
"     17,28,38",
"    </a>",
"    ]. In contrast to individuals with autism, boys with FXS who often exhibit autistic-like features generally take appropriate turns during conversation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Articulation is poor, and language is repetitive and characterized by short and fast utterances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/35\">",
"     35",
"    </a>",
"    ]. Cluttering is often present. Cluttering is a rapid, fluctuating rate of speech with repetitions of sounds, words, and phrases, and occasional garbled, slurred, or disorganized speech.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Behavioral features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The behavioral phenotype of boys with fragile X syndrome (FXS) shares features with attention deficit hyperactivity disorder, anxiety, and autism spectrum disorders (eg, hyperactivity, inattention, gaze aversion, and stereotypic movements, such as hand flapping, hyperarousal, social anxiety, unusual speech patterns) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/32,39-42\">",
"     32,39-42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/41/664?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical features of autism spectrum disorders\", section on 'Behavior'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/18/26922?source=see_link&amp;anchor=H2#H2\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation\", section on 'Core symptoms'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/18/26922?source=see_link&amp;anchor=H830607547#H830607547\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Boys with FXS are more inattentive, overactive, and impulsive than boys with other types of intellectual disability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/39\">",
"     39",
"    </a>",
"    ]. These symptoms may be related to sensory hyperreactivity and lack of stimulus inhibition. They may lead to a diagnosis of attention deficit hyperactivity disorder (ADHD). The ADHD-like symptoms tend to decline with age, but many adult males with FXS remain hyperactive. Treatment with stimulant medication may be beneficial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/30/17896?source=see_link&amp;anchor=H12#H12\">",
"     \"Management of children and adolescents with fragile X syndrome\", section on 'Hyperactivity and inattention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Boys with FXS may have avoidant behaviors, particularly when their intellectual disability is severe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/40\">",
"     40",
"    </a>",
"    ]. They tend to avoid new situations and to move away from new objects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/39\">",
"     39",
"    </a>",
"    ]. However, they do not remain socially withdrawn or avoid familiar people. Their social skills often correlate with their cognitive level [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Boys with FXS also may have anxiety symptoms (nervousness, obsessive-compulsive disorder-like obsessions and perseverations), mood instability, aggressive behavior, and self-injurious behavior [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/43-45\">",
"     43-45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Prader-Willi phenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;A subgroup of boys with fragile X syndrome (FXS) have a phenotype similar to that of Prader-Willi syndrome (ie, obesity and hyperphagia) but do not have the characteristic cytogenetic or methylation abnormalities at 15q11-13 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/46-49\">",
"     46-49",
"    </a>",
"    ]. Autism is more common in boys with FXS and the Prader-Willi phenotype than in boys with FXS without the Prader-Willi phenotype (54 versus approximately 30 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/8/134?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of Prader-Willi syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/8/16516?source=see_link\">",
"     \"Epidemiology and genetics of Prader-Willi syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Full mutation in girls",
"    </span>",
"    &nbsp;&mdash;&nbsp;The phenotype of full mutation fragile X syndrome (FXS) in girls is much more variable than in boys because of individual differences in inactivation of the fragile X chromosome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/17\">",
"     17",
"    </a>",
"    ]. Approximately 50 percent of girls with a full fragile X mutation have normal intellect. The remaining 50 percent usually have milder features than boys, but the full spectrum of cognitive, behavioral, and physical findings may occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As many as 50 percent of females with the full mutation have some of the characteristic physical features (eg, prominent ears) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/50\">",
"     50",
"    </a>",
"    ]. Approximately 50 percent of women with the full mutation have IQs in the borderline or mild intellectual disability range [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/50-53\">",
"     50-53",
"    </a>",
"    ]. Cognitive impairment appears to correlate with the activation ratio of the fragile X chromosome, rather than the size of the amplification [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/54\">",
"     54",
"    </a>",
"    ]. As in males with full mutation FXS, cognitive function may decline after early childhood. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/10/26793?source=see_link\">",
"     \"Intellectual disability (mental retardation) in children: Definition; causes; and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many girls with the full mutation have associated behavioral or emotional problems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/43,50,55\">",
"     43,50,55",
"    </a>",
"    ]. They typically present with learning difficulties (especially in math), attention problems (or full attention deficit hyperactivity disorder), and shyness or social anxiety [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/18\">",
"     18",
"    </a>",
"    ]. Deficits in visual-motor coordination, executive function (eg, the ability to organize information, plan ahead, problem solve), and language (including selective mutism) are common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/18,56-58\">",
"     18,56-58",
"    </a>",
"    ]. Girls with the full mutation are at risk for affective and schizophrenia spectrum disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/43,59\">",
"     43,59",
"    </a>",
"    ]. Autistic behaviors (eg, communication and social interaction deficits, stereotypies) are more commonly reported among 6- to 16-year-old girls with FXS than age- and IQ-matched controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/57/32665?source=see_link&amp;anchor=H8#H8\">",
"     \"Specific learning disabilities in children: Clinical features\", section on 'Clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/41/664?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical features of autism spectrum disorders\", section on 'Autistic disorder'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/18/26922?source=see_link&amp;anchor=H2#H2\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation\", section on 'Core symptoms'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/18/26922?source=see_link&amp;anchor=H830607547#H830607547\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Premutation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with fragile X premutation have between 50 and 200 CGG repeats. At this level, the fragile X mental retardation-1 gene remains transcriptionally active, and the classic fragile X syndrome (FXS) phenotype does not occur. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Genetics and etiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There are three potential areas of concern for individuals with fragile X premutations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Premature ovarian failure in women, which is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/2/36903?source=see_link\">",
"       \"Clinical manifestations and evaluation of spontaneous primary ovarian insufficiency (premature ovarian failure)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Tremor-ataxia syndrome later in life, which is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/35/29242?source=see_link&amp;anchor=H18#H18\">",
"       \"The spinocerebellar ataxias\", section on 'Fragile X-associated tremor/ataxia syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Neurocognitive deficits",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the past, fragile X premutation was not thought to affect cognitive function. However, there are reports of individuals with premutation and neurobehavioral manifestations, including cognitive and social-skills deficits, anxiety, executive dysfunction, and autism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/8,61-63\">",
"     8,61-63",
"    </a>",
"    ]. Decreased fragile X mental retardation protein (FMRP) levels have been detected in some of these individuals, suggesting a spectrum of clinical severity related to relative FMRP deficit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The author's clinical practice has identified several boys with fragile X premutation and learning problems, developmental delay, or autistic features. This may reflect an ascertainment bias. However, they have identified four times more premutations in boys younger than 16 years with developmental problems who were referred for FMR1 gene testing than would be expected based upon the known prevalence of the premutation in males (unpublished data). Larger and more longitudinal studies are necessary, but these data provide additional evidence that fragile X premutations may affect neurocognitive and behavioral functioning in children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Associated disorders",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Autism",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is estimated that approximately 25 to 30 percent of children with fragile X syndrome (FXS) meet the criteria for autism (using autism diagnostic scales), and another 20 percent meet criteria for pervasive developmental disorder-not otherwise specified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/18,64-66\">",
"     18,64-66",
"    </a>",
"    ]. Boys with FXS and autism have greater impairments in cognitive skills, social interaction, academic achievement, language ability, and adaptive behavior than boys with FXS alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/8,64,67,68\">",
"     8,64,67,68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/3/38969?source=see_link&amp;anchor=H9#H9\">",
"     \"Diagnosis of autism spectrum disorders\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/41/664?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical features of autism spectrum disorders\", section on 'Autistic disorder'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Epilepsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 10 to 20 percent of boys with fragile X syndrome (FXS) and 5 percent of girls with FXS develop seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/69-71\">",
"     69-71",
"    </a>",
"    ]. The risk of seizures seems to be highest in childhood (peak incidence between six months and four years; mean age of onset two years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/8,70,71\">",
"     8,70,71",
"    </a>",
"    ]. Most are simple or complex partial seizures, including benign childhood epilepsy with centrotemporal spikes (also known as benign rolandic epilepsy), although other types can occur. The seizures are relatively easy to control and often spontaneously remit during childhood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/57/921?source=see_link&amp;anchor=H2#H2\">",
"     \"Benign partial epilepsies of childhood\", section on 'Benign epilepsy with centrotemporal spikes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/30/17896?source=see_link&amp;anchor=H14#H14\">",
"     \"Management of children and adolescents with fragile X syndrome\", section on 'Seizures'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to make the diagnosis of fragile X syndrome as early as possible so that appropriate interventions (eg, speech and language therapy, special education support, genetic counseling) can be initiated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/18\">",
"     18",
"    </a>",
"    ]. Surveys of parents of children diagnosed with FXS indicate a significant delay between the onset of their concerns (average age approximately 12 months) and the diagnosis of FXS (average age 35 to 37 months); approximately one-fourth of families had a second child with a full mutation before the first child was diagnosed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/72,73\">",
"     72,73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Clinical suspicion",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of a family history of fragile X syndrome (FXS), the diagnosis of FXS requires clinical suspicion based upon cognitive, developmental, or behavioral concerns, as described above. The diagnosis is confirmed by molecular testing. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Clinical features'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H21\">",
"     'FMR1 DNA analysis'",
"    </a>",
"    below.).",
"   </p>",
"   <p>",
"    The American Academy of Pediatrics Committee on Genetics recommends testing for FXS in children with any of the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/74\">",
"     74",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Developmental delay",
"     </li>",
"     <li>",
"      Borderline intellectual abilities",
"     </li>",
"     <li>",
"      Mental retardation",
"     </li>",
"     <li>",
"      Diagnosis of autism without a specific etiology",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Genetic counseling and genetic testing are also suggested for at-risk family members of patients with FXS (even if asymptomatic). Genetic testing should also be offered to females with primary ovarian insufficiency and patients over 50 years of age with progressive cerebellar ataxia and intention tremor, after an appropriate explanation of the test and its potential implications for the patient and their family [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Testing is also recommended in adults with intellectual disability without a specific etiology and typical physical features.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Family history questions that are suggestive of FXS include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cognitive effects &mdash; Intellectual disability, developmental delay, learning disabilities, specific problems with mathematics",
"     </li>",
"     <li>",
"      Speech delay or unusual speech pattern",
"     </li>",
"     <li>",
"      Autism spectrum disorders or autistic-like behaviors",
"     </li>",
"     <li>",
"      Attention deficit or attention deficit hyperactivity disorder",
"     </li>",
"     <li>",
"      Dysmorphic features &mdash; Macrocephaly, large ears, long face, broad forehead, prominent jaw, strabismus, large testicles",
"     </li>",
"     <li>",
"      Features of loose connective tissue &mdash; Hyperextensible joints, flat feet, hypotonia, mitral valve prolapse, hernias",
"     </li>",
"     <li>",
"      Neurologic symptoms &mdash; Seizures, late-onset progressive tremor, ataxia, difficulty walking, balance problems, short-term memory loss, loss of sensation in limbs",
"     </li>",
"     <li>",
"      Mental",
"      <span class=\"nowrap\">",
"       illness/personality",
"      </span>",
"      disorders &mdash; Depression, schizophrenia, bipolar disorder, obsessive-compulsive disorder, schizoaffective disorder, schizoid personality",
"     </li>",
"     <li>",
"      Behavioral problems &mdash; Impulsiveness, anger outbursts, violent behavior, solitary behavior, counseling or medication for behavioral difficulties",
"     </li>",
"     <li>",
"      Shyness, social anxiety, excessive worrying, counseling or medication for emotional difficulties",
"     </li>",
"     <li>",
"      Premature menopause, fertility problems",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     FMR1 DNA analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of fragile X syndrome (FXS) is based upon detection of an alteration in the FMR1 gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/2\">",
"     2",
"    </a>",
"    ]. Testing methods and indications for prenatal screening are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/54/23399?source=see_link&amp;anchor=H13#H13\">",
"     \"Prenatal screening and diagnosis for fragile X syndrome\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/54/23399?source=see_link&amp;anchor=H14#H14\">",
"     \"Prenatal screening and diagnosis for fragile X syndrome\", section on 'Screening'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The American College of Medical Genetics, American Academy of Pediatrics, and American Academy of Neurology suggest molecular testing for FXS in children with developmental delay, intellectual disability, or autism, particularly when associated with physical and behavioral characteristics of FXS or a relative with undiagnosed intellectual disability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/75\">",
"     75",
"    </a>",
"    ]. Although the yield of molecular testing in such individuals is low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/76\">",
"     76",
"    </a>",
"    ], early diagnosis is important for timely genetic counseling. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/54/23399?source=see_link&amp;anchor=H15#H15\">",
"     \"Prenatal screening and diagnosis for fragile X syndrome\", section on 'Candidates for screening'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/3/38969?source=see_link&amp;anchor=H27#H27\">",
"     \"Diagnosis of autism spectrum disorders\", section on 'Genetic testing'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/8/5257?source=see_link&amp;anchor=H7#H7\">",
"     \"Intellectual disability (mental retardation) in children: Evaluation\", section on 'Genetic testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Testing for mutations in the FMR1 gene is also suggested for individuals who had cytogenetic testing in the past if the results of the testing and the",
"    <span class=\"nowrap\">",
"     clinical/behavioral",
"    </span>",
"    phenotype are inconsistent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A detailed description of molecular genetic tests and the testing strategy for FMR1-related disorders is available through",
"    <a class=\"external\" href=\"file://genetests.org/\">",
"     GeneTests.org",
"    </a>",
"    . (See",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&amp;part=fragilex\">",
"     www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&amp;part=fragilex",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Additional evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following initial diagnosis of fragile X syndrome, children and adolescents should undergo a multidisciplinary evaluation to determine the extent of disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/2\">",
"     2",
"    </a>",
"    ]. The evaluation should include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete developmental and educational assessments (including speech and language evaluation and physical and occupational evaluation) for educational planning.",
"     </li>",
"     <li>",
"      Behavioral and psychology assessment to evaluate cognitive abilities, concentration or attention problems, anxiety, obsessive-compulsive disorder, aggression, and depression.",
"     </li>",
"     <li>",
"      Medical evaluation for feeding problems, gastroesophageal reflux, hypotonia, joint laxity, mitral valve prolapse, history of possible seizures, strabismus, evidence of recurrent otitis media, and scoliosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of fragile X syndrome (FXS) includes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34889/abstract/2,77,78\">",
"     2,77,78",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autism spectrum disorder. Children with FXS often have autistic behaviors and may have comorbid autism. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/41/664?source=see_link&amp;anchor=H3#H3\">",
"       \"Clinical features of autism spectrum disorders\", section on 'Autistic disorder'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Attention deficit hyperactivity disorder. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/18/26922?source=see_link&amp;anchor=H830607547#H830607547\">",
"       \"Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation\", section on 'Clinical features'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/18/26922?source=see_link&amp;anchor=H2#H2\">",
"       \"Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation\", section on 'Core symptoms'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other causes of intellectual disability or developmental delay, including:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Fragile XE syndrome (FRAXE). FRAXE, which is extremely rare, is characterized by mild intellectual disability without consistent physical features. It has been described in boys with expanded CCG repeats in fragile X mental retardation-2 gene, near the FMR1 gene.",
"     </li>",
"     <li>",
"      XXY (Klinefelter syndrome). Boys with Klinefelter syndrome may have specific learning disabilities, particularly in expressive language. In contrast to postpubertal boys with FXS, boys with XXY usually have small testes.(See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/53/10073?source=see_link&amp;anchor=H20#H20\">",
"       \"The child with tall stature or abnormally rapid growth\", section on 'Klinefelter syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cerebral gigantism (also known as Sotos syndrome). Characteristic features of cerebral gigantism include typical facial appearance (macrocephaly, frontal bossing, prominent chin, pointed chin, downslanting palpebral fissures), overgrowth, learning disability, behavioral problems, and congenital cardiac anomalies. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/53/10073?source=see_link&amp;anchor=H8#H8\">",
"       \"The child with tall stature or abnormally rapid growth\", section on 'Cerebral gigantism'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prader Willi-syndrome. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/8/134?source=see_link\">",
"       \"Clinical features, diagnosis, and treatment of Prader-Willi syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/10/26793?source=see_link\">",
"     \"Intellectual disability (mental retardation) in children: Definition; causes; and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fragile X syndrome resources for healthcare providers and families include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The National Fragile X Foundation (",
"      <a class=\"external\" href=\"file://www.fragilex.org/\">",
"       www.fragilex.org",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      FRAXA Research Foundation (",
"      <a class=\"external\" href=\"file://www.fraxa.org/\">",
"       www.fraxa.org",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The National Institute of Child Health and Human Development (",
"      <a class=\"external\" href=\"file://www.nichd.nih.gov/health/topics/fragile_x_syndrome.cfm\">",
"       www.nichd.nih.gov/health/topics/fragile_x_syndrome.cfm",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      GeneTests (",
"      <a class=\"external\" href=\"file://www.genetests.org\">",
"       www.genetests.org",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/4/12355?source=see_link\">",
"       \"Patient information: Fragile X syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fragile X syndrome (FXS) is the most frequent form of inherited intellectual disability, with a prevalence between 1 in 4000 and 1 in 6000 in males. The prevalence in females is approximately one-half of that in males. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prevalence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      FXS is an X-linked disorder. It is caused by a loss of function mutation in the fragile X mental retardation 1 (FMR1) gene that leads to decreased or absent fragile X mental retardation protein. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Genetics and etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical features of fragile X syndrome (FXS) vary depending upon the mutation state (full mutation versus premutation), degree of methylation, sex, and tissue variation (",
"      <a class=\"graphic graphic_table graphicRef73067 \" href=\"mobipreview.htm?41/36/42572\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All males with full mutation fragile X syndrome (FXS) have manifestations of FXS, but there is a wide range of physical, cognitive, and behavioral features. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Full mutation in boys'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Classic physical features include long and narrow face with prominent forehead and chin, large ears, and testicular enlargement, but these features typically are not obvious until adolescence or adulthood. Physical features in younger males may include macrocephaly, strabismus, midface hypoplasia, arched palate, mitral valve prolapse, hyperextensible joints, hypotonia, soft skin, and flexible flat feet.",
"     </li>",
"     <li>",
"      Intellectual disability is usually in the moderate range; expressive language is more affected than receptive language.",
"     </li>",
"     <li>",
"      Behavioral features may include hyperactivity, inattention, gaze aversion, stereotypic movements (eg, hand flapping, hand biting), hyperarousal, social anxiety, and unusual speech.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Girls with the full mutation usually have milder features than boys, and 50 percent have normal cognitive function, but the full spectrum of cognitive, behavioral, and physical findings may occur. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Full mutation in girls'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the absence of a family history of FXS, diagnosis of FXS requires clinical suspicion based upon cognitive, developmental, or behavioral concerns, as described above. Diagnosis is confirmed by molecular testing. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following initial diagnosis of fragile X syndrome, children and adolescents should undergo a multidisciplinary evaluation for educational planning, assessment of behavioral and emotional needs, and associated medical problems (eg, gastroesophageal reflux, hypotonia, joint laxity, mitral valve prolapse, seizures, strabismus, recurrent otitis media, scoliosis). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Additional evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of FXS includes autism spectrum disorders, attention deficit hyperactivity disorder, and other causes of intellectual disability or developmental delay. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/1\">",
"      Turner G, Webb T, Wake S, Robinson H. Prevalence of fragile X syndrome. Am J Med Genet 1996; 64:196.",
"     </a>",
"    </li>",
"    <li>",
"     Saul RA, Tarleton JC. FMR1-related disorders. GeneReviews. www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&amp;part=fragilex (Accessed on December 31, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/3\">",
"      de Vries BB, van den Ouweland AM, Mohkamsing S, et al. Screening and diagnosis for the fragile X syndrome among the mentally retarded: an epidemiological and psychological survey. Collaborative Fragile X Study Group. Am J Hum Genet 1997; 61:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/4\">",
"      Rousseau F, Rouillard P, Morel ML, et al. Prevalence of carriers of premutation-size alleles of the FMRI gene--and implications for the population genetics of the fragile X syndrome. Am J Hum Genet 1995; 57:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/5\">",
"      McConkie-Rosell A, Finucane B, Cronister A, et al. Genetic counseling for fragile x syndrome: updated recommendations of the national society of genetic counselors. J Genet Couns 2005; 14:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/6\">",
"      Verkerk AJ, Pieretti M, Sutcliffe JS, et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 1991; 65:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/7\">",
"      Rooms L, Kooy RF. Advances in understanding fragile X syndrome and related disorders. Curr Opin Pediatr 2011; 23:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/8\">",
"      Hagerman RJ, Berry-Kravis E, Kaufmann WE, et al. Advances in the treatment of fragile X syndrome. Pediatrics 2009; 123:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/9\">",
"      De Boulle K, Verkerk AJ, Reyniers E, et al. A point mutation in the FMR-1 gene associated with fragile X mental retardation. Nat Genet 1993; 3:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/10\">",
"      Coffee B, Ikeda M, Budimirovic DB, et al. Mosaic FMR1 deletion causes fragile X syndrome and can lead to molecular misdiagnosis: a case report and review of the literature. Am J Med Genet A 2008; 146A:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/11\">",
"      Reiss AL, Aylward E, Freund LS, et al. Neuroanatomy of fragile X syndrome: the posterior fossa. Ann Neurol 1991; 29:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/12\">",
"      Hessl D, Rivera SM, Reiss AL. The neuroanatomy and neuroendocrinology of fragile X syndrome. Ment Retard Dev Disabil Res Rev 2004; 10:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/13\">",
"      Reiss AL, Abrams MT, Greenlaw R, et al. Neurodevelopmental effects of the FMR-1 full mutation in humans. Nat Med 1995; 1:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/14\">",
"      McConkie-Rosell A, Lachiewicz AM, Spiridigliozzi GA, et al. Evidence that methylation of the FMR-I locus is responsible for variable phenotypic expression of the fragile X syndrome. Am J Hum Genet 1993; 53:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/15\">",
"      Merenstein SA, Sobesky WE, Taylor AK, et al. Molecular-clinical correlations in males with an expanded FMR1 mutation. Am J Med Genet 1996; 64:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/16\">",
"      Wright-Talamante C, Cheema A, Riddle JE, et al. A controlled study of longitudinal IQ changes in females and males with fragile X syndrome. Am J Med Genet 1996; 64:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/17\">",
"      Visootsak J, Warren ST, Anido A, Graham JM Jr. Fragile X syndrome: an update and review for the primary pediatrician. Clin Pediatr (Phila) 2005; 44:371.",
"     </a>",
"    </li>",
"    <li>",
"     Tsai AC, Pickler L, Tartaglia N, Hagerman R. Chromosomal disorders and fragile X syndrome. In: Developmental-behavioral pediatrics, 4th ed, Carey WB, Crocker AC, Coleman WL, et al (Eds), Saunders Elsevier, Philadelphia 2009. p.224.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/19\">",
"      Fryns JP. The fragile X syndrome. A study of 83 families. Clin Genet 1984; 26:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/20\">",
"      Lachiewicz AM, Dawson DV, Spiridigliozzi GA. Physical characteristics of young boys with fragile X syndrome: reasons for difficulties in making a diagnosis in young males. Am J Med Genet 2000; 92:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/21\">",
"      Butler MG, Brunschwig A, Miller LK, Hagerman RJ. Standards for selected anthropometric measurements in males with the fragile X syndrome. Pediatrics 1992; 89:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/22\">",
"      Cant&uacute; JM, Scaglia HE, Medina M, et al. Inherited congenital normofunctional testicular hyperplasia and mental deficiency. Hum Genet 1976; 33:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/23\">",
"      Cant&uacute; JM, Scaglia HE, Gonz&aacute;lez-Diddi M, et al. Inherited congenital normofunctional testicular hyperplasia and mental deficiency. A corroborative study. Hum Genet 1978; 41:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/24\">",
"      Lachiewicz AM, Dawson DV. Do young boys with fragile X syndrome have macroorchidism? Pediatrics 1994; 93:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/25\">",
"      Laxova R. Fragile X syndrome. Adv Pediatr 1994; 41:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/26\">",
"      Hagerman RJ, Van Housen K, Smith AC, McGavran L. Consideration of connective tissue dysfunction in the fragile X syndrome. Am J Med Genet 1984; 17:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/27\">",
"      Davids JR, Hagerman RJ, Eilert RE. Orthopaedic aspects of fragile-X syndrome. J Bone Joint Surg Am 1990; 72:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/28\">",
"      Kau AS, Meyer WA, Kaufmann WE. Early development in males with Fragile X syndrome: a review of the literature. Microsc Res Tech 2002; 57:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/29\">",
"      Kemper MB, Hagerman RJ, Altshul-Stark D. Cognitive profiles of boys with the fragile X syndrome. Am J Med Genet 1988; 30:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/30\">",
"      Dykens EM, Hodapp RM, Leckman JF. Strengths and weaknesses in the intellectual functioning of males with fragile X syndrome. Am J Ment Defic 1987; 92:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/31\">",
"      Freund LS, Reiss AL. Cognitive profiles associated with the fra(X) syndrome in males and females. Am J Med Genet 1991; 38:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/32\">",
"      Reiss AL, Hall SS. Fragile X syndrome: assessment and treatment implications. Child Adolesc Psychiatr Clin N Am 2007; 16:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/33\">",
"      Borghgraef M, Swillen A, Van den Berghe H, Fryns JP. Fragile X boys: evolution of the mental age in childhood. Preliminary data on 10 prepubertal boys. Genet Couns 1995; 6:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/34\">",
"      Fisch GS, Simensen R, Tarleton J, et al. Longitudinal study of cognitive abilities and adaptive behavior levels in fragile X males: a prospective multicenter analysis. Am J Med Genet 1996; 64:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/35\">",
"      Borghgraef M, Fryns JP, Dielkens A, et al. Fragile (X) syndrome: a study of the psychological profile in 23 prepubertal patients. Clin Genet 1987; 32:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/36\">",
"      Skinner M, Hooper S, Hatton DD, et al. Mapping nonverbal IQ in young boys with fragile X syndrome. Am J Med Genet A 2005; 132A:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/37\">",
"      Roberts JE, Mirrett P, Burchinal M. Receptive and expressive communication development of young males with fragile X syndrome. Am J Ment Retard 2001; 106:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/38\">",
"      Sudhalter V, Belser RC. Conversational characteristics of children with fragile X syndrome: tangential language. Am J Ment Retard 2001; 106:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/39\">",
"      Kau AS, Reider EE, Payne L, et al. Early behavior signs of psychiatric phenotypes in fragile X syndrome. Am J Ment Retard 2000; 105:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/40\">",
"      Budimirovic DB, Bukelis I, Cox C, et al. Autism spectrum disorder in Fragile X syndrome: differential contribution of adaptive socialization and social withdrawal. Am J Med Genet A 2006; 140A:1814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/41\">",
"      Baumgardner TL, Reiss AL, Freund LS, Abrams MT. Specification of the neurobehavioral phenotype in males with fragile X syndrome. Pediatrics 1995; 95:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/42\">",
"      Reiss AL, Freund L. Behavioral phenotype of fragile X syndrome: DSM-III-R autistic behavior in male children. Am J Med Genet 1992; 43:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/43\">",
"      Garber KB, Visootsak J, Warren ST. Fragile X syndrome. Eur J Hum Genet 2008; 16:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/44\">",
"      Tsiouris JA, Brown WT. Neuropsychiatric symptoms of fragile X syndrome: pathophysiology and pharmacotherapy. CNS Drugs 2004; 18:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/45\">",
"      Berry-Kravis E, Potanos K. Psychopharmacology in fragile X syndrome--present and future. Ment Retard Dev Disabil Res Rev 2004; 10:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/46\">",
"      Fryns JP, Haspeslagh M, Dereymaeker AM, et al. A peculiar subphenotype in the fra(X) syndrome: extreme obesity-short stature-stubby hands and feet-diffuse hyperpigmentation. Further evidence of disturbed hypothalamic function in the fra(X) syndrome? Clin Genet 1987; 32:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/47\">",
"      de Vries BB, Fryns JP, Butler MG, et al. Clinical and molecular studies in fragile X patients with a Prader-Willi-like phenotype. J Med Genet 1993; 30:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/48\">",
"      Schrander-Stumpel C, Gerver WJ, Meyer H, et al. Prader-Willi-like phenotype in fragile X syndrome. Clin Genet 1994; 45:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/49\">",
"      Nowicki ST, Tassone F, Ono MY, et al. The Prader-Willi phenotype of fragile X syndrome. J Dev Behav Pediatr 2007; 28:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/50\">",
"      Hagerman RJ, Jackson C, Amiri K, et al. Girls with fragile X syndrome: physical and neurocognitive status and outcome. Pediatrics 1992; 89:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/51\">",
"      Franke P, Leboyer M, Hardt J, et al. Neuropsychological profiles of FMR-1 premutation and full-mutation carrier females. Psychiatry Res 1999; 87:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/52\">",
"      Bennetto L, Pennington BF, Porter D, et al. Profile of cognitive functioning in women with the fragile X mutation. Neuropsychology 2001; 15:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/53\">",
"      de Vries BB, Wiegers AM, Smits AP, et al. Mental status of females with an FMR1 gene full mutation. Am J Hum Genet 1996; 58:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/54\">",
"      Willemsen R, Olmer R, De Diego Otero Y, Oostra BA. Twin sisters, monozygotic with the fragile X mutation, but with a different phenotype. J Med Genet 2000; 37:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/55\">",
"      Freund LS, Reiss AL, Abrams MT. Psychiatric disorders associated with fragile X in the young female. Pediatrics 1993; 91:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/56\">",
"      Hagerman RJ, Hills J, Scharfenaker S, Lewis H. Fragile X syndrome and selective mutism. Am J Med Genet 1999; 83:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/57\">",
"      Keysor CS, Mazzocco MM. A developmental approach to understanding Fragile X syndrome in females. Microsc Res Tech 2002; 57:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/58\">",
"      Cronister A, Hagerman RJ, Wittenberger M, Amiri K. Mental impairment in cytogenetically positive fragile X females. Am J Med Genet 1991; 38:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/59\">",
"      Reiss AL, Hagerman RJ, Vinogradov S, et al. Psychiatric disability in female carriers of the fragile X chromosome. Arch Gen Psychiatry 1988; 45:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/60\">",
"      Mazzocco MM, Kates WR, Baumgardner TL, et al. Autistic behaviors among girls with fragile X syndrome. J Autism Dev Disord 1997; 27:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/61\">",
"      Tassone F, Hagerman RJ, Taylor AK, et al. Clinical involvement and protein expression in individuals with the FMR1 premutation. Am J Med Genet 2000; 91:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/62\">",
"      Aziz M, Stathopulu E, Callias M, et al. Clinical features of boys with fragile X premutations and intermediate alleles. Am J Med Genet B Neuropsychiatr Genet 2003; 121B:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/63\">",
"      Farzin F, Perry H, Hessl D, et al. Autism spectrum disorders and attention-deficit/hyperactivity disorder in boys with the fragile X premutation. J Dev Behav Pediatr 2006; 27:S137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/64\">",
"      Bailey DB Jr, Mesibov GB, Hatton DD, et al. Autistic behavior in young boys with fragile X syndrome. J Autism Dev Disord 1998; 28:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/65\">",
"      Rogers SJ, Wehner DE, Hagerman R. The behavioral phenotype in fragile X: symptoms of autism in very young children with fragile X syndrome, idiopathic autism, and other developmental disorders. J Dev Behav Pediatr 2001; 22:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/66\">",
"      Zingerevich C, Greiss-Hess L, Lemons-Chitwood K, et al. Motor abilities of children diagnosed with fragile X syndrome with and without autism. J Intellect Disabil Res 2009; 53:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/67\">",
"      Philofsky A, Hepburn SL, Hayes A, et al. Linguistic and cognitive functioning and autism symptoms in young children with fragile X syndrome. Am J Ment Retard 2004; 109:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/68\">",
"      Bailey DB Jr, Hatton DD, Skinner M, Mesibov G. Autistic behavior, FMR1 protein, and developmental trajectories in young males with fragile X syndrome. J Autism Dev Disord 2001; 31:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/69\">",
"      Hagerman PJ, Stafstrom CE. Origins of epilepsy in fragile X syndrome. Epilepsy Curr 2009; 9:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/70\">",
"      Berry-Kravis E. Epilepsy in fragile X syndrome. Dev Med Child Neurol 2002; 44:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/71\">",
"      Musumeci SA, Hagerman RJ, Ferri R, et al. Epilepsy and EEG findings in males with fragile X syndrome. Epilepsia 1999; 40:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/72\">",
"      Centers for Disease Control and Prevention (CDC). Delayed diagnosis of fragile X syndrome--United States, 1990-1999. MMWR Morb Mortal Wkly Rep 2002; 51:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/73\">",
"      Bailey DB Jr, Raspa M, Bishop E, Holiday D. No change in the age of diagnosis for fragile x syndrome: findings from a national parent survey. Pediatrics 2009; 124:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/74\">",
"      Hersh JH, Saul RA, Committee on Genetics. Health supervision for children with fragile X syndrome. Pediatrics 2011; 127:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/75\">",
"      Sherman S, Pletcher BA, Driscoll DA. Fragile X syndrome: diagnostic and carrier testing. Genet Med 2005; 7:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/76\">",
"      Rauch A, Hoyer J, Guth S, et al. Diagnostic yield of various genetic approaches in patients with unexplained developmental delay or mental retardation. Am J Med Genet A 2006; 140:2063.",
"     </a>",
"    </li>",
"    <li>",
"     Wilson GN, Cooley WC. The fragile X syndrome. In: Preventive management of children with congenital anomalies and syndromes, Cambridge University Press, Cambridge, United Kingdom 2000. p.175.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34889/abstract/78\">",
"      Wiesner GL, Cassidy SB, Grimes SJ, et al. Clinical consult: developmental delay/fragile X syndrome. Prim Care 2004; 31:621.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2924 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-218.7.204.202-77C9F1D2D0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_4_34889=[""].join("\n");
var outline_f34_4_34889=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENETICS AND ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      NEUROANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Full mutation in boys",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Physical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Cognitive function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Language and speech",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Behavioral features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Prader-Willi phenotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Full mutation in girls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Premutation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Associated disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Autism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Clinical suspicion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Family history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      FMR1 DNA analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Additional evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2924\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2924|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/9/11412\" title=\"picture 1\">",
"      Typical facial features in a patient with Fragile X syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2924|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/36/42572\" title=\"table 1\">",
"      Fragile X syndrome genotype phenotype correlations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/18/26922?source=related_link\">",
"      Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/57/921?source=related_link\">",
"      Benign partial epilepsies of childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/41/664?source=related_link\">",
"      Clinical features of autism spectrum disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/8/134?source=related_link\">",
"      Clinical features, diagnosis, and treatment of Prader-Willi syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/2/36903?source=related_link\">",
"      Clinical manifestations and evaluation of spontaneous primary ovarian insufficiency (premature ovarian failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/3/38969?source=related_link\">",
"      Diagnosis of autism spectrum disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/8/16516?source=related_link\">",
"      Epidemiology and genetics of Prader-Willi syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/13/7386?source=related_link\">",
"      Genetic and environmental causes of birth defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/10/26793?source=related_link\">",
"      Intellectual disability (mental retardation) in children: Definition; causes; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/8/5257?source=related_link\">",
"      Intellectual disability (mental retardation) in children: Evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/30/17896?source=related_link\">",
"      Management of children and adolescents with fragile X syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/4/12355?source=related_link\">",
"      Patient information: Fragile X syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/54/23399?source=related_link\">",
"      Prenatal screening and diagnosis for fragile X syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/57/32665?source=related_link\">",
"      Specific learning disabilities in children: Clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/53/10073?source=related_link\">",
"      The child with tall stature or abnormally rapid growth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/35/29242?source=related_link\">",
"      The spinocerebellar ataxias",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_4_34890="Overview of running injuries of the lower extremity";
var content_f34_4_34890=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of running injuries of the lower extremity",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/4/34890/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/4/34890/contributors\">",
"     Lisa R Callahan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/4/34890/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/4/34890/contributors\">",
"     Karl B Fields, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/4/34890/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/4/34890/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/4/34890/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H24287076\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Running is one of the world&rsquo;s most popular forms of exercise, with millions of regular participants. In the United States alone, up to 40 million people run regularly, with more than 10 million running at least 100 days a year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/1\">",
"     1",
"    </a>",
"    ]. Although running is an effective way to achieve many health benefits, it is associated with a high risk of injury; yearly, up to half of runners report an injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/2\">",
"     2",
"    </a>",
"    ]. Although some injuries are traumatic, most are due to overuse.",
"   </p>",
"   <p>",
"    Given the popularity of running and the high rate of associated overuse injuries amenable to nonsurgical management, the primary care physician is likely to manage many injured runners and should be familiar with the diagnosis and treatment of the more common problems. The diagnosis and management of common lower extremity injuries associated with running are reviewed here. Detailed discussions of some specific injuries are found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34296?source=see_link\">",
"     \"Ankle sprain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43993?source=see_link\">",
"     \"Patellofemoral pain syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/35/14906?source=see_link\">",
"     \"Hamstring injuries\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/61/33747?source=see_link\">",
"     \"Stress fractures of the metatarsal shaft\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24287083\">",
"    <span class=\"h1\">",
"     GENERAL EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of lower extremity injuries in runners ranges from 19.4 to 79.3 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/3\">",
"     3",
"    </a>",
"    ]. The knee is the most commonly injured body part. The most common diagnoses include: patellofemoral pain syndrome, medial tibial stress syndrome (shin splints), Achilles tendinopathy, iliotibial band syndrome, plantar fasciitis, and stress fractures of the metatarsals and tibia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. According to a 2009 survey of more than 11,000 year-round runners, more than 10 percent experienced hip",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    low back pain in the previous 12 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/7\">",
"     7",
"    </a>",
"    ]. Among marathon runners, men report more hamstring and calf problems, whereas women report more hip complaints [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One retrospective survey of 2886 runners reported an overall injury rate of 46 percent, but found a higher incidence of soft tissue injuries to the calf, Achilles tendon, and hamstring among masters runners (&gt;40 years), who comprised 34 percent of the participants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/9\">",
"     9",
"    </a>",
"    ]. Injured runners were more likely to be male and to run six days per week and more than 30 miles each week.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24287090\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the popularity of running and the prevalence of related injuries, few studies have successfully identified the individual factors most responsible, suggesting that many running injuries are multifactorial. A history of prior injury is one of the few variables that has consistently been shown to increase the risk of incurring a subsequent running injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. Therefore, every injured runner seeking medical attention should be questioned about prior injuries, including treatments. Incomplete rehabilitation and failure to address potential risk factors associated with a prior injury increases the likelihood of recurrence. Greater mileage is another factor that is consistently associated with increased injury risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple risk factors are likely to contribute to running injuries. These can be stratified into intrinsic risk factors (eg, anatomic and other individual variables, including gender and BMI) and extrinsic risk factors (eg, training variables and equipment).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24287097\">",
"    <span class=\"h2\">",
"     Intrinsic risk factors",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24287105\">",
"    <span class=\"h3\">",
"     Anatomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Running injuries have been attributed to a number of anatomic variables, but the literature does not support many of these commonly held beliefs. A prime example is patellofemoral pain syndrome, a common cause of knee pain in runners. Lower extremity alignment that results in a greater Q angle at the knee (common in women) has often been cited as a cause of patellofemoral pain, but the large majority of studies refute this assertion.",
"   </p>",
"   <p>",
"    Foot type is another purported risk factor, but most studies of runners have not found consistent relationships between foot structure and specific injuries. One group studying collegiate cross country runners failed to identify any association between structural variations and the likelihood of developing exercise-related leg pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. One notable exception is cavus foot (high arch), which is associated with myriad injuries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/2,13\">",
"     2,13",
"    </a>",
"    ]. Specific injuries implicated in one or more studies include tibial stress fractures, patellofemoral pain syndrome, plantar fasciitis, and Achilles tendinopathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/4/19527?source=see_link\">",
"     \"Stress fractures of the tibia and fibula\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43993?source=see_link\">",
"     \"Patellofemoral pain syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/40/44681?source=see_link\">",
"     \"Plantar fasciitis and other causes of heel pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32537?source=see_link\">",
"     \"Achilles tendinopathy and tendon rupture\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some researchers have proposed that limb asymmetry (ie, leg length discrepancy) may increase injury risk, including stress fracture, [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/14,15\">",
"     14,15",
"    </a>",
"    ], but not all studies support this conclusion. These conflicting results suggest that anatomy alone is not sufficient to explain the high risk of injury among runners. Many experienced sports medicine clinicians believe that the important issue is whether the difference in leg length affects gait, rather than whether some measurement threshold is reached.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24287112\">",
"    <span class=\"h3\">",
"     Gender and age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gender and age may play a role in some running injuries, but the literature is conflicting in this regard:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective study of 844 male and female runners following a training program in preparation for a 10 km race reported an increased risk of injury among women age 50 or older and a lower risk among those 30 or younger [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective study of 532 novice runners participating in a 13 week training program noted that higher BMI was a risk factor for male but not female runners (HR 1.15; 95% CI, 1.05-1.26) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/17\">",
"       17",
"      </a>",
"      ]. Conversely, navicular drop was associated with injury in females but not males (HR 0.85; 95% CI, 0.75-0.97).",
"     </li>",
"     <li>",
"      A longitudinal study of former high school cross country runners over a 15 year period reported that girls had significantly higher injury rates than boys (16.7 versus 10.9 injuries per 1000 athletic exposures) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies consistently report an association between female gender and stress fracture risk, particularly among females with lower bone density, menstrual disturbances, and dietary deficiencies, as seen in the female athlete triad. The risk factors for stress fracture are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/19/23866?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of stress fractures\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While not consistently identified as a risk factor for running injury, age has been associated with a number of injuries in several observational studies. In contrast to the prospective study described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/16\">",
"     16",
"    </a>",
"    ], a retrospective study of more than 2000 runners found that age",
"    <strong>",
"     under",
"    </strong>",
"    34 was associated with an increased risk for patellofemoral pain syndrome in both men and women and an increased risk for iliotibial band syndrome, patellar tendinopathy, and tibial stress syndrome among men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/5\">",
"     5",
"    </a>",
"    ]. These findings may reflect that master runners (&gt;40 years) are primarily those with low injury rates, while runners who sustain multiple injuries are more likely to give up the sport.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24287119\">",
"    <span class=\"h2\">",
"     Extrinsic risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies have not consistently supported many traditional beliefs about the association between anatomic variations and injury risk. This has led many researchers to focus both on the effects of extrinsic factors on running injury and on the combination of intrinsic and extrinsic variables.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24287126\">",
"    <span class=\"h3\">",
"     Training variables",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measures to reduce running injuries often include modifying training variables, such as mileage and intensity. A systematic review concluded that reducing the distance, frequency, and duration of running may be effective in preventing soft tissue injuries in runners [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In male runners, excessive mileage is associated with higher injury rates. Multiple observational studies report that training volumes of 65 kilometers (40 miles) or more per week increase the risk of injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/2,3,9,10\">",
"     2,3,9,10",
"    </a>",
"    ]. While most sports medicine practitioners believe excessive mileage also affects female runners, well designed clinical studies have not been performed. It is unclear if more experienced runners are less susceptible.",
"   </p>",
"   <p>",
"    Abrupt changes in training regimens can contribute to running injuries. Studies of military recruits report that sudden increases in training volume or changes in the type of training (eg, adding hill running) increase injury rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/20\">",
"     20",
"    </a>",
"    ]. Although many sports medicine physicians advocate the 10 percent rule (ie, increase training volume by no more than 10 percent per week), a randomized trial of this approach in 532 novice runners reported no reduction in injuries (20.8 versus 20.3 percent with standard training) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/21\">",
"     21",
"    </a>",
"    ]. Nevertheless, common sense would suggest that gradual increases in training volume are less likely to cause injury than sudden increases. &nbsp;",
"   </p>",
"   <p>",
"    Some types of training may be protective. As an example, one research group found that regular interval training is protective against knee injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/22\">",
"     22",
"    </a>",
"    ]. Running surface probably affects injury rates. Running on concrete is associated with increased risk, while running on a treadmill reduces the stresses placed on the tibia and may thereby reduce the risk of tibial stress fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24287134\">",
"    <span class=\"h3\">",
"     Stretching and warm-ups",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is hard to draw firm conclusions about the effectiveness of stretching for reducing the risk of running injuries due to the large number of variables involved. These variables include a runner&rsquo;s baseline flexibility, the timing of stretching (pre-exercise, post-exercise, or not in conjunction with exercise), and the method of stretching (eg, dynamic, static, or proprioceptive neuromuscular facilitation). Despite a dearth of convincing evidence, many sports medicine physicians, running coaches, and runners believe that stretching is beneficial. However, further research is needed to determine which runners benefit and what methods to use.",
"   </p>",
"   <p>",
"    Multiple studies question the benefit of stretching, long a piece of injury prevention advice given to runners [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. A systematic review of randomized trials that assessed multiple interventions designed to prevent running injuries included six studies involving 5130 runners that looked at stretching exercises and concluded that stretching regimens do not protect against soft tissue injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/25\">",
"     25",
"    </a>",
"    ]. The stretching regimens included in these studies varied in the muscle groups targeted, the timing of the intervention (eg, before or after training), whether a warm-up was also performed, and other factors. Another review that included both randomized trials and cohort studies investigating the effect of stretching on injury reduction during sports also concluded that stretching was not associated with a reduction in total injuries (OR 0.93; CI 0.78-1.11) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stretching may have other benefits. As an example, in a study of 900 military recruits, those who stretched regularly experienced lower rates of low back and soft tissue pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/26\">",
"     26",
"    </a>",
"    ]. Stretching may also play a useful role in the management of other injuries, such as plantar fasciitis and Achilles tendinopathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/40/44681?source=see_link\">",
"     \"Plantar fasciitis and other causes of heel pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32537?source=see_link\">",
"     \"Achilles tendinopathy and tendon rupture\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is insufficient high-quality research in runners to determine whether warming up reduces injury rates. One randomized trial involving 421 runners found that an educational intervention regarding warm-up, cool-down, and stretching did not significantly reduce the risk of injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/27\">",
"     27",
"    </a>",
"    ]. Nevertheless, many clinicians advocate a dynamic warm-up or light jogging before engaging in strenuous running and we concur with this approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24287141\">",
"    <span class=\"h3\">",
"     Shoes and orthotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Debate continues about the role running shoes and orthotics may play in reducing the risk of injury. Based on limited evidence and clinical experience, we suggest using the running shoe that feels most comfortable and is well suited to the shape of the runner&rsquo;s foot [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are three basic types of running shoes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Shoes for runners with a low foot arch (overpronators) that are designed to minimize foot motion and maintain the foot in a neutral position",
"     </li>",
"     <li>",
"      Shoes for runners with a neutral foot shape",
"     </li>",
"     <li>",
"      Shoes with extensive cushioning for runners with a cavus foot (oversupinators)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many clinicians and runners believe that selecting the shoe best suited to the runner&rsquo;s foot type prevents injury; however, this concept is not well supported by the literature.",
"   </p>",
"   <p>",
"    The most robust studies of running shoes come from the military. Studies of recruits in the United States Marine Corps and Air Force undergoing basic training found that assigning shoes to recruits based on foot type did not significantly reduce injury rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. In addition, a systematic review did not find sufficient evidence to support the prescription of running shoes based upon foot type [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/31\">",
"     31",
"    </a>",
"    ]. However, one crossover randomized trial found that some popular, neutral-cushioned running shoes reduced plantar pressures in the cavus foot, theoretically reducing injury risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/32\">",
"     32",
"    </a>",
"    ]. It is possible that particular shoe types reduce the risk of injury in particular subpopulations of runners (eg, runners with cavus feet), but further study is needed to determine if this is so.",
"   </p>",
"   <p>",
"    Regardless of shoe type, several studies of the shock absorption properties of running shoes have shown that new shoes lose up to half their cushioning after 250 to 500 running miles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/33\">",
"     33",
"    </a>",
"    ]. Therefore, most sports medicine practitioners counsel runners to change their running shoes every 350 to 500 miles.",
"   </p>",
"   <p>",
"    Orthotics may reduce the risk of some injuries. A randomized controlled trial of 400 military officer trainees found a significant reduction in lower extremity overuse injuries in the trainees given customized orthotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/34\">",
"     34",
"    </a>",
"    ], while systematic reviews performed prior to this study concluded that orthotics &ldquo;probably&rdquo; reduce the risk of stress fracture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Other reports have found that orthotics reduce the pain associated with patellofemoral pain syndrome and cavus foot, both common issues in runners [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/37-39\">",
"     37-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although running barefoot or with &ldquo;minimalist&rdquo; shoes (eg, Vibram fivefingers&reg;) is gaining popularity, no controlled study to date has found evidence that such shoes have negative or positive effects upon performance or injury rates. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43993?source=see_link&amp;anchor=H1144607#H1144607\">",
"     \"Patellofemoral pain syndrome\", section on 'Barefoot running and minimalist shoes'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24287148\">",
"    <span class=\"h3\">",
"     Gait, strength, and biomechanics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many laboratory and observational studies have tried to determine the role of running biomechanics, vertical load, and plantar pressures in the development of running injuries. However, it is difficult to draw firm conclusions because many such studies involve small numbers and multiple factors are likely to contribute to the risk of injury. The following studies are illustrative:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A systematic review identified 13 articles comparing ground reaction forces (GRF) and vertical load in runners with and without stress fractures and found no significant difference in GRF between the two groups, but did find a significant difference in vertical loading rates [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study of 46 college students with running-related lower extremity injuries reported that specific components of gait, including increased pronation associated with increased pressure under the medial side of the foot, increased the risk of injury [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study of 45 healthy recreational runners found that subtle increases in step rate reduce the loads placed on the hip and knee during running, possibly reducing injury risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24287156\">",
"    <span class=\"h3\">",
"     Nutrition and supplementation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Little data exists to confirm or refute associations between nutritional factors and running injuries, with the important exception of stress fractures in female runners. Multiple studies report that inadequate vitamin D, calcium, and calorie intake increases the risk of stress fracture in female military recruits and runners. In addition, a prospective study of 86 female runners found that low-fat intake increased the risk of sustaining a low extremity injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/19/23866?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of stress fractures\", section on 'Risk factors'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    While there is little high-quality evidence to support any particular diet to prevent running injuries, optimal nutrition does enhance performance and recovery; common sense suggests that runners should eat a balanced diet that includes adequate lean protein and all essential vitamins and minerals. A position paper on nutrition and performance authored jointly by Dietitians of Canada, the American College of Sports Medicine, and the American Dietetic Association makes the following recommendations for athletes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/44\">",
"     44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Consume adequate calories. Insufficient calories can lead to reduced muscle mass and bone density, cessation of menses, and delayed recovery, and can increase fatigue and the risk of injury and illness. In general, fewer than 1800 to 2000",
"      <span class=\"nowrap\">",
"       kcals/day",
"      </span>",
"      is inadequate for an exercising individual, although many female runners restrict calories to this level. Several tools are available to estimate calorie needs, including the Dietary Reference Intakes and the Dietary Guidelines from the United States Department of Agriculture (available at",
"      <a class=\"external\" href=\"file://fnic.nal.usda.gov/interactiveDRI/\">",
"       fnic.nal.usda.gov/interactiveDRI/",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Consume adequate carbohydrates. Runners need approximately 6 to 10",
"      <span class=\"nowrap\">",
"       grams/kg",
"      </span>",
"      body weight of carbohydrates daily. Carbohydrates are critical for maintaining blood glucose during exercise and replenishing muscle glycogen. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/47/38649?source=see_link\">",
"       \"Dietary carbohydrates\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Consume adequate protein. Endurance athletes need 1.2 to 1.7",
"      <span class=\"nowrap\">",
"       grams/kg",
"      </span>",
"      body weight of protein daily.",
"     </li>",
"     <li>",
"      Consume adequate healthy fats. Healthy fats are a source of energy and provide essential fatty acids and fat-soluble vitamins, and should comprise 20 to 35 percent of total calorie intake. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/34/2601?source=see_link\">",
"       \"Dietary fat\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Stay hydrated. Water loss of as little as 2 percent body mass can decrease performance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/44\">",
"       44",
"      </a>",
"      ]. Runners should drink before, during, and after exercise. An easy rule of thumb is to weigh yourself before and after running, and drink 16 to 24 ounces (450 to 675 mL) of fluid for every pound (0.5 kg) lost during exercise. For long or intense exercise (eg, marathon), it is also important to replace electrolytes. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/42/1706?source=see_link\">",
"       \"Exercise-associated hyponatremia\"",
"      </a>",
"      .) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The timing of nutrient intake is important [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. A snack high in carbohydrate, moderate in protein, and low in fat and fiber is generally well-tolerated prior to exercise, whereas a snack higher in fat and fiber may cause gastrointestinal cramping or other distress. During exercise that lasts more than one hour, the athlete needs fluids and small amounts of carbohydrate, such as that found in sports drinks. The runner should be encouraged to replenish glycogen stores by consuming carbohydrate, 1.0 to 1.5",
"    <span class=\"nowrap\">",
"     gram/kg",
"    </span>",
"    of body weight, within 30 minutes of exercise, and to continue &ldquo;refueling&rdquo; every two hours for four to six hours. These goals can be met with relatively small amounts of food.",
"   </p>",
"   <p>",
"    Some researchers suggest adding protein to post-training snacks to aid muscle recovery; this is likely most beneficial to the runner who does not take in adequate carbohydrate following exercise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/47\">",
"     47",
"    </a>",
"    ]. Regardless of the specific approach, it is helpful for runners to become familiar with the concepts of &ldquo;grams&rdquo; and to learn how to apply this to their preferred foods.",
"   </p>",
"   <p>",
"    Although an adequate, well-rounded diet provides the majority of vitamins and minerals needed by athletes, special mention should be made of iron. Iron requirements are greater in endurance runners than in non-endurance athletes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/48\">",
"     48",
"    </a>",
"    ]. Iron is lost through sweat, the gastrointestinal tract, and menstruation. Thus, iron depletion is particularly common among premenopausal female runners. Any runner complaining of fatigue and decreased performance, especially females, should have a serum ferritin measured. If low, iron levels can be increased through diet and supplementation, but dietary replacement appears to be more effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although muscle adapts to regular exercise, some exercise-induced muscle damage occurs, mediated in part by the production of reactive oxygen species (ROS). As antioxidants reduce ROS, some athletes take high doses of the antioxidants (eg, vitamins C and E) hoping to attenuate muscle damage. However, there is little evidence to support this practice, and there is some evidence that interfering with ROS signals may impair muscle performance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/49\">",
"     49",
"    </a>",
"    ]. Runners should be informed of the potential risks associated with taking high doses of antioxidants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24287163\">",
"    <span class=\"h3\">",
"     Psychology",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little evidence that psychological factors play an important role in running injuries. One study of 30 runners found that those with type A personality traits did not have higher injury rates than others, but did have a higher risk of multiple injuries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/52\">",
"     52",
"    </a>",
"    ]. General studies of athletes have found a weak association between injury risk and such psychological factors as aggressiveness, exhaustion, and stressful life events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58496913\">",
"    <span class=\"h2\">",
"     Training suggestions to reduce injury risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the dearth of high-quality evidence to determine best practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/25\">",
"     25",
"    </a>",
"    ], we have found the training tips listed below to be helpful and to reduce the risk of injury for many runners:",
"   </p>",
"   <p>",
"    Beginning runners:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inexperienced runners often progress best using a combination of running and walking for a set time, and gradually increasing the percentage of time spent running.",
"     </li>",
"     <li>",
"      Beginning runners should start with no more than 20 minutes of total training time per day and increase training time no more than 5 minutes every 14 days.",
"     </li>",
"     <li>",
"      Most beginners do best on an every other day training program, which enables gradual improvement of their aerobic and musculoskeletal fitness.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mileage and rest guidelines:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      With the exception of elite runners, most individuals develop fewer injuries by limiting their total mileage to 40 miles (65 km) per week. (See",
"      <a class=\"local\" href=\"#H24287126\">",
"       'Training variables'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Runs longer than 13 miles (20 km) are best done no more frequently than once every 14 days",
"     </li>",
"     <li>",
"      Most individuals do best running no more than four or five days per week, with at least one rest day and one to two days doing other activities (ie, cross-training)",
"     </li>",
"     <li>",
"      Runners should limit themselves to two to three marathons per year",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Warm-up:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ease into training with a dynamic warm-up or light jog.",
"     </li>",
"     <li>",
"      Stretching before runs does not appear to reduce injuries; runners may do better stretching after their run or improving their strength and flexibility using other techniques, such as Yoga or Pilates. (See",
"      <a class=\"local\" href=\"#H24287134\">",
"       'Stretching and warm-ups'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Training variables:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Runners who experience frequent injuries are likely to benefit from running on a treadmill or a soft surface. Older athletes reduce their injury risk by running on soft surfaces. (See",
"      <a class=\"local\" href=\"#H24287126\">",
"       'Training variables'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Training techniques:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Runners need a solid base of aerobic fitness before adding speed work.",
"     </li>",
"     <li>",
"      Speed work is generally less risky if runners begin with the &ldquo;Fartlek&rdquo; (speed play) approach for 20 to 30 percent of their continuous runs for at least one month, before progressing to interval training (alternating fixed activity and rest periods) or timed repeat speed distances (eg, 10 sets of 200 M runs). Fartlek training consists of running at a faster pace at random times of variable duration during an otherwise standard distance run.",
"     </li>",
"     <li>",
"      Most runners need to limit the total mileage for interval or repeat distance speed training to 3 miles (5 km) or less.",
"     </li>",
"     <li>",
"      Fast downhill runs increase impact and injury risk and should be avoided.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Footwear:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Athletes should select a running shoe that feels extremely comfortable and is well-suited to their foot structure (eg, high arch). (See",
"      <a class=\"local\" href=\"#H24287141\">",
"       'Shoes and orthotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Barefoot running, while it may help to improve the biomechanics of some runners, probably only benefits those with sound running biomechanics at baseline and a foot structure that does not increase their injury risk, and should be limited to softer surfaces. Many running clinics are seeing an increase in metatarsal stress fractures in individuals new to this approach.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nutrition and recovery:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Runners should maintain adequate hydration and increase their salt intake if they tend to sweat heavily.",
"     </li>",
"     <li>",
"      Carbohydrate and protein intake soon (within about 30 minutes) after an intense workout speeds recovery. (See",
"      <a class=\"local\" href=\"#H24287156\">",
"       'Nutrition and supplementation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Supplemental strength training:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Many runners have disproportionately strong hamstrings. Cross training with a road or stationary bicycle or other equipment that develops quadriceps strength helps to balance the hamstring dominance of runners.",
"     </li>",
"     <li>",
"      Many runners have weak hip flexors and hip abductors. Performing supplemental strength exercises for these muscles may reduce the risk of injury.",
"     </li>",
"     <li>",
"      Achilles tendon flexibility wanes with age. Regular performance of eccentric strength exercises for the calf complex may help prevent injury. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32537?source=see_link&amp;anchor=H21#H21\">",
"       \"Achilles tendinopathy and tendon rupture\", section on 'Eccentric exercise rehabilitation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24287170\">",
"    <span class=\"h1\">",
"     EVALUATION OF THE INJURED RUNNER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of the injured runner begins with a thorough history, which should include inquiries about:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prior injuries and related treatments (including the runner&rsquo;s compliance with treatment)",
"     </li>",
"     <li>",
"      Current training patterns, including mileage, frequency, and training methods (eg, hill running); Inquire about changes in training that preceded the injury &nbsp;",
"     </li>",
"     <li>",
"      Shoe and orthotic use, including any recent change in shoes",
"     </li>",
"     <li>",
"      Training surface, including any recent change",
"     </li>",
"     <li>",
"      Injury details (eg, what provokes and reduces symptoms, duration of symptoms)",
"     </li>",
"     <li>",
"      Athletic activities other than running",
"     </li>",
"     <li>",
"      Detailed training history, including running and racing experience",
"     </li>",
"     <li>",
"      Medical conditions; prior surgeries",
"     </li>",
"     <li>",
"      Medication and supplement use",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Examination of the injured runner includes assessment not only of the injured area but of all related structures (ie, the runner&rsquo;s entire &ldquo;kinetic chain&rdquo;), noting any imbalances or deficits in structure (eg, leg length discrepancy), strength, flexibility, or motion. Discrepancies may exist between legs or between muscle groups of the same leg (eg, quadriceps disproportionately stronger than hamstrings). One way to organize each element (eg, observation, strength testing) of the physical examination is to begin with proximal structures (eg, spine and pelvis) and work distally. Careful observation of the patient&rsquo;s walking and running gaits helps to confirm that the anatomic problems identified during a stationary examination affect biomechanical performance.",
"   </p>",
"   <p>",
"    Begin your assessment by asking the injured runner to stand in front of you, noting their posture and lower extremity alignment. Observe the legs from hip-to-foot looking for symmetry. Note the structure of the knee, especially genu varum (which may be associated with iliotibial band syndrome or medial meniscal pathology) or valgus (often seen in women with patellofemoral pain). Note the position of the patella and any apparent muscular asymmetry. Ask the patient to stand on one foot and then the other, watching for balance, control, and posture. Does the unsupported hip sag (ie, a positive Trendelenberg test)? A positive Trendelenberg test suggests weakness of the gluteus medius, a common finding in runners with hip and knee pain. Make note of foot structure and position. Does the runner have a normal, high, or flat arch? Ask the patient to walk and to squat. Watch for a limp, stiffness of one limb, and a tendency to shift weight off one limb.",
"   </p>",
"   <p>",
"    Screen for tenderness and altered mobility of the spine, pelvis (including sacroiliac joints), hips, knees, ankles, and feet before turning your attention to the area of complaint. Be sure to assess muscle strength and neurovascular status throughout the lower extremity. Weakness of the hip musculature (particularly hip abductors) is common among novice runners, frequently contributing to lower extremity pain, especially patellofemoral pain syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43993?source=see_link\">",
"     \"Patellofemoral pain syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following findings may be noted during the examination:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hip flexion, rotation, or abduction weakness is present with many lower extremity injuries, particularly those affecting the hip or knee.",
"     </li>",
"     <li>",
"      Increased lumbar lordosis suggests weak anterior core muscles, a common condition in runners with hip weakness.",
"     </li>",
"     <li>",
"      Vastus medialis atrophy or asymmetry can occur with patellofemoral pain syndrome (PFPS), or in athletes who have had knee surgery.",
"     </li>",
"     <li>",
"      Tenderness along the medial tibial border bilaterally is often present with medial tibial stress syndrome (MTSS), or &ldquo;shin splints.&rdquo;",
"     </li>",
"     <li>",
"      Loss of normal lumbar lordosis (with or without back pain) is often present with tight hamstrings.",
"     </li>",
"     <li>",
"      Loss of internal rotation of the hip occurs with femoral neck stress fracture.",
"     </li>",
"     <li>",
"      Asymmetry of the quadriceps muscles is common in runners with osteoarthritis of the hip.",
"     </li>",
"     <li>",
"      Pain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a sense of &ldquo;catching&rdquo; in the groin with the knee flexed to 90 degrees suggests a labral tear, but also may be seen with iliopsoas tendinopathy.",
"     </li>",
"     <li>",
"      Localized tenderness and a positive hop test suggest a tibial stress fracture.",
"     </li>",
"     <li>",
"      Achilles tendon thickening or nodules suggests Achilles tendinopathy.",
"     </li>",
"     <li>",
"      Tenderness at the medial insertion of the plantar fascia into the calcaneus suggests plantar fasciitis.",
"     </li>",
"     <li>",
"      Hallux limitus or hallux rigidus and reduced ankle dorsiflexion can develop with plantar fasciitis or calf muscle injuries.",
"     </li>",
"     <li>",
"      Splayed toe sign and forefoot widening can occur with metatarsalgia.",
"     </li>",
"     <li>",
"      Leg length inequality may be present with stress fractures, and possibly with iliotibial band syndrome and lower back and pelvic injuries.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Diagnostic imaging, including plain radiographs, ultrasound, magnetic resonance imaging (MRI), computed tomography (CT), and bone scan may be necessary in some cases to make a definitive diagnosis. However, the clinician should have a clear differential diagnosis in mind before ordering such studies.",
"   </p>",
"   <p>",
"    Once a diagnosis is made and a treatment plan established, the clinician and athlete should work together to uncover and eliminate potential contributing factors, as many running injuries appear to be multifactorial. The mainstay of treatment for the vast majority of running injuries is &ldquo;relative rest,&rdquo; which means stopping running, or at a minimum significantly reducing mileage, while the injury heals. Depending upon the injury, most runners can maintain reasonable conditioning by performing non-impact exercises in a pool or on a bike, or by using other equipment (eg, rowing machine).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7409762\">",
"    <span class=\"h1\">",
"     SPECIFIC INJURIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2791000\">",
"    <span class=\"h2\">",
"     Hip injuries",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2791008\">",
"    <span class=\"h3\">",
"     Overview and approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hip injuries are less common in runners than injuries to the lower extremity and they can be difficult to diagnose. Nevertheless, during jogging, the hip joint is subjected to loads up to eight times body weight and both acute and chronic injuries can occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/54\">",
"     54",
"    </a>",
"    ]. In runners, the differential diagnosis of hip pain includes gluteus medius tendinopathy, piriformis syndrome, stress fracture of the femoral neck, labral tear, and, less often, radicular pain from the lumbar spine. Better understanding of the functional anatomy of the hip suggests a correlation between hip muscle weakness and injury to the low back or lower extremity in athletes, including runners [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/55-57\">",
"     55-57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2791015\">",
"    <span class=\"h3\">",
"     Gluteus medius weakness and tendinopathy and piriformis syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gluteus medius originates along the external surface of the ilium and runs distally and laterally to its attachment on the greater trochanter of the femur (",
"    <a class=\"graphic graphic_figure graphicRef53747 \" href=\"mobipreview.htm?12/34/12841\">",
"     figure 1",
"    </a>",
"    ). The gluteus medius abducts the hip and assists with pelvic stability during running. Weakness of the muscle typically causes pain with hip abduction and rotation. Pain generally increases when the muscle is stretched and there may be focal tenderness at the muscle&rsquo;s insertion, just medial and superior to the greater trochanter. Difficulty maintaining a level pelvis while standing on one leg (positive Trendelenburg sign) may be noted.",
"   </p>",
"   <p>",
"    The piriformis muscle is a small but important external rotator of the hip that crosses the sciatic nerve and is believed by some to cause sciatica-type pain when it compresses the nerve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. However, the existence of this so-called &ldquo;piriformis syndrome&rdquo; remains controversial and diagnosis is difficult [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]. Piriformis syndrome in the runner may be associated with foot overpronation, weakness of the gluteal muscles and other hip abductors, and tightness of the hip adductors.",
"   </p>",
"   <p>",
"    The mainstay of treatment for both gluteus medius tendinopathy and piriformis syndrome is physical therapy and correction of biomechanical abnormalities. Orthotics and massage therapy may be useful;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and nonsteroidal antiinflammatory drugs may be used for analgesia. There are reports of using injections of local anesthetics, glucocorticoids, and botulinum toxin (Botox) to treat piriformis syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2791022\">",
"    <span class=\"h3\">",
"     Femoral neck stress fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stress fractures of the femoral neck are an uncommon but important cause of hip or groin pain in the adult runner because of the relatively high risk of nonunion. (See",
"    <a class=\"local\" href=\"#H24287205\">",
"     'Stress fractures'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2791029\">",
"    <span class=\"h3\">",
"     Labral tear",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acetabular labrum is a ring of fibrocartilage and dense connective tissue attached to the bony rim of the acetabulum. It is thought to be largely avascular. Although the labrum&rsquo;s function is not fully understood, it is thought to provide stability and decrease the stress placed on the hip joint. Therefore, a significant tear in the labrum can increase stress on the hip joint, decrease stability, and ultimately lead to damage of the articular cartilage.",
"   </p>",
"   <p>",
"    Labral tears are reported in sports that require frequent hip rotation, such as soccer and hockey, and in runners, especially female runners. Runners with a labral tear typically complain of pain in the anterior hip or groin. They may have mechanical symptoms, including clicking, locking, catching, or giving way (so-called &ldquo;snapping hip&rdquo;). Other hip injuries that may produce such mechanical symptoms include iliopsoas tendinopathy.",
"   </p>",
"   <p>",
"    Labral tears are complex and often frustrating to treat. Physical therapy has mixed results. Arthroscopic surgery is often helpful, but the recovery can be prolonged. Runners diagnosed with labral tears should be counseled carefully regarding the paucity of evidence for determining the best treatment and the benefits and risks of each approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2791036\">",
"    <span class=\"h3\">",
"     Iliopsoas tendinopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iliopsoas tendinopathy produces symptoms similar to a labral tear but presents more often as anterior hip pain in younger athletes, especially after a rapid growth spurt, and is more easily treated. Athletes who repeatedly engage in forceful flexion of the hip, including track and field athletes (eg, hurdlers, jumpers), are at greatest risk. Examination usually reveals tight, painful hip flexors (",
"    <a class=\"graphic graphic_figure graphicRef52413 \" href=\"mobipreview.htm?24/44/25282\">",
"     figure 2",
"    </a>",
"    ). Iliopsoas tendinopathy typically responds within a few weeks to activity modification,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and nonsteroidal antiinflammatory drugs, and physical therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7409898\">",
"    <span class=\"h2\">",
"     Knee and thigh injuries",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24287177\">",
"    <span class=\"h3\">",
"     Knee pain (patellofemoral pain syndrome)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Knee pain is among the most common complaints from runners. Most such runners are diagnosed with patellofemoral pain syndrome (PFPS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/5,64\">",
"     5,64",
"    </a>",
"    ]. Despite the prevalence of this diagnosis, no consensus exists about its etiology or the factors most responsible for causing pain. Overuse and malalignment are commonly cited causative factors. In addition, runners (especially females) with PFPS often have decreased strength in hip abduction, external rotation, and extension compared to healthy controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. Patients with PFPS typically complain of anterior knee pain that worsens with squatting, running, prolonged sitting, or when ascending or descending steps. Pain is often poorly localized \"under\" or \"around\" the patella. Details about the diagnosis and management of PFPS are provided separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43993?source=see_link\">",
"     \"Patellofemoral pain syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24287184\">",
"    <span class=\"h3\">",
"     Iliotibial band syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The iliotibial band (ITB) consists of connective tissue that runs from the ilium to the anterolateral aspect of the proximal tibia (",
"    <a class=\"graphic graphic_figure graphicRef70825 \" href=\"mobipreview.htm?31/32/32260\">",
"     figure 3",
"    </a>",
"    ). It is involved in hip abduction and internal rotation, knee extension and flexion, and helps to stabilize the knee during running. &nbsp;",
"   </p>",
"   <p>",
"    The iliotibial band syndrome (ITBS), which occurs primarily in runners, is characterized by an aching or burning pain at the site where the ITB courses over the lateral femoral condyle; occasionally the pain radiates up the thigh toward the hip. Runners often complain of such lateral knee pain while running, but pain may persist after training, especially with activity that requires repetitive flexion and extension of the knee, such as ascending or descending stairs or standing from a seated position. The diagnosis of ITBS is clinical; no imaging is typically needed.",
"   </p>",
"   <p>",
"    The ITB does not attach to bone between the hip and knee, and for years many clinicians believed that repeated flexion and extension of the knee caused the band to rub back and forth over the lateral femoral condyle, creating friction and inflaming the tissue beneath the band. However, subsequent investigations suggest that the ITB moves very little and that the pain of ITBS results from compression of a layer of innervated fat and connective tissue between the ITB and lateral femoral epicondyle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Biomechanical studies and our clinical experience suggest that the underlying causes of ITBS are multifactorial but that patients often fall into two major categories [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/68-70\">",
"     68-70",
"    </a>",
"    ]. One group (usually less experienced or female runners) demonstrates weak hip abduction, increased hip adduction, and internal rotation of the knee (genu valgum); the other group (often advanced runners) manifests decreased hip adduction and external rotation of the knee (genu varum). Physical therapy for the first group should emphasize strengthening the hip abductors; therapy for the latter group should include stretching exercises to improve hip adduction. Other risk factors for ITBS include excessive running mileage, worn shoes, repetitive running on uneven terrain, and continually running in only one direction on a track [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ice, analgesics (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and nonsteroidal antiinflammatory drugs), and a short period of rest are usually effective at reducing acute discomfort. Glucocorticoid injections may be helpful for symptomatic relief in refractory or severe cases, or when there is associated bursitis, but there is little evidence supporting such treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/72\">",
"     72",
"    </a>",
"    ]. Once inflammation is reduced, the patient begins stretching and strengthening exercises to correct identified deficits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. A study comparing three common stretches for the ITB found all to be effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/75\">",
"     75",
"    </a>",
"    ]. In one limited randomized trial, deep transverse friction massage was not beneficial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24287191\">",
"    <span class=\"h3\">",
"     Hamstring injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hamstring injuries are typically acute; the injured runner complains of developing a sudden, sharp pain in the posterior thigh while running at high speed or up hills. Examination findings depend upon the severity of injury and may include a limping gait (due to the inability to fully extend the knee); ecchymosis; a visible or palpable defect in the hamstring muscle; focal tenderness; and pain or weakness with muscle contraction. Details about the diagnosis and management of hamstring muscle injuries are provided separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/35/14906?source=see_link\">",
"     \"Hamstring injuries\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24287198\">",
"    <span class=\"h3\">",
"     Knee OA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise is recommended for most patients with OA of the hip or knee. Although water-based exercise is often suggested, multiple studies confirm the value of regimens involving full weightbearing exercise. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/30/2538?source=see_link&amp;anchor=H9#H9\">",
"     \"Nonpharmacologic therapy of osteoarthritis\", section on 'Exercise'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite this evidence, many clinicians subscribe to the traditional teaching that patients with osteoarthritis (OA) of the knee should not run because it exacerbates the condition. The medical literature, however, does not support the contention that running contributes to the degeneration of articular cartilage in the knee [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/77\">",
"     77",
"    </a>",
"    ]. Examples of such studies include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective cohort study followed 45 runners and 53 controls over 18 years and, using a validated score to assess for OA, found no difference between the two groups in the progression or the number of severe cases of knee OA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/78\">",
"       78",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another prospective study of 16 runners and 13 nonrunners found no evidence that running predisposes to OA of the lower extremities [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Multiple retrospective studies have found no evidence of premature damage of articular cartilage or increased risk for OA among long-distance runners [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/80-82\">",
"       80-82",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Small clinical and laboratory studies using MRI to evaluate the knees of long-distance runners report no significant damage to articular cartilage following a race and no major differences when images were compared to those of active nonrunners [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/83-85\">",
"       83-85",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24287205\">",
"    <span class=\"h2\">",
"     Stress fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stress fractures in runners occur most often in the tibia, but can develop in any bone of the lower extremity, including the metatarsals, navicular, and femoral neck [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/86\">",
"     86",
"    </a>",
"    ]. Detailed discussions of stress fractures, including a description of those at high risk for nonunion, appear separately; a brief description and information of particular importance for runners is provided here. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/19/23866?source=see_link\">",
"     \"Overview of stress fractures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/4/19527?source=see_link\">",
"     \"Stress fractures of the tibia and fibula\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/61/33747?source=see_link\">",
"     \"Stress fractures of the metatarsal shaft\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When evaluating the runner with a suspected stress fracture, the clinician should ask for a description of the pain, running patterns and recent changes in training, shoe and orthotic wear, and prior injuries. Information about the patient&rsquo;s nutrition and menstrual history, and any family history of metabolic bone disease, are also important.",
"   </p>",
"   <p>",
"    Typically, the runner with a stress fracture complains of focal pain that is insidious in onset, increases as a run progresses, and improves with rest. Over time, if the athlete persists in running despite such symptoms, pain occurs with less strenuous activity and ultimately at rest. Some runners present with acute onset of severe pain, which may result from a complete fracture at the site of a preexisting stress fracture.",
"   </p>",
"   <p>",
"    Important risk factors for developing stress fractures include a history of prior stress fracture, increasing volume and intensity of training, poor running biomechanics, female gender and menstrual irregularity, a diet poor in calcium, and poor bone health. The management of stress fractures in runners is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/19/23866?source=see_link&amp;anchor=H39#H39\">",
"     \"Overview of stress fractures\", section on 'Treatment concepts'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinician should be aware that stress fractures at high risk for nonunion (eg, femoral neck and navicular) are more common in runners than in other athletes. If a high-risk stress fracture is suspected, an aggressive work-up is warranted and immediate orthopedic consultation should be obtained if the diagnosis is confirmed. A history of recurrent stress fracture or a fracture in cancellous bone suggests that the runner&rsquo;s bone mineral density may be low and should be measured.",
"   </p>",
"   <p>",
"    Femoral neck stress fractures should be suspected in any distance runner with groin pain of insidious onset, especially female distance runners at risk for the &ldquo;female athlete triad&rdquo; (eating disorder, amenorrhea, and osteoporosis). The female athlete triad is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/3/36919?source=see_link\">",
"     \"Amenorrhea and infertility associated with exercise\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Navicular stress fractures occur more often in male athletes participating in track and field events (eg, hurdlers, jumpers, sprinters) and middle distance runners [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/86\">",
"     86",
"    </a>",
"    ]. The athlete with a navicular stress fracture often presents with insidious pain in the midfoot or arch that increases with jumping.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24287212\">",
"    <span class=\"h2\">",
"     Medial tibial stress syndrome (shin splints) and tibial stress fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians confronted by runners with shin pain must distinguish between stress fractures of the tibia and medial tibial stress syndrome (MTSS), often referred to as &ldquo;shin splints.&rdquo; Although the history may be similar, a focal, palpable area of tenderness is present in most patients with stress fractures, whereas tenderness is much more diffuse and there are no discrete palpable lesions in those with MTSS. Imaging may be necessary in some cases to rule out a stress fracture. Plain radiographs are normal in patients with shin splints, but may also be unrevealing early in the course of a stress fracture. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/4/19527?source=see_link&amp;anchor=H4#H4\">",
"     \"Stress fractures of the tibia and fibula\", section on 'Clinical presentation and examination'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/4/19527?source=see_link&amp;anchor=H5#H5\">",
"     \"Stress fractures of the tibia and fibula\", section on 'Radiographic findings'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Distinguishing between the two diagnoses affects treatment: a runner with a stress fracture should avoid running and pursue non-impact activities like swimming or cycling while the stress fracture heals, while the runner with MTSS can continue running but should reduce the total mileage. A systematic review found that shock-absorbing insoles may reduce symptoms and prevent recurrence of MTSS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H957904\">",
"    <span class=\"h2\">",
"     Chronic exertional compartment syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic exertional compartment syndrome (CECS) occurs when increased pressure within a muscle compartment reduces blood flow, leading to muscle ischemia and pain when metabolic demands cannot be met. The patient with CECS is often a young runner who describes gradually increasing pain in a specific muscle region (usually the lower leg) during exertion. The pain may be described as aching, squeezing, cramping, or tightness. Pain generally begins within several minutes of starting a run, often at a specific point in training. Runners can often describe the time or distance required for symptoms to develop. Pain resolves completely with rest, although not immediately upon stopping exercise. The diagnosis and management of CECS is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/35/28215?source=see_link\">",
"     \"Chronic exertional compartment syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24287219\">",
"    <span class=\"h2\">",
"     Foot and ankle injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Foot and ankle injuries account for up to 20 percent of running injuries, and are the most common injury reported by distance runners and marathoners [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/88\">",
"     88",
"    </a>",
"    ]. This is not surprising given that the ground reaction forces the foot must absorb with each stride are several times body weight. The most common foot injuries in runners are overuse injuries of soft tissues, including tendons and fascia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24287226\">",
"    <span class=\"h3\">",
"     Plantar fasciitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plantar fasciitis (PF) is the most common cause of rearfoot pain in runners. The predominant symptom of PF is pain in the plantar region of the foot that increases when initiating push-off while walking or running. The hallmark for diagnosis is focal point tenderness. The etiology of PF remains unclear but the condition is often attributed to training errors, biomechanical problems, and excessive foot pronation or supination, and is more common in older and heavier runners [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/88-90\">",
"     88-90",
"    </a>",
"    ]. The biomechanical abnormality most often associated with PF is decreased dorsiflexion of the foot and toes and thus stretching is an important part of treatment. Another common biomechanical problem is weakness of the plantar flexors, which some clinicians believe is best treated with eccentric strengthening exercises. The diagnosis and management of PF is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/40/44681?source=see_link&amp;anchor=H2#H2\">",
"     \"Plantar fasciitis and other causes of heel pain\", section on 'Plantar fasciitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24287240\">",
"    <span class=\"h3\">",
"     Tendon injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Runners are susceptible to tendon injuries at a number of sites, the Achilles being most common. Others include the peroneal, posterior tibial, and anterior tibial tendons (",
"    <a class=\"graphic graphic_figure graphicRef58376 \" href=\"mobipreview.htm?27/42/28326\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Achilles tendinopathy occurs in up to 10 percent of elite runners annually [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/91\">",
"     91",
"    </a>",
"    ]; runners with more than 10 years of experience are at higher risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/92\">",
"     92",
"    </a>",
"    ]. Among former elite male distance runners, the lifetime risk is reported to be as high as 52 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/93\">",
"     93",
"    </a>",
"    ]. The biomechanical factors that predispose runners to Achilles tendinopathy remain unclear but are the subject of research [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/94-96\">",
"     94-96",
"    </a>",
"    ]. Poor flexibility of the Achilles tendon, overpronation, and valgus or varus deformity of the calcaneus all affect rear-foot mechanics, possibly increasing torque on the Achilles. Some clinicians advocate using a heel pad or orthotic in runners to counteract this effect.",
"   </p>",
"   <p>",
"    Patients with Achilles tendinopathy typically complain of pain or stiffness 2 to 6 cm above the posterior calcaneus. The pain is frequently described as burning, increases with activity, and is relieved by rest. Runners with the condition often have recently increased their training intensity or have been training rigorously for a long time. A history of excessive foot supination, increased speed work or hill training, or improper (eg, poorly fitting shoes, tennis instead of running shoes) or worn out footwear may be found. The diagnosis and management of Achilles tendinopathy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32537?source=see_link\">",
"     \"Achilles tendinopathy and tendon rupture\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Peroneal tendon injury may be traumatic, usually from a lateral ankle sprain, or related to overuse and associated with excessive foot pronation and weak foot plantar flexors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/97\">",
"     97",
"    </a>",
"    ]. Examination reveals tenderness along the course of the tendon posterior or inferior to the lateral malleolus, which increases with resisted eversion.",
"   </p>",
"   <p>",
"    Posterior tibial tendinopathy is typically an overuse injury that develops following an abrupt increase in training intensity, and is associated with poor foot and calf flexibility and excessive foot pronation. Examination findings include tenderness along the course of the posterior tibial tendon posterior or inferior to the medial malleolus, which increases with resisted inversion.",
"   </p>",
"   <p>",
"    Anterior tibial tendinopathy is a common cause of anterior ankle pain in runners, and often develops following abrupt increases in training, particularly hill running. Examination often reveals tenderness, and possibly swelling, of the tendon as it crosses the ankle joint. Pain increases with resisted dorsiflexion.",
"   </p>",
"   <p>",
"    The treatment of overuse tendinopathies is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/39/20089?source=see_link\">",
"     \"Overview of the management of overuse (chronic) tendinopathy\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24287247\">",
"    <span class=\"h3\">",
"     First metatarsal phalangeal joint",
"    </span>",
"    &nbsp;&mdash;&nbsp;Running generates substantial forces across the forefoot and thus can aggravate hallux rigidus or hallux valgus (bunion) of the metatarsal phalangeal (MTP) joint of the great toe (ie, first MTP joint). The sesamoid bones located on the plantar surface of the MTP joint can become inflamed from running and may cause discomfort. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38750562\">",
"    <span class=\"h4\">",
"     Hallux rigidus and hallux valgus (bunion)",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little high-quality evidence to provide insight into the causes and guide the management of hallux rigidus. Hallux rigidus is presumed to be a degenerative condition of the first MTP joint associated with either an acute injury (eg, forced hypertension of the great toe, so-called &ldquo;turf toe&rdquo;) or repetitive microtrauma, as would occur with running [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/98,99\">",
"     98,99",
"    </a>",
"    ]. Genetic predisposition may play a role. The result is limited dorsiflexion of the first MTP joint; approximately 60 degrees of dorsiflexion is needed for normal gait.",
"   </p>",
"   <p>",
"    Runners with hallux rigidus are typically older than 30 and complain of pain at the dorsum of the great toe. However, some runners may present with vague lateral forefoot pain. This presentation is likely due to runners shifting their body weight to the lateral foot during the foot-strike phase of running to reduce the load on the great toe. It remains unclear whether running is a cause of hallux rigidus or aggravates symptoms elicited by other factors. Shoes with a toe box that is too small or pointed may contribute.",
"   </p>",
"   <p>",
"    Hallux valgus (ie, bunion) deformity is defined as a lateral deviation of the hallux (great toe) on the first metatarsal. The etiology of hallux valgus is multifactorial and likely involves abnormal mechanics and anatomy. Patients generally complain of a deformed and painful great toe. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/58/1960?source=see_link\">",
"     \"Hallux valgus deformity (bunion)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In runners with either of these conditions, mechanically limiting first MTP joint motion by using appropriate shoes and unloading techniques can be helpful. We suggest walking shoes with a wide toe box, stiff soles, rocker bottoms, and low heels. Comfortable running shoes with a wide toe box combined with techniques to reduce the impact on the first MTP joint, such as custom orthotics or cushioned insoles, reduce symptoms in many runners.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     Acetaminophen",
"    </a>",
"    or nonsteroidal antiinflammatory drugs may be used for short-term pain relief. Ice can be applied following running. Glucocorticoid injections may provide short-term pain relief for those with mild hallux rigidus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/100\">",
"     100",
"    </a>",
"    ]. Consultation with a foot surgeon should be obtained for severe or recalcitrant cases, although there is little high-quality evidence to guide decisions about surgery or conservative care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38750569\">",
"    <span class=\"h4\">",
"     Sesamoiditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sesamoids are pea-sized bones that function as pulleys for tendons (just as the patella does for the knee extensors) and assist with weightbearing. Inflammation or injury of the sesamoid bones located on the plantar surface of the first MTP joint can cause focal pain in runners, particularly sprinters (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80813 \" href=\"mobipreview.htm?15/6/15471\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef71857 \" href=\"mobipreview.htm?2/20/2375\">",
"     figure 5",
"    </a>",
"    ). The runner with sesamoiditis typically complains of pain at the area of the MTP joint with weightbearing that is exacerbated by walking, and even more so by running. Exquisite tenderness of the sesamoids is present, and is exacerbated by dorsiflexion of the great toe. Imaging is required to differentiate between sesamoiditis and a stress fracture.",
"   </p>",
"   <p>",
"    Both sesamoiditis and sesamoid stress fractures are notoriously difficult to treat and may require a short period of immobilization followed by prolonged rest from running. Runners can use alternative, nonweightbearing forms of exercise to maintain fitness. Treatment with custom orthotics, soft pads cut to relieve pressure on the sesamoids, and in severe cases glucocorticoid injections may be helpful, but there is little evidence to guide treatment. Women runners should avoid wearing high heels; shoes with a stiff sole (eg, clog) are often helpful. Consultation with a foot surgeon is reasonable in recalcitrant cases.",
"   </p>",
"   <p>",
"    Treatment of sesamoiditis does not differ significantly from that for sesamoid fractures. The evaluation and management of sesamoid fractures is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/52/28485?source=see_link\">",
"     \"Sesamoid fractures of the foot\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24287254\">",
"    <span class=\"h3\">",
"     Metatarsalgia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain in a runner&rsquo;s forefoot that is not due to a metatarsal stress fracture is likely due to metatarsalgia or an interdigital neuroma. (See",
"    <a class=\"local\" href=\"#H24287205\">",
"     'Stress fractures'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Metatarsalgia is a general term for pain that occurs along the ball of the foot. Most runners with metatarsalgia complain of pain in the forefoot during running; the examiner will find tenderness along the plantar surface just proximal to the metatarsal heads. The condition is often associated with overpronation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    collapse of the transverse arch. A metatarsal pad placed proximal to the area of tenderness often relieves symptoms; in more severe cases, a custom orthotic may be needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38750749\">",
"    <span class=\"h3\">",
"     (Mortons) neuroma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interdigital neuromas (often referred to as Mortons neuroma) are thought to be due to swelling and scar tissue formation on the small interdigital nerves. They most commonly involve the third webspace, but may also be seen in the second and fourth.",
"   </p>",
"   <p>",
"    The runner with a neuroma may complain of numbness of the involved toes or pain that increases with activity and is usually felt in the interspace between the third and fourth toes (",
"    <a class=\"graphic graphic_figure graphicRef65666 \" href=\"mobipreview.htm?0/3/56\">",
"     figure 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/101\">",
"     101",
"    </a>",
"    ]. The diagnosis can be confirmed by noting a clicking sensation (Mulders sign) when palpating this interspace while simultaneously squeezing the metatarsal joints. Overpronation and tight shoes are often associated with the condition.",
"   </p>",
"   <p>",
"    An intermetatarsal bursitis can cause a similar pain. The use of magnetic resonance imaging (MRI) to diagnose Morton's neuroma is problematic because features consistent with neuroma may appear in as many as one-third of asymptomatic individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/102,103\">",
"     102,103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Conservative treatment should precede expensive diagnostic procedures. This approach involves decreasing pressure on the metatarsal heads by using a metatarsal support or bar or padded shoe insert. Several studies have measured the loading pressures placed on metatarsals before and after use of metatarsal pads, bars, orthotics, and specialized orthopedic shoes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/104-109\">",
"     104-109",
"    </a>",
"    ]. In all reports, pain relief correlated with reduction in pressure. Proper placement of the inserts just proximal to the metatarsal head is important. Strength exercises for the intrinsic foot muscles are often part of conservative treatment. No randomized controlled studies have been performed to assess these interventions.",
"   </p>",
"   <p>",
"    Treatment inserts are often placed in both shoes, even when symptoms are unilateral, to ensure that the patient walks evenly, but bilateral pads are not always needed. Symptomatic relief often begins within a few days of insert use and pain may completely subside over several weeks.",
"   </p>",
"   <p>",
"    A broad-toed shoe that allows spreading of the metatarsal heads may be helpful. Proper shoe width should be determined while standing, using a professional shoe fitting device. If width has changed, older shoes should be discarded.",
"   </p>",
"   <p>",
"    If conservative measures fail to relieve symptoms, a single injection of a local anesthetic and glucocorticoid into the site of tenderness can be performed using a dorsal,",
"    <strong>",
"     not",
"    </strong>",
"    plantar, approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/110,111\">",
"     110,111",
"    </a>",
"    ]. A plantar approach is more likely to cause complications. A combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (20 mg, or 0.5 mL) and one percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    (0.5 mL) may be used.",
"   </p>",
"   <p>",
"    Ultrasound guided injection is preferred by many practitioners although studies are limited. Ultrasound can distinguish neuroma from adjacent joint synovitis or bursitis. The majority of patients experience some relief with ultrasound-guided injection according to three case series involving a total of 113 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/112-114\">",
"     112-114",
"    </a>",
"    ]. Complications are rare; metatarsal fat pad atrophy can be debilitating but may occur less often if a dorsal injection is used. No randomized controlled trials of ultrasound guided injection have been published.",
"   </p>",
"   <p>",
"    Surgical removal of the neuroma and nerve may be necessary in patients who remain symptomatic",
"    <strong>",
"     after",
"    </strong>",
"    9 to 12 months of nonoperative therapy. Surgical success rates of up to 80 to 90 percent have been reported in uncontrolled studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/110,115-117\">",
"     110,115-117",
"    </a>",
"    ]. Surgery performed using a dorsal approach resulted in more timely weightbearing, return to work, and less painful scarring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/118\">",
"     118",
"    </a>",
"    ]. No randomized trials of surgery for plantar neuroma have been reported. Rarely, a neuroma may recur following surgery. Experience with injections of alcohol, phenol, and other substances and with nerve transplants is limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H957956\">",
"    <span class=\"h3\">",
"     Tarsal tunnel syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tarsal tunnel syndrome (TTS) is an uncommon source of foot pain in runners due to entrapment of the posterior tibial nerve (PTN) or one of its branches as it courses behind the medial malleolus. The most common causes include an acute injury and its sequelae (eg, scar tissue) or repetitive microtrauma, as occurs with running, particularly in runners who overpronate. Runners with TTS complain of numbness or burning pain, usually along the plantar surface of the foot, although complaints may be localized to the medial plantar surface of the heel, mimicking plantar fasciitis. TTS typically worsens with running or at night. Findings are almost always sensory; muscle weakness is uncommon. A positive Tinel sign may be present. As in carpal tunnel syndrome, a positive sign occurs when symptoms are elicited by tapping over the path of the nerve. TTS is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/15/42233?source=see_link&amp;anchor=H27#H27\">",
"     \"Overview of lower extremity peripheral nerve syndromes\", section on 'Tarsal tunnel syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26387930\">",
"    <span class=\"h3\">",
"     Toenail injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Athletes in many sports sustain toenail injuries from repetitive trauma to the nail or nail bed. In runners, this condition is commonly called &ldquo;jogger&rsquo;s toenail&rdquo; and it most frequently affects the great toe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/4/34890/abstract/119\">",
"     119",
"    </a>",
"    ]. The nail may turn black (due to subungual bleeding) or may fall off, especially after a long distance run such as a marathon. The differential diagnosis for these injuries includes fungal infection and subungual melanoma. The management of acute subungual hematoma, fungal infection of the nail (onychomycosis), and melanoma are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/8/9351?source=see_link\">",
"     \"Subungual hematoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/8/5258?source=see_link\">",
"     \"Onychomycosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26585?source=see_link&amp;anchor=H18#H18\">",
"     \"Initial surgical management of melanoma of the skin and unusual sites\", section on 'Subungual'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the author&rsquo;s experience, toenail injuries in runners are most often due to poorly fitting shoes. Thus, injuries can be prevented by using properly fitted running shoes. Such shoes provide sufficient space in the toe-box and are sized to accommodate the longest toe. The midfoot portion of the shoe should fit properly and be sufficiently snug to prevent the toes from slipping forward and striking against the end of the toe box. &nbsp;&nbsp;&nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/14/17634?source=see_link\">",
"       \"Patient information: Achilles tendinopathy (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/37/8786?source=see_link\">",
"       \"Patient information: Metatarsalgia (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/10/18594?source=see_link\">",
"       \"Patient information: Patellofemoral pain syndrome (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/27/5554?source=see_link\">",
"       \"Patient information: Iliotibial band syndrome (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/3/1074?source=see_link\">",
"       \"Patient information: Hamstring injury (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/30/36321?source=see_link\">",
"       \"Patient information: Shin splints (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38751164\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Up to half of regular runners report an injury each year. Some injuries are traumatic, but most are due to overuse and many of these involve the knee. The most common diagnoses include: patellofemoral pain syndrome, medial tibial stress syndrome (ie, &ldquo;shin splints&rdquo;), Achilles tendinopathy, iliotibial band syndrome, plantar fasciitis, and stress fractures of the metatarsals and tibia. (See",
"      <a class=\"local\" href=\"#H24287083\">",
"       'General epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of intrinsic and extrinsic risk factors are associated with running-related lower extremity injuries. Perhaps the most important and most easily changed are training variables, such as mileage and intensity. The role of other factors, such as shoes, stretching, and biomechanics, is less clear. Training suggestions to reduce the risk of injury are provided in the text. (See",
"      <a class=\"local\" href=\"#H24287090\">",
"       'Risk factors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H58496913\">",
"       'Training suggestions to reduce injury risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A careful history and physical examination are essential for determining the differential diagnosis and the need for diagnostic imaging. Guidance about how best to evaluate the injured runner is provided in the text. (See",
"      <a class=\"local\" href=\"#H24287170\">",
"       'Evaluation of the injured runner'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Descriptions of important and common causes of running-related lower extremity injuries, organized anatomically, are provided in the text, along with links to more detailed discussions. (See",
"      <a class=\"local\" href=\"#H7409762\">",
"       'Specific injuries'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/1\">",
"      Messier SP, Legault C, Schoenlank CR, et al. Risk factors and mechanisms of knee injury in runners. Med Sci Sports Exerc 2008; 40:1873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/2\">",
"      Fields KB, Sykes JC, Walker KM, Jackson JC. Prevention of running injuries. Curr Sports Med Rep 2010; 9:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/3\">",
"      van Gent RN, Siem D, van Middelkoop M, et al. Incidence and determinants of lower extremity running injuries in long distance runners: a systematic review. Br J Sports Med 2007; 41:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/4\">",
"      Wen DY. Risk factors for overuse injuries in runners. Curr Sports Med Rep 2007; 6:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/5\">",
"      Taunton JE, Ryan MB, Clement DB, et al. A retrospective case-control analysis of 2002 running injuries. Br J Sports Med 2002; 36:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/6\">",
"      Junior LC, Carvalho AC, Costa LO, Lopes AD. The prevalence of musculoskeletal injuries in runners: a systematic review. Br J Sports Med 2011; 45:351.",
"     </a>",
"    </li>",
"    <li>",
"     USA State of the Sport Report. www.runningusa.org (Accessed on May 01, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/8\">",
"      Fredericson M, Misra AK. Epidemiology and aetiology of marathon running injuries. Sports Med 2007; 37:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/9\">",
"      McKean KA, Manson NA, Stanish WD. Musculoskeletal injury in the masters runners. Clin J Sport Med 2006; 16:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/10\">",
"      Bovens AM, Janssen GM, Vermeer HG, et al. Occurrence of running injuries in adults following a supervised training program. Int J Sports Med 1989; 10 Suppl 3:S186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/11\">",
"      Reinking MF, Hayes AM. Intrinsic factors associated with exercise-related leg pain in collegiate cross-country runners. Clin J Sport Med 2006; 16:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/12\">",
"      Reinking MF, Austin TM, Hayes AM. Exercise-related leg pain in collegiate cross-country athletes: extrinsic and intrinsic risk factors. J Orthop Sports Phys Ther 2007; 37:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/13\">",
"      Cowan DN, Jones BH, Robinson JR. Foot morphologic characteristics and risk of exercise-related injury. Arch Fam Med 1993; 2:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/14\">",
"      Brunet ME, Cook SD, Brinker MR, Dickinson JA. A survey of running injuries in 1505 competitive and recreational runners. J Sports Med Phys Fitness 1990; 30:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/15\">",
"      Korpelainen R, Orava S, Karpakka J, et al. Risk factors for recurrent stress fractures in athletes. Am J Sports Med 2001; 29:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/16\">",
"      Taunton JE, Ryan MB, Clement DB, et al. A prospective study of running injuries: the Vancouver Sun Run \"In Training\" clinics. Br J Sports Med 2003; 37:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/17\">",
"      Buist I, Bredeweg SW, Lemmink KA, et al. Predictors of running-related injuries in novice runners enrolled in a systematic training program: a prospective cohort study. Am J Sports Med 2010; 38:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/18\">",
"      Rauh MJ, Margherita AJ, Rice SG, et al. High school cross country running injuries: a longitudinal study. Clin J Sport Med 2000; 10:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/19\">",
"      Yeung EW, Yeung SS. Interventions for preventing lower limb soft-tissue injuries in runners. Cochrane Database Syst Rev 2001; :CD001256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/20\">",
"      Ryan M, MacLean C, Taunton JE. A review of anthropometric, biomechanical, neuromuscular and training related factors associated with injury in runners. Int J Sports Med 2006; 7:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/21\">",
"      Buist I, Bredeweg SW, van Mechelen W, et al. No effect of a graded training program on the number of running-related injuries in novice runners: a randomized controlled trial. Am J Sports Med 2008; 36:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/22\">",
"      Van Middelkoop M, Kolkman J, Van Ochten J, et al. Risk factors for lower extremity injuries among male marathon runners. Scand J Med Sci Sports 2008; 18:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/23\">",
"      Milgrom C, Finestone A, Segev S, et al. Are overground or treadmill runners more likely to sustain tibial stress fracture? Br J Sports Med 2003; 37:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/24\">",
"      Thacker SB, Gilchrist J, Stroup DF, Kimsey CD Jr. The impact of stretching on sports injury risk: a systematic review of the literature. Med Sci Sports Exerc 2004; 36:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/25\">",
"      Yeung SS, Yeung EW, Gillespie LD. Interventions for preventing lower limb soft-tissue running injuries. Cochrane Database Syst Rev 2011; :CD001256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/26\">",
"      Amako M, Oda T, Masuoka K, et al. Effect of static stretching on prevention of injuries for military recruits. Mil Med 2003; 168:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/27\">",
"      van Mechelen W, Hlobil H, Kemper HC, et al. Prevention of running injuries by warm-up, cool-down, and stretching exercises. Am J Sports Med 1993; 21:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/28\">",
"      Reinschmidt C, Nigg BM. Current issues in the design of running and court shoes. Sportverletz Sportschaden 2000; 14:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/29\">",
"      Knapik JJ, Trone DW, Swedler DI, et al. Injury reduction effectiveness of assigning running shoes based on plantar shape in Marine Corps basic training. Am J Sports Med 2010; 38:1759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/30\">",
"      Knapik JJ, Brosch LC, Venuto M, et al. Effect on injuries of assigning shoes based on foot shape in air force basic training. Am J Prev Med 2010; 38:S197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/31\">",
"      Richards CE, Magin PJ, Callister R. Is your prescription of distance running shoes evidence-based? Br J Sports Med 2009; 43:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/32\">",
"      Wegener C, Burns J, Penkala S. Effect of neutral-cushioned running shoes on plantar pressure loading and comfort in athletes with cavus feet: a crossover randomized controlled trial. Am J Sports Med 2008; 36:2139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/33\">",
"      Cook SD, Kester MA, Brunet ME. Shock absorption characteristics of running shoes. Am J Sports Med 1985; 13:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/34\">",
"      Franklyn-Miller A, Wilson C, Bilzon J, McCrory P. Foot orthoses in the prevention of injury in initial military training: a randomized controlled trial. Am J Sports Med 2011; 39:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/35\">",
"      Gillespie WJ, Grant I. Interventions for preventing and treating stress fractures and stress reactions of bone of the lower limbs in young adults. Cochrane Database Syst Rev 2000; :CD000450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/36\">",
"      Rome K, Handoll HH, Ashford R. Interventions for preventing and treating stress fractures and stress reactions of bone of the lower limbs in young adults. Cochrane Database Syst Rev 2005; :CD000450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/37\">",
"      Murley GS, Landorf KB, Menz HB, Bird AR. Effect of foot posture, foot orthoses and footwear on lower limb muscle activity during walking and running: a systematic review. Gait Posture 2009; 29:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/38\">",
"      Razeghi M, Batt ME. Biomechanical analysis of the effect of orthotic shoe inserts: a review of the literature. Sports Med 2000; 29:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/39\">",
"      McMillan A, Payne C. Effect of foot orthoses on lower extremity kinetics during running: a systematic literature review. J Foot Ankle Res 2008; 1:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/40\">",
"      Zadpoor AA, Nikooyan AA. The relationship between lower-extremity stress fractures and the ground reaction force: a systematic review. Clin Biomech (Bristol, Avon) 2011; 26:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/41\">",
"      Willems TM, Witvrouw E, De Cock A, De Clercq D. Gait-related risk factors for exercise-related lower-leg pain during shod running. Med Sci Sports Exerc 2007; 39:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/42\">",
"      Heiderscheit BC, Chumanov ES, Michalski MP, et al. Effects of step rate manipulation on joint mechanics during running. Med Sci Sports Exerc 2011; 43:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/43\">",
"      Gerlach KE, Burton HW, Dorn JM, et al. Fat intake and injury in female runners. J Int Soc Sports Nutr 2008; 5:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/44\">",
"      American Dietetic Association, Dietitians of Canada, American College of Sports Medicine, et al. American College of Sports Medicine position stand. Nutrition and athletic performance. Med Sci Sports Exerc 2009; 41:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/45\">",
"      Bonci LJ. Eating for performance: bringing science to the training table. Clin Sports Med 2011; 30:661.",
"     </a>",
"    </li>",
"    <li>",
"     Skolnik, Heidi and Chernus, Andrea. Nutrient timing for peak performance, 1st ed., Human Kinetics., Champaign, IL. 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/47\">",
"      Beelen M, Burke LM, Gibala MJ, van Loon L JC. Nutritional strategies to promote postexercise recovery. Int J Sport Nutr Exerc Metab 2010; 20:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/48\">",
"      Whiting SJ, Barabash WA. Dietary Reference Intakes for the micronutrients: considerations for physical activity. Appl Physiol Nutr Metab 2006; 31:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/49\">",
"      Peake J, Nosaka K, Suzuki K. Characterization of inflammatory responses to eccentric exercise in humans. Exerc Immunol Rev 2005; 11:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/50\">",
"      McGinley C, Shafat A, Donnelly AE. Does antioxidant vitamin supplementation protect against muscle damage? Sports Med 2009; 39:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/51\">",
"      Ristow M, Zarse K, Oberbach A, et al. Antioxidants prevent health-promoting effects of physical exercise in humans. Proc Natl Acad Sci U S A 2009; 106:8665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/52\">",
"      Fields KB, Delaney M, Hinkle JS. A prospective study of type A behavior and running injuries. J Fam Pract 1990; 30:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/53\">",
"      Van Mechelen W, Twisk J, Molendijk A, et al. Subject-related risk factors for sports injuries: a 1-yr prospective study in young adults. Med Sci Sports Exerc 1996; 28:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/54\">",
"      Anderson K, Strickland SM, Warren R. Hip and groin injuries in athletes. Am J Sports Med 2001; 29:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/55\">",
"      Nadler SF, Malanga GA, DePrince M, et al. The relationship between lower extremity injury, low back pain, and hip muscle strength in male and female collegiate athletes. Clin J Sport Med 2000; 10:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/56\">",
"      Nadler SF, Malanga GA, Feinberg JH, et al. Relationship between hip muscle imbalance and occurrence of low back pain in collegiate athletes: a prospective study. Am J Phys Med Rehabil 2001; 80:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/57\">",
"      Niemuth PE, Johnson RJ, Myers MJ, Thieman TJ. Hip muscle weakness and overuse injuries in recreational runners. Clin J Sport Med 2005; 15:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/58\">",
"      Filler AG, Haynes J, Jordan SE, et al. Sciatica of nondisc origin and piriformis syndrome: diagnosis by magnetic resonance neurography and interventional magnetic resonance imaging with outcome study of resulting treatment. J Neurosurg Spine 2005; 2:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/59\">",
"      Lewis AM, Layzer R, Engstrom JW, et al. Magnetic resonance neurography in extraspinal sciatica. Arch Neurol 2006; 63:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/60\">",
"      Halpin RJ, Ganju A. Piriformis syndrome: a real pain in the buttock? Neurosurgery 2009; 65:A197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/61\">",
"      Papadopoulos EC, Khan SN. Piriformis syndrome and low back pain: a new classification and review of the literature. Orthop Clin North Am 2004; 35:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/62\">",
"      Hopayian K, Song F, Riera R, Sambandan S. The clinical features of the piriformis syndrome: a systematic review. Eur Spine J 2010; 19:2095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/63\">",
"      Stewart JD, Foye PM, Cole JL. Piriformis syndrome. Muscle Nerve 2010; 41:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/64\">",
"      Baquie P, Brukner P. Injuries presenting to an Australian sports medicine centre: a 12-month study. Clin J Sport Med 1997; 7:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/65\">",
"      Prins MR, van der Wurff P. Females with patellofemoral pain syndrome have weak hip muscles: a systematic review. Aust J Physiother 2009; 55:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/66\">",
"      Fagan V, Delahunt E. Patellofemoral pain syndrome: a review on the associated neuromuscular deficits and current treatment options. Br J Sports Med 2008; 42:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/67\">",
"      Fairclough J, Hayashi K, Toumi H, et al. Is iliotibial band syndrome really a friction syndrome? J Sci Med Sport 2007; 10:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/68\">",
"      Noehren B, Davis I, Hamill J. ASB clinical biomechanics award winner 2006 prospective study of the biomechanical factors associated with iliotibial band syndrome. Clin Biomech (Bristol, Avon) 2007; 22:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/69\">",
"      Ferber R, Noehren B, Hamill J, Davis IS. Competitive female runners with a history of iliotibial band syndrome demonstrate atypical hip and knee kinematics. J Orthop Sports Phys Ther 2010; 40:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/70\">",
"      Grau S, Krauss I, Maiwald C, et al. Kinematic classification of iliotibial band syndrome in runners. Scand J Med Sci Sports 2011; 21:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/71\">",
"      Messier SP, Edwards DG, Martin DF, et al. Etiology of iliotibial band friction syndrome in distance runners. Med Sci Sports Exerc 1995; 27:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/72\">",
"      Gunter P, Schwellnus MP. Local corticosteroid injection in iliotibial band friction syndrome in runners: a randomised controlled trial. Br J Sports Med 2004; 38:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/73\">",
"      Fredericson M, Wolf C. Iliotibial band syndrome in runners: innovations in treatment. Sports Med 2005; 35:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/74\">",
"      Fredericson M, Weir A. Practical management of iliotibial band friction syndrome in runners. Clin J Sport Med 2006; 16:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/75\">",
"      Jenkins J, Beazell J. Flexibility for runners. Clin Sports Med 2010; 29:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/76\">",
"      Brosseau L, Casimiro L, Milne S, et al. Deep transverse friction massage for treating tendinitis. Cochrane Database Syst Rev 2002; :CD003528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/77\">",
"      Willick SE, Hansen PA. Running and osteoarthritis. Clin Sports Med 2010; 29:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/78\">",
"      Chakravarty EF, Hubert HB, Lingala VB, et al. Long distance running and knee osteoarthritis. A prospective study. Am J Prev Med 2008; 35:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/79\">",
"      Panush RS, Hanson CS, Caldwell JR, et al. Is Running Associated with Osteoarthritis? An Eight-Year Follow-up Study. J Clin Rheumatol 1995; 1:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/80\">",
"      Konradsen L, Hansen EM, S&oslash;ndergaard L. Long distance running and osteoarthrosis. Am J Sports Med 1990; 18:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/81\">",
"      Lane NE, Bloch DA, Jones HH, et al. Long-distance running, bone density, and osteoarthritis. JAMA 1986; 255:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/82\">",
"      Sohn RS, Micheli LJ. The effect of running on the pathogenesis of osteoarthritis of the hips and knees. Clin Orthop Relat Res 1985; :106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/83\">",
"      Stahl R, Luke A, Ma CB, et al. Prevalence of pathologic findings in asymptomatic knees of marathon runners before and after a competition in comparison with physically active subjects-a 3.0 T magnetic resonance imaging study. Skeletal Radiol 2008; 37:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/84\">",
"      Schueller-Weidekamm C, Schueller G, Uffmann M, Bader TR. Does marathon running cause acute lesions of the knee? Evaluation with magnetic resonance imaging. Eur Radiol 2006; 16:2179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/85\">",
"      Kessler MA, Glaser C, Tittel S, et al. Volume changes in the menisci and articular cartilage of runners: an in vivo investigation based on 3-D magnetic resonance imaging. Am J Sports Med 2006; 34:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/86\">",
"      Harrast MA, Colonno D. Stress fractures in runners. Clin Sports Med 2010; 29:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/87\">",
"      Craig DI. Medial tibial stress syndrome: evidence-based prevention. J Athl Train 2008; 43:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/88\">",
"      Barr KP, Harrast MA. Evidence-based treatment of foot and ankle injuries in runners. Phys Med Rehabil Clin N Am 2005; 16:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/89\">",
"      Buchbinder R. Clinical practice. Plantar fasciitis. N Engl J Med 2004; 350:2159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/90\">",
"      Riddle DL, Pulisic M, Pidcoe P, Johnson RE. Risk factors for Plantar fasciitis: a matched case-control study. J Bone Joint Surg Am 2003; 85-A:872.",
"     </a>",
"    </li>",
"    <li>",
"     Wheaton MT, Molnar TJ. Overuse injuries of the lower extremity. In: Orthopedic Knowledge Update, Griffin LY.  (Ed), American Academy of Orthopaedic Surgeons, 1997. p.225.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/92\">",
"      Knobloch K, Yoon U, Vogt PM. Acute and overuse injuries correlated to hours of training in master running athletes. Foot Ankle Int 2008; 29:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/93\">",
"      Zafar MS, Mahmood A, Maffulli N. Basic science and clinical aspects of achilles tendinopathy. Sports Med Arthrosc 2009; 17:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/94\">",
"      Donoghue OA, Harrison AJ, Coffey N, Hayes K. Functional data analysis of running kinematics in chronic Achilles tendon injury. Med Sci Sports Exerc 2008; 40:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/95\">",
"      Williams DS, Zambardino JA, Banning VA. Transverse-plane mechanics at the knee and tibia in runners with and without a history of achilles tendonopathy. J Orthop Sports Phys Ther 2008; 38:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/96\">",
"      Child S, Bryant AL, Clark RA, Crossley KM. Mechanical properties of the achilles tendon aponeurosis are altered in athletes with achilles tendinopathy. Am J Sports Med 2010; 38:1885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/97\">",
"      Simpson MR, Howard TM. Tendinopathies of the foot and ankle. Am Fam Physician 2009; 80:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/98\">",
"      Coughlin MJ, Shurnas PS. Hallux rigidus: demographics, etiology, and radiographic assessment. Foot Ankle Int 2003; 24:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/99\">",
"      Nihal A, Trepman E, Nag D. First ray disorders in athletes. Sports Med Arthrosc 2009; 17:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/100\">",
"      Solan MC, Calder JD, Bendall SP. Manipulation and injection for hallux rigidus. Is it worthwhile? J Bone Joint Surg Br 2001; 83:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/101\">",
"      Locke RK. Morton's neuroma. J Am Podiatr Med Assoc 1993; 83:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/102\">",
"      Studler U, Mengiardi B, Bode B, et al. Fibrosis and adventitious bursae in plantar fat pad of forefoot: MR imaging findings in asymptomatic volunteers and MR imaging-histologic comparison. Radiology 2008; 246:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/103\">",
"      Bencardino J, Rosenberg ZS, Beltran J, et al. Morton's neuroma: is it always symptomatic? AJR Am J Roentgenol 2000; 175:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/104\">",
"      Kang JH, Chen MD, Chen SC, Hsi WL. Correlations between subjective treatment responses and plantar pressure parameters of metatarsal pad treatment in metatarsalgia patients: a prospective study. BMC Musculoskelet Disord 2006; 7:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/105\">",
"      Jannink M, van Dijk H, Ijzerman M, et al. Effectiveness of custom-made orthopaedic shoes in the reduction of foot pain and pressure in patients with degenerative disorders of the foot. Foot Ankle Int 2006; 27:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/106\">",
"      Hsi WL, Kang JH, Lee XX. Optimum position of metatarsal pad in metatarsalgia for pressure relief. Am J Phys Med Rehabil 2005; 84:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/107\">",
"      Jackson L, Binning J, Potter J. Plantar pressures in rheumatoid arthritis using prefabricated metatarsal padding. J Am Podiatr Med Assoc 2004; 94:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/108\">",
"      Chang AH, Abu-Faraj ZU, Harris GF, et al. Multistep measurement of plantar pressure alterations using metatarsal pads. Foot Ankle Int 1994; 15:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/109\">",
"      Holmes GB Jr, Timmerman L. A quantitative assessment of the effect of metatarsal pads on plantar pressures. Foot Ankle 1990; 11:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/110\">",
"      Wu KK. Morton's interdigital neuroma: a clinical review of its etiology, treatment, and results. J Foot Ankle Surg 1996; 35:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/111\">",
"      Rasmussen MR, Kitaoka HB, Patzer GL. Nonoperative treatment of plantar interdigital neuroma with a single corticosteroid injection. Clin Orthop Relat Res 1996; :188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/112\">",
"      Markovic M, Crichton K, Read JW, et al. Effectiveness of ultrasound-guided corticosteroid injection in the treatment of Morton's neuroma. Foot Ankle Int 2008; 29:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/113\">",
"      Sofka CM, Adler RS, Ciavarra GA, Pavlov H. Ultrasound-guided interdigital neuroma injections: short-term clinical outcomes after a single percutaneous injection--preliminary results. HSS J 2007; 3:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/114\">",
"      Hassouna H, Singh D, Taylor H, Johnson S. Ultrasound guided steroid injection in the treatment of interdigital neuralgia. Acta Orthop Belg 2007; 73:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/115\">",
"      Gauthier G. Thomas Morton's disease: a nerve entrapment syndrome. A new surgical technique. Clin Orthop Relat Res 1979; :90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/116\">",
"      Dereymaeker G, Schroven I, Steenwerckx A, Stuer P. Results of excision of the interdigital nerve in the treatment of Morton's metatarsalgia. Acta Orthop Belg 1996; 62:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/117\">",
"      Pace A, Scammell B, Dhar S. The outcome of Morton's neurectomy in the treatment of metatarsalgia. Int Orthop 2010; 34:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/118\">",
"      Nashi M, Venkatachalam AK, Muddu BN. Surgery of Morton's neuroma: dorsal or plantar approach? J R Coll Surg Edinb 1997; 42:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/4/34890/abstract/119\">",
"      Adams BB. Jogger's toenail. J Am Acad Dermatol 2003; 48:S58.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16321 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-2.133.93.82-D9A3241E76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_4_34890=[""].join("\n");
var outline_f34_4_34890=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H38751164\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24287076\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24287083\">",
"      GENERAL EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24287090\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24287097\">",
"      Intrinsic risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24287105\">",
"      - Anatomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24287112\">",
"      - Gender and age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24287119\">",
"      Extrinsic risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24287126\">",
"      - Training variables",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24287134\">",
"      - Stretching and warm-ups",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24287141\">",
"      - Shoes and orthotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24287148\">",
"      - Gait, strength, and biomechanics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24287156\">",
"      - Nutrition and supplementation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24287163\">",
"      - Psychology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H58496913\">",
"      Training suggestions to reduce injury risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24287170\">",
"      EVALUATION OF THE INJURED RUNNER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7409762\">",
"      SPECIFIC INJURIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2791000\">",
"      Hip injuries",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2791008\">",
"      - Overview and approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2791015\">",
"      - Gluteus medius weakness and tendinopathy and piriformis syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2791022\">",
"      - Femoral neck stress fracture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2791029\">",
"      - Labral tear",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2791036\">",
"      - Iliopsoas tendinopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7409898\">",
"      Knee and thigh injuries",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24287177\">",
"      - Knee pain (patellofemoral pain syndrome)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24287184\">",
"      - Iliotibial band syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24287191\">",
"      - Hamstring injuries",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24287198\">",
"      - Knee OA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24287205\">",
"      Stress fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24287212\">",
"      Medial tibial stress syndrome (shin splints) and tibial stress fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H957904\">",
"      Chronic exertional compartment syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24287219\">",
"      Foot and ankle injuries",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24287226\">",
"      - Plantar fasciitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24287240\">",
"      - Tendon injuries",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24287247\">",
"      - First metatarsal phalangeal joint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H38750562\">",
"      Hallux rigidus and hallux valgus (bunion)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H38750569\">",
"      Sesamoiditis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24287254\">",
"      - Metatarsalgia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38750749\">",
"      - (Mortons) neuroma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H957956\">",
"      - Tarsal tunnel syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26387930\">",
"      - Toenail injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38751164\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/16321\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/16321|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?15/6/15471\" title=\"diagnostic image 1\">",
"      1st mcp sesamoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/16321|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/34/12841\" title=\"figure 1\">",
"      Muscles of gluteal region and posterior thigh",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/44/25282\" title=\"figure 2\">",
"      Iliopsoas anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/32/32260\" title=\"figure 3\">",
"      Iliotibial band anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?27/42/28326\" title=\"figure 4\">",
"      Achilles tendon anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/20/2375\" title=\"figure 5\">",
"      Foot anatomy superior view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/3/56\" title=\"figure 6\">",
"      Morton neuroma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32537?source=related_link\">",
"      Achilles tendinopathy and tendon rupture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/3/36919?source=related_link\">",
"      Amenorrhea and infertility associated with exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34296?source=related_link\">",
"      Ankle sprain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/35/28215?source=related_link\">",
"      Chronic exertional compartment syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/47/38649?source=related_link\">",
"      Dietary carbohydrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/34/2601?source=related_link\">",
"      Dietary fat",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/42/1706?source=related_link\">",
"      Exercise-associated hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/58/1960?source=related_link\">",
"      Hallux valgus deformity (bunion)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/35/14906?source=related_link\">",
"      Hamstring injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26585?source=related_link\">",
"      Initial surgical management of melanoma of the skin and unusual sites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/30/2538?source=related_link\">",
"      Nonpharmacologic therapy of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/8/5258?source=related_link\">",
"      Onychomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/15/42233?source=related_link\">",
"      Overview of lower extremity peripheral nerve syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/19/23866?source=related_link\">",
"      Overview of stress fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/39/20089?source=related_link\">",
"      Overview of the management of overuse (chronic) tendinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43993?source=related_link\">",
"      Patellofemoral pain syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/14/17634?source=related_link\">",
"      Patient information: Achilles tendinopathy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/3/1074?source=related_link\">",
"      Patient information: Hamstring injury (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/27/5554?source=related_link\">",
"      Patient information: Iliotibial band syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/37/8786?source=related_link\">",
"      Patient information: Metatarsalgia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/10/18594?source=related_link\">",
"      Patient information: Patellofemoral pain syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/30/36321?source=related_link\">",
"      Patient information: Shin splints (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/40/44681?source=related_link\">",
"      Plantar fasciitis and other causes of heel pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/52/28485?source=related_link\">",
"      Sesamoid fractures of the foot",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/61/33747?source=related_link\">",
"      Stress fractures of the metatarsal shaft",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/4/19527?source=related_link\">",
"      Stress fractures of the tibia and fibula",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/8/9351?source=related_link\">",
"      Subungual hematoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_4_34891="HAV vaccine recs PI";
var content_f34_4_34891=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F78137&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F78137&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Hepatitis A vaccine pre-exposure recommendations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Person or group",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vaccine or IG",
"       </td>",
"       <td class=\"subtitle1\">",
"        Second dose needed?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        All children age 12 to 23 months",
"       </td>",
"       <td>",
"        Vaccine",
"       </td>",
"       <td>",
"        Yes, 6 to 12 months after first dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        At-risk adults*",
"       </td>",
"       <td>",
"        Vaccine",
"       </td>",
"       <td>",
"        Yes, 6 to 12 months after first dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        People who are allergic to vaccine components",
"       </td>",
"       <td>",
"        IG",
"       </td>",
"       <td>",
"        If still living in area where HAV common, second dose of IG recommended 4 months after first dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Older adults and people with a weakened immune system, chronic liver disease, or other underlying medical problem who plan to travel to a high-risk area within two weeks",
"       </td>",
"       <td>",
"        IG plus vaccine",
"       </td>",
"       <td>",
"        Yes, second dose of vaccine is recommended 6 to 12 months after first dose",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     *",
"     <strong>",
"      At-risk adults include:",
"     </strong>",
"     <br/>",
"     <ul>",
"      <li>",
"       Travelers to countries where HAV is common; the vaccine can be given at any time before traveling",
"      </li>",
"      <li>",
"       Injection and non-injection illegal drug users",
"      </li>",
"      <li>",
"       Men who have sex with men",
"      </li>",
"      <li>",
"       People with chronic liver disease",
"      </li>",
"      <li>",
"       Adults with blood clotting factor disorders",
"      </li>",
"      <li>",
"       Adults who are at risk for infection at work, including day care center staff, personnel in health care facilities (eg, nursing homes), and food handlers",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_4_34891=[""].join("\n");
var outline_f34_4_34891=null;
var title_f34_4_34892="Conservative schedule";
var content_f34_4_34892=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F60803&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F60803&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Aeroallergen subcutaneous immunotherapy (SCIT) - Example of conservative schedule for very sensitive patients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Concentration: 1:1000 v/v dilution of maintenance vial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Dose:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.05 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.10 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.20 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.40 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Concentration: 1:100 v/v",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Dose:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.05 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.10 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.20 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.30 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.40 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.50 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Concentration: 1:10 v/v",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Dose:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.05 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.07 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.10 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.15 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.25 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.35 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.40 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.45 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.50 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Maintenance concentration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Dose:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.05 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.07 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.10 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.15 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.20 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.25 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.30 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.35 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.40 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.45 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.50 mL",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     v/v: volume/volume.",
"    </div>",
"    <div class=\"reference\">",
"     Original figure modified for this publication. Cox L, Nelson H, Lockey R. Allergen immunotherapy: A practice parameter third update. J Allergy Clin Immunol 2011; 127(1 Supp):S1. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_4_34892=[""].join("\n");
var outline_f34_4_34892=null;
var title_f34_4_34893="Agents responsible for RADS-I";
var content_f34_4_34893=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F55545&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F55545&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Agents responsible for reactive airways dysfunction syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Study",
"       </td>",
"       <td class=\"subtitle1\">",
"        Evidence",
"       </td>",
"       <td class=\"subtitle1\">",
"        References",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Acetic acid",
"       </td>",
"       <td>",
"        epidemiologic",
"       </td>",
"       <td>",
"        H, S, BR",
"       </td>",
"       <td>",
"        Am Rev Respir Dis 1991; 144:1058",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        case report",
"       </td>",
"       <td>",
"        H, S, P",
"       </td>",
"       <td>",
"        Br J Ind Med 1989; 4 6:67",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Sulfuric acid",
"       </td>",
"       <td>",
"        case report",
"       </td>",
"       <td>",
"        H, S, BR",
"       </td>",
"       <td>",
"        Chest 1988; 94:476",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Hydrochloridic acid",
"       </td>",
"       <td>",
"        case report",
"       </td>",
"       <td>",
"        H, S",
"       </td>",
"       <td>",
"        Chest 1988; 94:476",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        case report",
"       </td>",
"       <td rowspan=\"2\">",
"        H, S, BR",
"       </td>",
"       <td>",
"        Chest 1985; 88:376",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chest 1990; 98:928",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Various acids",
"       </td>",
"       <td rowspan=\"2\">",
"        case report",
"       </td>",
"       <td rowspan=\"2\">",
"        H, S, BR, P",
"       </td>",
"       <td>",
"        Chest 1985; 88:376",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        JOM 1994; 36:623",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Heated acid",
"       </td>",
"       <td>",
"        case report",
"       </td>",
"       <td>",
"        H, S, BR, P",
"       </td>",
"       <td>",
"        Chest 1985; 88:376",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Ammonia",
"       </td>",
"       <td rowspan=\"2\">",
"        case report",
"       </td>",
"       <td rowspan=\"2\">",
"        H, S",
"       </td>",
"       <td>",
"        Mayo Clin Proc 1983; 58:389",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thorax 1992; 47:755",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Bleaching agent",
"       </td>",
"       <td>",
"        case report",
"       </td>",
"       <td>",
"        H, S, BR",
"       </td>",
"       <td>",
"        Chest 1988; 94:476",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        epidemiologic",
"       </td>",
"       <td>",
"        H",
"       </td>",
"       <td>",
"        Am J Ind Med 2003; 43:532",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Bromochlorodifluoro- methane",
"       </td>",
"       <td>",
"        case report",
"       </td>",
"       <td>",
"        H, S, BR",
"       </td>",
"       <td>",
"        Occup Env Med 2004; 61:712",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Bromotrifluoromethane",
"       </td>",
"       <td>",
"        case report",
"       </td>",
"       <td>",
"        H, S",
"       </td>",
"       <td>",
"        Eur Respir J 1999; 13:1192",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Chlorine",
"       </td>",
"       <td>",
"        epidemiologic",
"       </td>",
"       <td>",
"        H, S, BR",
"       </td>",
"       <td>",
"        Occup Env Med 1994; 61:712",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        epidemiologic",
"       </td>",
"       <td>",
"        H",
"       </td>",
"       <td>",
"        Env Res 2002; 88:89",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        clinical",
"       </td>",
"       <td>",
"        H, S, BR, P",
"       </td>",
"       <td>",
"        Toxicol Industrial Health 1993; 9:439",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Chloropicrin",
"       </td>",
"       <td>",
"        experimental",
"       </td>",
"       <td>",
"        P",
"       </td>",
"       <td>",
"        Toxicol Appl Pharm 1984; 74:417",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Cleaning agents",
"       </td>",
"       <td>",
"        case report",
"       </td>",
"       <td>",
"        H, S",
"       </td>",
"       <td>",
"        Chest 1976; 69:372",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Diesel exhaust",
"       </td>",
"       <td rowspan=\"2\">",
"        case report",
"       </td>",
"       <td rowspan=\"2\">",
"        H, S, BR",
"       </td>",
"       <td>",
"        Chest 1985; 88:376",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        J Occup Med 1993; 35:149",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Diethylaminoethanol",
"       </td>",
"       <td>",
"        epidemiologic",
"       </td>",
"       <td>",
"        H, S",
"       </td>",
"       <td>",
"        J Occup Med 1994; 36:623",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Epichlorohydrin",
"       </td>",
"       <td>",
"        experimental",
"       </td>",
"       <td>",
"        P",
"       </td>",
"       <td>",
"        Toxicol Appl Pharm 1984; 74:417",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Ethylene oxide",
"       </td>",
"       <td>",
"        case report",
"       </td>",
"       <td>",
"        H, S, BR, P",
"       </td>",
"       <td>",
"        Br J Ind Med 1992; 49:523",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"5\">",
"        Fire/smoke",
"       </td>",
"       <td>",
"        case report",
"       </td>",
"       <td>",
"        H, S, BR",
"       </td>",
"       <td>",
"        Chest 1988; 94:476",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        epidemiologic, case report",
"       </td>",
"       <td>",
"        H, S, BR, P",
"       </td>",
"       <td>",
"        Occup Med 1993; 8:431",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        case report",
"       </td>",
"       <td rowspan=\"2\">",
"        H, S",
"       </td>",
"       <td>",
"        Chest 1985; 88:376",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        J Occup Med 1991; 33:458",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        epidemiologic",
"       </td>",
"       <td>",
"        H, S, BR",
"       </td>",
"       <td>",
"        Am J Respir Crit Care Med 2003; 168:54",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Formaldehyde",
"       </td>",
"       <td>",
"        case report",
"       </td>",
"       <td>",
"        H, S, BR",
"       </td>",
"       <td>",
"        Allergy 2004; 59:15",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     H: clinical history; S: spirometry; BR: bronchial responsiveness; P: pathology.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_4_34893=[""].join("\n");
var outline_f34_4_34893=null;
var title_f34_4_34894="Synthesis of gastrin";
var content_f34_4_34894=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F52877&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F52877&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Synthesis of gastrin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 439px; height: 547px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_4_34894=[""].join("\n");
var outline_f34_4_34894=null;
var title_f34_4_34895="Normal TM mobility";
var content_f34_4_34895=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/55117/pneumat1_conv.mp4?title=Normal+TM+mobility\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal tympanic membrane mobility",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A normal tympanic membrane moves briskly in response to both positive and negative pressure. A good seal between the speculum and the external auditory canal is essential.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ellen R Wald, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_4_34895=[""].join("\n");
var outline_f34_4_34895=null;
